(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 12 July 2001 (12.07.2001)

PCT

English

(10) International Publication Number WO 01/49097 A2

(51) International Patent Classification: Not classified

PCT/IB01/00797 (21) International Application Number:

(22) International Filing Date: 9 May 2001 (09.05.2001)

(26) Publication Language: **English**

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

09/416,901 (CON) 10 March 1999 (10.03.1999)

(71) Applicants and

Filed on

(25) Filing Language:

(72) Inventors: BIENKOWSKI, Michael, Jerome [US/US]; Global Intellectual Property, Building 209, 301 Henrietta Street, Kalamazoo, MI 49001-0199 (US). GURNEY, Mark, E. [US/IS]; Lynghals 1, IS-110 Rey Kavik (IS). HEINRIKSON, Robert, Leroy [US/US]; Global Intellectual Property, Building 209, 301 Henrietta Street, Kalamazoo, MI 49001-0199 (US). PARODI, Luis, A. [US/SE]; Grevgafan 24, S-115 43 Stockholm (SE). YAN, Riqiang [US/US]; Global Intellectual Property, Building 209, 301 Henrietta Street, Kalamazoo, MI 49001-0199 (US).

(74) Agent: GASS, David, A.; Marshall, O'Toole, Gerstein, Murray & Borun, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL 60606-6402 (US).

(81) Designated State (national): US.

Published:

- Upon request of the applicant under Article 64(3)(c)(i).
- Upon request of the applicant, before the expiration of the time limit referred to in Article 21(2)(a).
- Without international search report and to be republished upon receipt of that report.
- Without classification; title and abstract not checked by the International Searching Authority.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



Alzheimer's Disease Secretase, APP Substrates Therefor, and Uses Therefor

The present application is a continuation of United States Application Serial No. 09/416,901, filed October 13, 1999 which claims priority benefit of United States Provisional Patent Application No. 60/155,493, filed September 23, 1999. The present application also claims priority benefit as a continuation-in-part of United States Patent Application Serial No. 09/404,133 and PCT/US99/20881, both filed September 23, 1999, both of which in turn claim priority benefit of United States Provisional Patent Application No. 60/101,594, filed September 24, 1998. All of these priority applications are hereby incorporated by reference in their entirety.

5

10

15

20

25

FIELD OF THE INVENTION

The present invention relates to Alzheimer's Disease, amyloid protein precursor, amyloid beta peptide, and human aspartyl proteases, as well as a method for the identification of agents that modulate the activity of these polypeptides and thereby are candidates to modulate the progression of Alzheimer's disease.

BACKGROUND OF THE INVENTION

Alzheimer's disease (AD) causes progressive dementia with consequent formation of amyloid plaques, neurofibrillary tangles, gliosis and neuronal loss. The disease occurs in both genetic and sporadic forms whose clinical course and pathological features are quite similar. Three genes have been discovered to date which, when mutated, cause an autosomal dominant form of Alzheimer's disease. These encode the amyloid protein precursor (APP) and two related proteins, presenilin-1 (PS1) and presenilin-2 (PS2), which, as their names suggest, are structurally and functionally related. Mutations in any of the three proteins have been observed to enhance proteolytic processing of APP via an intracellular pathway that produces amyloid beta peptide (Aβ peptide ,or sometimes here as Abeta), a 40-42 amino acid long peptide that is the primary component of amyloid plaque in AD.

5

10

15

20

25

30

Dysregulation of intracellular pathways for proteolytic processing may be central to the pathophysiology of AD. In the case of plaque formation, mutations in APP, PS1 or PS2 consistently alter the proteolytic processing of APP so as to enhance formation of Aβ 1-42, a form of the Aβ peptide which seems to be particularly amyloidogenic, and thus very important in AD. Different forms of APP range in size from 695-770 amino acids, localize to the cell surface, and have a single C-terminal transmembrane domain. Examples of specific isotypes of APP which are currently known to exist in humans are the 695-amino acid polypeptide described by Kang et. al. (1987), Nature 325: 733-736 which is designated as the "normal" APP; the 751 amino acid polypeptide described by Ponte et al. (1988), Nature 331: 525-527 (1988) and Tanzi et al. (1988), Nature 331: 528-530; and the 770 amino acid polypeptide described by Kitaguchi et. al. (1988), Nature 331: 530-532. The Abeta peptide is derived from a region of APP adjacent to and containing a portion of the transmembrane domain. Normally, processing of APP at the α -secretase site cleaves the midregion of the $A\beta$ sequence adjacent to the membrane and releases the soluble, extracellular domain of APP from the cell surface. This α-secretase APP processing creates soluble APP- α, which is normal and not thought to contribute to AD. Pathological processing of APP at the β- and γ-secretase sites, which are located Nterminal and C-terminal to the α-secretase site, respectively, produces a very different result than processing at the α site. Sequential processing at the β - and γ -secretase sites releases the Aβ peptide, a peptide possibly very important in AD pathogenesis. Processing at the β- and γ-secretase sites can occur in both the endoplasmic reticulum (in neurons) and in the endosomal/lysosomal pathway after reinternalization of cell surface APP (in all cells). Despite intense efforts, for 10 years or more, to identify the enzymes responsible for processing APP at the β and γ sites, to produce the A β peptide, those proteases remained unknown until this disclosure.

SUMMARY OF THE INVENTION

Here, for the first time, we report the identification and characterization of the β secretase enzyme, termed Aspartyl Protease 2 (Asp2). We disclose some known

and some novel human aspartic proteases that can act as β -secretase proteases and, for the first time, we explain the role these proteases have in AD. We describe regions in the proteases critical for their unique function and for the first time characterize their substrate. This is the first description of expressed isolated purified active protein of this type, assays that use the protein, in addition to the identification and creation of useful cell lines and inhibitors.

Here we disclose a number of variants of the Asp2 gene and peptide.

5

10

15

20

25

30

In one aspect, the invention provides any isolated or purified nucleic acid polynucleotide that codes for a protease capable of cleaving the beta (β) secretase cleavage site of APP that contains two or more sets of special nucleic acids, where the special nucleic acids are separated by nucleic acids that code for about 100 to 300 amino acid positions, where the amino acids in those positions may be any amino acids, where the first set of special nucleic acids consists of the nucleic acids that code for the peptide DTG, where the first nucleic acid of the first special set of nucleic acids is the first special nucleic acid, and where the second set of nucleic acids code for either the peptide DSG or DTG, where the last nucleic acid of the second set of nucleic acids is the last special nucleic acid, with the proviso that the nucleic acids disclosed in SEQ ID NO. 1 and SEQ ID NO. 3 are not included. In a preferred embodiment, the two sets of special nucleic acids are separated by nucleic acids that code for about 125 to 222 amino acid positions, which may be any amino acids. In a highly preferred embodiment, the two sets of special nucleic acids are separated by nucleic acids that code for about 150 to 196, or 150-190, or 150 to 172 amino acid positions, which may be any amino acids. In a particular preferred embodiment, the two sets are separated by nucleic acids that code for about 172 amino acid positions, which may be any amino acids. An exemplary nucleic acid polynucleotide comprises the acid nucleotide sequence in SEQ ID NO. 5. In another particular preferred embodiment, the two sets are separated by nucleic acids that code for about 196 amino acids. An exemplary polynucleotide comprises the nucleotide sequence in SEO ID NO. 5. In another particular embodiment, the two sets of nucleotides are separated by nucleic acids that code for about 190 amino acids. An exemplary polynucleotide

comprises the nucleotide sequence in SEQ ID NO. 1. Preferably, the first nucleic acid of the first special set of amino acids, that is, the first special nucleic acid, is operably linked to any codon where the nucleic acids of that codon codes for any peptide comprising from 1 to 10,000 amino acid (positions). In one variation, the first special nucleic acid is operably linked to nucleic acid polymers that code for any peptide selected from the group consisting of: any reporter proteins or proteins which facilitate purification. For example, the first special nucleic acid is operably linked to nucleic acid polymers that code for any peptide selected from the group consisting of: immunoglobin-heavy chain, maltose binding protein, glutathione S transferase, Green Fluorescent protein, and ubiquitin. In another variation, the last nucleic acid of the second set of special amino acids, that is, the last special nucleic acid, is operably linked to nucleic acid polymers that code for any peptide comprising any amino acids from 1 to 10,000 amino acids. In still another variation, the last special nucleic acid is operably linked to nucleic acid polymers that code for any peptide selected from the group consisting of: any reporter proteins or proteins which facilitate purification. For example, the last special nucleic acid is operably linked to nucleic acid polymers that code for any peptide selected from the group consisting of: immunoglobin-heavy chain, maltose binding protein, glutathione S transferase, Green Fluorescent protein, and ubiquitin.

20

25

15

5

10

In a related aspect, the invention provides any isolated or purified nucleic acid polynucleotide that codes for a protease capable of cleaving the beta secretase cleavage site of APP that contains two or more sets of special nucleic acids, where the special nucleic acids are separated by nucleic acids that code for about 100 to 300 amino acid positions, where the amino acids in those positions may be any amino acids, where the first set of special nucleic acids consists of the nucleic acids that code for DTG, where the first nucleic acid of the first special set of nucleic acids is the first special nucleic acid, and where the second set of nucleic acids code for either DSG or DTG, where the last nucleic acid of the second set of special nucleic acids is the last special nucleic acid, where the first special nucleic acid is operably linked to nucleic acids that code for any number of amino acids from zero to 81 amino acids and where

30

each of those codons may code for any amino acid. In a preferred embodiment, the first special nucleic acid is operably linked to nucleic acids that code for any number of from 64 to 77 amino acids where each codon may code for any amino acid. In a particular embodiment, the first special nucleic acid is operably linked to nucleic acids that code for 71 amino acids. For example, the first special nucleic acid is operably linked to 71 amino acids and where the first of those 71 amino acids is the amino acid T. In a preferred embodiment, the polynucleotide comprises a sequence that is at least 95% identical to a human Asp1 or Asp2 sequence as taught herein. In another preferred embodiment, the first special nucleic acid is operably linked to nucleic acids that code for any number of from 30 to 54 amino acids, or 35 to 47 amino acids, or 40 to 54 amino acids where each codon may code for any amino acid. In a particular embodiment, the first special nucleic acid is operably linked to nucleic acids that code for 47 amino acids. For example, the first special nucleic acid is operably linked to 47 codons where the first those 47 amino acids is the amino acid E.

15

20

25

10

5

In another related aspect, the invention provides for any isolated or purified nucleic acid polynucleotide that codes for a protease capable of cleaving the beta (β) secretase cleavage site of APP and that contains two or more sets of special nucleic acids, where the special nucleic acids are separated by nucleic acids that code for about 100 to 300 amino acid positions, where the amino acids in those positions may be any amino acids, where the first set of special nucleic acids consists of the nucleic acids that code for the peptide DTG, where the first nucleic acid of the first special set of amino acids is, the first special nucleic acid, and where the second set of special nucleic acids code for either the peptide DSG or DTG, where the last nucleic acid of the second set of special nucleic acids, the last special nucleic acid, is operably linked to nucleic acids that code for any number of codons from 50 to 170 codons. In a preferred embodiment, the last special nucleic acid is operably linked to nucleic acids comprising from 100 to 170 codons. In a highly preferred embodiment, the last special nucleic acid is operably linked to nucleic acids comprising from 142 to 163 codons. In a particular embodiment, the last special nucleic acid is operably linked to nucleic acids comprising about 142 codons, or about 163 codons, or about 170

30

codons. In a highly preferred embodiment, the polynucleotide comprises a sequence that is at least 95% identical to aspartyl-protease encoding sequences taught herein. In one variation, the second set of special nucleic acids code for the peptide DSG. In another variation, the first set of nucleic acid polynucleotide is operably linked to a peptide purification tag. For example, the nucleic acid polynucleotide is operably linked to a peptide purification tag which is six histidine. In still another variation, the first set of special nucleic acids are on one polynucleotide and the second set of special nucleic acids are on a second polynucleotide, where both first and second polynucleotides have at lease 50 codons. In one embodiment of this type, both of the polynucleotides are in the same solution. In a related aspect, the invention provides a vector which contains a polynucleotide as described above, or a cell or cell line which is transformed or transfected with a polynucleotide as described above or with a vector containing such a polynucleotide.

5

10

15

20

25

30

In still another aspect, the invention provides an isolated or purified peptide or protein comprising an amino acid polymer that is a protease capable of cleaving the beta (β) secretase cleavage site of APP that contains two or more sets of special amino acids, where the special amino acids are separated by about 100 to 300 amino acid positions, where each amino acid position can be any amino acid, where the first set of special amino acids consists of the peptide DTG, where the first amino acid of the first special set of amino acids is, the first special amino acid, where the second set of amino acids is selected from the peptide comprising either DSG or DTG, where the last amino acid of the second set of special amino acids is the last special amino acid, with the proviso that the proteases disclosed in SEQ ID NO. 2 and SEQ ID NO. 4 are not included. In preferred embodiments, the two sets of amino acids are separated by about 125 to 222 amino acid positions or about 150 to 196 amino acids, or about 150-190 amino acids, or about 150 to 172 amino acids, where in each position it may be any amino acid. In a particular embodiment, the two sets of amino acids are separated by about 172 amino acids. For example, the protease has the amino acid sequence described in SEQ ID NO 6. In another particular embodiment, the two sets of amino acids are separated by about 196 amino acids. For example, the two sets of amino

5

10

15

20

25

30

acids are separated by the same amino acid sequences that separate the same set of special amino acids in SEQ ID NO 4. In another particular embodiment, the two sets of nucleotides are separated by about 190 amino acids. For example, the two sets of nucleotides are separated by the same amino acid sequences that separate the same set of special amino acids in SEQ ID NO 2. In one embodiment, the first amino acid of the first special set of amino acids, that is, the first special amino acid, is operably linked to any peptide comprising from 1 to 10,000 amino acids. In another embodiment, the first special amino acid is operably linked to any peptide selected from the group consisting of: any reporter proteins or proteins which facilitate purification. In particular embodiments, the first special amino acid is operably linked to any peptide selected from the group consisting of: immunoglobin-heavy chain, maltose binding protein, glutathione S transferase, Green Fluorescent protein, and ubiquitin. In still another variation, the last amino acid of the second set of special amino acids, that is, the last special amino acid, is operably linked to any peptide comprising any amino acids from 1 to 10,000 amino acids. By way of nonlimiting example, the last special amino acid is operably linked any peptide selected from the group consisting of any reporter proteins or proteins which facilitate purification. In particular embodiments, the last special amino acid is operably linked to any peptide selected from the group consisting of: immunoglobin-heavy chain, maltose binding protein, glutathione S transferase, Green Fluorescent protein, and ubiquitin.

In a related aspect, the invention provides any isolated or purified peptide or protein comprising an amino acid polypeptide that codes for a protease capable of cleaving the beta secretase cleavage site of APP that contains two or more sets of special amino acids, where the special amino acids are separated by about 100 to 300 amino acid positions, where each amino acid in each position can be any amino acid, where the first set of special amino acids consists of the amino acids DTG, where the first amino acid of the first special set of amino acids is, the first special amino acid, D, and where the second set of amino acids is either DSG or DTG, where the last amino acid of the second set of special amino acids is the last special amino acid, G, where the first special amino acid is operably linked to amino acids that code for any

5

10

15

20

25

30

number of amino acids from zero to 81 amino acid positions where in each position it may be any amino acid. In a preferred embodiment, the first special amino acid is operably linked to a peptide from about 30-77 or about 64 to 77 amino acids positions where each amino acid position may be any amino acid. In a particular embodiment, the first special amino acid is operably linked to a peptide 35, 47, 71, or 77 amino acids. In a very particular embodiment, the first special amino acid is operably linked to 71 amino acids and the first of those 71 amino acids is the amino acid T. For example, the polypeptide comprises a sequence that is at least 95% identical to an aspartyl protease sequence as described herein. In another embodiment, the first special amino acid is operably linked to any number of from 40 to 54 amino acids (positions) where each amino acid position may be any amino acid. In a particular embodiment, the first special amino acid is operably linked to amino acids that code for a peptide of 47 amino acids. In a very particular embodiment, the first special amino acid is operably linked to a 47 amino acid peptide where the first those 47 amino acids is the amino acid E. In another particular embodiment, the first special amino acid is operably linked to the same corresponding peptides from SEO ID NO. 3 that are 35, 47, 71, or 77 peptides in length, beginning counting with the amino acids on the first special sequence, DTG, towards the N-terminal of SEQ ID NO. 3. In another particular embodiment, the polypeptide comprises a sequence that is at least 95% identical to the same corresponding amino acids in SEQ ID NO. 4, that is, identical to that portion of the sequences in SEQ ID NO. 4, including all the sequences from both the first and or the second special nucleic acids, toward the terminal, through and including 71, 47, 35 amino acids before the first special amino acids. For example, the complete polypeptide comprises the peptide of 71 amino acids, where the first of the amino acid is T and the second is Q.

In still another related aspect, the invention provides any isolated or purified amino acid polypeptide that is a protease capable of cleaving the beta (β) secretase cleavage site of APP that contains two or more sets of special amino acids, where the special amino acids are separated by about 100 to 300 amino acid positions, where each amino acid in each position can be any amino acid, where the first set of special

5

10

15

20

25

30

amino acids consists of the amino acids that code for DTG, where the first amino acid of the first special set of amino acids is, the first special amino acid, D, and where the second set of amino acids are either DSG or DTG, where the last amino acid of the second set of special amino acids is the last special amino acid, G, which is operably linked to any number of amino acids from 50 to 170 amino acids, which may be any amino acids. In preferred embodiments, the last special amino acid is operably linked to a peptide of about 100 to 170 amino acids or about 142-163 amino acids. In particular embodiments, the last special amino acid is operably linked to a peptide of about 142 amino acids, or about 163 amino acids, or about 170 amino acids. For example, the polypeptide comprises a sequence that is at least 95% identical (and preferably 100% identical) to an aspartyl protease sequence as described herein. In one particular embodiment, the second set of special amino acids is comprised of the peptide with the amino acid sequence DSG. Optionally, the amino acid polypeptide is operably linked to a peptide purification tag, such as purification tag which is six histidine. In one variation, the first set of special amino acids are on one polypeptide and the second set of special amino acids are on a second polypeptide, where both first and second polypeptide have at lease 50 amino acids, which may be any amino acids. In one embodiment of this type, both of the polypeptides are in the same vessel. The invention further includes a process of making any of the polynucleotides, vectors, or cells described herein; and a process of making any of the polypeptides described herein.

In yet another related aspect, the invention provides a purified polynucleotide comprising a nucleotide sequence that encodes a polypeptide having aspartyl protease activity, wherein the polypeptide has an amino acid sequence characterized by: (a) a first tripeptide sequence DTG; (b) a second tripeptide sequence selected from the group consisting of DSG and DTG; and (c) about 100 to 300 amino acids separating the first and second tripeptide sequences, wherein the polypeptide cleaves the beta secretase cleavage site of amyloid protein precursor. In one embodiment, the polypeptide comprises an amino acid sequence depicted in SEQ ID NO: 2 or 4, whereas in another embodiment, the polypeptide comprises an amino acid sequence

other than the amino acid sequences set forth in SEQ ID NOs: 2 and 4. Similarly, the invention provides a purified polynucleotide comprising a nucleotide sequence that encodes a polypeptide that cleaves the beta secretase cleavage site of amyloid protein precursor; wherein the polynucleotide includes a strand that hybridizes to one or more of SEQ ID NOs: 3, 5, and 7 under the following hybridization conditions: hybridization overnight at 42°C for 2.5 hours in 6 X SSC/0.1% SDS, followed by washing in 1.0 X SSC at 65°C, 0.1% SDS. In one embodiment, the polypeptide comprises an amino acid sequence depicted in SEQ ID NO: 2 or 4, whereas in another embodiment, the polypeptide comprises an amino acid sequence other than the amino acid sequences set forth in SEQ ID NOs: 2 and 4. Likewise, the invention provides a purified polypeptide having aspartyl protease activity, wherein the polypeptide is encoded by polynucleotides as described in the preceding sentences. The invention also provides a vector or host cell comprising such polynucleotides, and a method of making the polypeptides using the vectors or host cells to recombinantly express the polypeptide.

5

10

15

25

30

In yet another aspect, the invention provides an isolated nucleic acid molecule comprising a polynucleotide, said polynucleotide encoding a Hu-Asp polypeptide and having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

- 20 (a) a nucleotide sequence encoding a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b), wherein said Hu-Asp1, Hu-Asp2(a) and Hu-Asp2(b) polypeptides have the complete amino acid sequence of SEQ ID NO. 2, SEQ ID NO. 4, and SEQ ID NO. 6, respectively; and
 - (b) a nucleotide sequence complementary to the nucleotide sequence of (a).

Several species are particularly contemplated. For example, the invention provides a nucleic acid and molecule wherein said Hu-Asp polypeptide is Hu-Asp1, and said polynucleotide molecule of 1(a) comprises the nucleotide sequence of SEQ ID NO. 1; and a nucleic acid molecule wherein said Hu-Asp polypeptide is Hu-Asp2(a), and said polynucleotide molecule of 1(a) comprises the nucleotide

sequence of SEQ ID NO. 4; and a nucleic acid molecule wherein said Hu-Asp polypeptide is Hu-Asp2(b), and said polynucleotide molecule of 1(a) comprises the nucleotide sequence of SEQ ID NO. 5. In addition to the foregoing, the invention provides an isolated nucleic acid molecule comprising polynucleotide which hybridizes under stringent conditions to a polynucleotide having the nucleotide sequence in (a) or (b) as described above.

Additionally, the invention provides a vector comprising a nucleic acid molecule as described in the preceding paragraph. In a preferred embodiment, the nucleic acid molecule is operably linked to a promoter for the expression of a Hu-Asp polypeptide. Individual vectors which encode Hu-Asp1, and Hu-Asp2(a), and Hu-Asp2(b) are all contemplated. Likewise, the invention contemplates a host cell comprising any of the foregoing vectors, as well as a method of obtaining a Hu-Asp polypeptide comprising culturing such a host cell and isolating the Hu-Asp polypeptide. Host cells of the invention include bacterial cells, such as *E. coli*, and eukaryotic cells. Among the eukaryotic cells that are contemplated are insect cells, such as sf9 or High 5 cells; and mammalian cells, such as human, rodent, lagomorph, and primate. Preferred human cells include HEK293, and IMR-32 cells. Other preferred mammalian cells include COS-7, CHO-K1, Neuro-2A, and 3T3 cells. Also among the eukaryotic cells that are contemplated are a yeast cell and an avian cell.

20

5

10

15

In a related aspect, the invention provides an isolated Hu-Asp1 polypeptide comprising an amino acid sequence at least 95% identical to a sequence comprising the amino acid sequence of SEQ ID NO. 2. The invention also provides an isolated Hu-Asp2(a) polypeptide comprising an amino acid sequence at least 95% identical to a sequence comprising the amino acid sequence of SEQ ID NO. 4. The invention also provides an isolated Hu-Asp2(a) polypeptide comprising an amino acid sequence at least 95% identical to a sequence comprising the amino acid sequence of SEQ ID NO. 8.

25

In still another aspect, the invention provides an isolated antibody that binds specifically to any Hu-Asp polypeptide described herein, especially the polypeptide described in the preceding paragraphs.

30

The invention also provides several assays involving aspartyl protease enzymes of the invention. For example, the invention provides

a method to identify a cell that can be used to screen for inhibitors of β secretase activity comprising:

(a) identifying a cell that expresses a protease capable of cleaving APP at the β secretase site, comprising:

5

15

20

25

30

- i) collect the cells or the supernatant from the cells to be identified
- peptide is selected from the group consisting of either the APP C-terminal peptide or soluble APP,
 - iii) select the cells which produce the critical peptide.

In one variation, the cells are collected and the critical peptide is the APP C-terminal peptide created as a result of the β secretase cleavage. In another variation, the supernatant is collected and the critical peptide is soluble APP, where the soluble APP has a C-terminus created by β secretase cleavage. In preferred embodiments, the cells contain any of the nucleic acids or polypeptides described above and the cells are shown to cleave the β secretase site of any peptide having the following peptide structure, P2, P1, P1', P2', where P2 is K or N, where P1 is M or L, where P1' is D, where P2' is A. The method of claim 111 where P2 is K and P1 is M. The method of claim 112 where P2 is N and P1 is L.

In still another aspect, the invention provides novel isoforms of amyloid protein precursor (APP) where the last two carboxy terminus amino acids of that isoform are both lysine residues. In this context, the term "isoform" is defined as any APP polypeptide, including APP variants (including mutations), and APP fragments that exists in humans, such as those described in US 5,766,846, col 7, lines 45-67, incorporated into this document by reference, modified as described herein by the inclusion of two C-terminal lysine residues. For example, the invention provides a polypeptide comprising the isoform known as APP695, modified to include two lysine residues as its last two carboxy terminus amino acids. An exemplary polypeptide

comprises the amino acid sequence set forth in SEQ ID NO. 16. The invention further includes APP isoform variants as set forth in SEQ ID NOs. 18 and 20. The invention further includes all polynucleotides that encode an APP protein that has been modified to include two C-terminal lysines; as well has any eukaryotic cell line comprising such nucleic acids or polypeptides. Preferred cell lines include a mammalian cell line (*e.g.*, HEK293, Neuro2a).

5

10

15

20

25

30

Thus, in one embodiment, the invention provides a polypeptide comprising the amino acid sequence of a mammalian amyloid protein precursor (APP) or fragment thereof containing an APP cleavage site recognizable by a mammalian β-secretase, and further comprising two lysine residues at the carboxyl terminus of the amino acid sequence of the mammalian APP or APP fragment. As taught herein in detail, the addition of two additional lysine residues to APP sequences has been found to greatly increase A\beta processing of the APP in APP processing assays. Thus, the di-lysine modified APP reagents of the invention are particularly useful in assays to identify modulators of A β production, for use in designing the appearing for the treatment or prevention of Alzheimer's disease. In one embodiment, the polypeptide comprises the complete amino acid sequence of a mammalian amyloid protein precursor (APP), and further comprises the two lysine residues at the carboxyl terminus of the amino acid sequence of the mammalian amyloid protein precursor. In an alternative embodiment, the polypeptide comprises only a fragment of the APP, the fragment containing at least that portion of APP that is cleaved by a mammalian β-secretase in the formation of Aß peptides.

The practice of assays that monitor cleavage of APP can be facilitated by attaching a marker to a portion of the APP. Measurment of retained or liberated marker can be used to quantitate the amount of APP cleavage that occurs in the assay, e.g., in the presence or absence of a putative modulator of cleavage activity. Thus, in one preferred embodiment, the polypeptide of the invention further includes a marker. For example, the marker comprises a reporter protein amino acid sequence attached to the APP amino acid sequence. Exemplary reporter proteins include a fluorescing protein (e.g., green fluorescing proteins, luciferase) or an enzyme that is used to

5

10

15

20

25

30

cleave a substrate to produce a colorimetric cleavage product. Also contemplated are tag sequences which are commonly used as epitopes for quantitative immunoassays.

In a preferred embodiment, the di-lysine-modified APP of the invention is a human APP. For example, human APP isoforms such as APP695, APP751, and APP770, modified to include the two lysines, are contemplated. In a preferred embodiment, the APP isoform comprises at least one variation selected from the group consisting of a Swedish KM-NL mutation and a London V717-F mutation, or any other mutation that has been observed in a subpopulation that is particularly prone to development of Alzheimer's disease. These mutations are recognized as mutations that influence APP processing into Aβ. In a highly preferred embodiment, the APP protein or fragment thereof comprises the APP-Sw β-secretase peptide sequence NLDA (SEQ ID NO: 66), which is associated with increased levels of Aβ processing and therefore is particularly useful in assays relating to Alzheimer's research. More particularly, the APP protein or fragment thereof preferably comprises the APP-Sw β-secretase peptide sequence SEVNLDAEFR (SEQ ID NO: 63).

In one preferred embodiment, the APP protein or fragment thereof further includes an APP transmembrane domain carboxy-terminal to the APP-Sw β-secretase peptide sequence. Polypeptides that include the TM domain are particularly useful in cell-based APP processing assays. In contrast, embodiments lacking the TM domain are useful in cell-free assays of APP processing.

In addition to working with APP from humans and various animal models, researchers in the field of Alzheimer's also have construct chimeric APP polypeptides which include stretches of amino acids from APP of one species (e.g., humans) fused to stretches of APP from one or more other species (e.g., rodent). Thus, in another embodiment of the polypeptide of the invention, the APP protein or fragment thereof comprises a chimeric APP, the chimeric APP including partial APP amino acid sequences from at least two species. A chimeric APP that includes amino acid sequence of a human APP and a rodent APP is particularly contemplated.

In a related aspect, the invention provides a polynucleotide comprising a nucleotide sequence that encodes a polypeptide as described in the preceding

paragraphs. Such a polynucleotide is useful for recominant expression of the polypeptide of the invention for use in APP processing assays. In addition, the polynucleotide is useful for transforming into cells to produce recombinant cells that express the polypeptide of the invention, which cells are useful in cell-based assays to identify modulators of APP processing. Thus, in addition to polynucleotides, the invention provides a vector comprising such polynucleotides, especially expression vectors where the polynucleotide is operably linked to a promoter to promote expression of the polypeptide encoded by the polynucleotide in a host cell. The invention further provides a host cell transformed or transfected with a polynucleotide according to claim 14 or a vector according to claim 15 or 16. Among the preferred host cells are mammalian cells, especially human cells.

5

10

15

20

25

30

In another, related embodiment, the invention provides a polypeptide useful for assaying for modulators of β-secretase activity, said polypeptide comprising an amino acid sequence of the formula NH₂-X-Y-Z-KK-COOH; wherein X, Y, and Z each comprise an amino acid sequence of at least one amino acid; wherein-NH₂-X comprises an amino-terminal amino acid sequence having at least one amino acid residue; wherein Y comprises an amino acid sequence of a β-secretase recognition site of a mammalian amyloid protein precursor (APP); and wherein Z-KK-COOH comprises a carboxy-terminal amino acid sequence ending in two lysine (K) residues. In one preferred variation, the carboxyl-terminal amino acid sequence Z includes a hyrdrophobic domain that is a transmembrane domain in host cells that express the polypeptide. Host cells that express such a polypeptide are particularly useful in assays described herein for identifying modulators of APP processing. In another preferred variation, the amino-terminal amino acid sequence X includes an amino acid sequence of a reporter or marker protein, as described above. In still another preferred variation, the β -secretase recognition site Y comprises the human APP-Sw β -secretase peptide sequence NLDA (SEQ ID NO: 66). It will be apparent that these preferred variations are not mutually exclusive of each other -- they may be combined in a single polypeptide. The invention further provides a polynucleotide comprising a nucleotide sequence that encodes such polypeptides, vectors which comprise such

polynucleotides, and host cells which comprises such vectors, polynucleotides, and/or polypeptides.

In yet another aspect, the invention provides a method for identifying inhibitors of an enzyme that cleaves the beta secretase cleavable site of APP comprising:

5

10

15

20

25

30

- a) culturing cells in a culture medium under conditions in which the enzyme causes processing of APP and release of amyloid beta-peptide into the medium and causes the accumulation of CTF99 fragments of APP in cell lysates,
- b) exposing the cultured cells to a test compound; and specifically determining whether the test compound inhibits the function of the enzyme by measuring the amount of amyloid beta-peptide released into the medium and/or the amount of CTF99 fragments of APP in cell lysates;
- c) identifying test compounds diminishing the amount of soluble amyloid beta peptide present in the culture medium and diminution of CTF99 fragments of APP in cell lysates as Asp2 inhibitors. In preferred embodiments, the cultured cells are a human, rodent or insect cell line. It is also preferred that the human or rodent cell line exhibits β secretase activity in which processing of APP occurs with release of amyloid beta-peptide into the culture medium and accumulation of CTF99 in cell lysates. Among the contemplated test compounds are antisense oligomers directed against the enzyme that exhibits β secretase activity, which oligomers reduce release of soluble amyloid beta-peptide into the culture medium and accumulation of CTF99 in cell lysates.

In yet another aspect, the invention provides a method for the identification of an agent that decreases the activity of a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b), the method comprising:

- a) determining the activity of said Hu-Asp polypeptide in the presence of a test agent and in the absence of a test agent; and
- b) comparing the activity of said Hu-Asp polypeptide determined in the presence of said test agent to the activity of said Hu-Asp polypeptide determined in the absence of said test agent; whereby a lower level of activity in the presence of said

test agent than in the absence of said test agent indicates that said test agent has decreased the activity of said Hu-Asp polypeptide.

In a related aspect, the invention provides a method for assaying for modulators of β -secretase activity, comprising the steps of:

5

10

15

(a) contacting a first composition with a second composition both in the presence and in the absence of a putative modulator compound, wherein the first composition comprises a mammalian β-secretase polypeptide or biologically active fragment thereof, and wherein the second composition comprises a substrate polypeptide having an amino acid sequence comprising a β-secretase cleavage site; (b) measuring cleavage of the substrate polypeptide in the presence and in the absence of the putative modulator compound; and (c) identifying modulators of β-secretase activity from a difference in cleavage in the presence versus in the absence of the putative modulator compound. A modulator that is a β-secretase antagonist (inhibitor) reduces such cleavage, whereas a modulator that is a β-secretase agonist increases such cleavage. Since such assays are relevant to development of Alzheimer's disease therapeutics for humans, it will be readily apparent that, in one preferred embodiment, the first composition comprises a purified human Asp2 polypeptide. In one variation, the first composition comprises a soluble fragment of a human Asp2 polypeptide that retains Asp2 β-secretase activity. Several such fragments (including ΔTM fragments) are described herein in detail. Thus, in a particular embodiment, the soluble fragment is a fragment lacking an Asp2

20

transmembrane domain.

The β -secretase cleavage site in APP is known, and it will be appreciated that the oassays of the invention can be performed with either intact APP or fragments or analogs of APP that retain the β -secretase recognition and cleavage site. Thus, in one variation, the substrate polypeptide of the second composition comprises the amino acid sequence SEVNLDAEFR (SEQ ID NO: 63), which includes the β -secretase recognition site of human APP that contains the "Swiss" mutation. In another variation, the substrate polypeptide of the second composition comprises the amino acid sequence EVKMDAEF (SEQ ID NO: 67). In another

30

25

variation, the second composition comprises a polypeptide having an amino acid sequence of a human amyloid precursor protein (APP). For example, the human amyloid precursor protein is selected from the group consisting of: APP695, APP751, and APP770. Preferably, the human amyloid precursor protein (irrespective of isoform selected) includes at least on mutation selected from a KM-NL Swiss mutation and a V-F London mutation. As explained elsewhere, one preferred embodiment involves a variation wherein the polypeptide having an amino acid sequence of a human APP further comprises an amino acid sequence comprising a marker sequence attached amino-terminal to the amino acid sequence of the human amyloid precursor protein. Preferably, the polypeptide having an amino acid sequence of a human APP further comprises two lysine residues attached to the carboxyl terminus of the amino acid sequence of the human APP. The assays can be performed in a cell free setting, using cell-free enzyme and cell-free substrate, or can be performed in a cell-based assay wherein the second composition comprises a eukaryotic cell that expresses amyloid precursor protein (APP) or a fragment thereof containing a β-secretase cleavage site. Preferably, the APP expressed by the host cell is an APP variant that includes two carboxyl-terminal lysine residues. It will also be appreciated that the β -secretase enzyme can be an enzyme that is expressed on the surface of the same cells.

20

25

15

5

10

The present invention provides isolated nucleic acid molecules comprising a polynucleotide that codes for a polypeptide selected from the group consisting of human aspartyl proteases. In particular, human aspartyl protease 1 (Hu-Asp1) and two alternative splice variants of human aspartyl protease-2 (Hu-Asp2), a "long" (L) form designated herein as Hu-Asp2(a) and a "short" (S) form designated Hu-Asp2(b). As used herein, all references to "Hu-Asp" should be understood to refer to all of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b). In addition, as used herein, all references to "Hu-Asp2" should be understood to refer to both Hu-Asp2(a) and Hu-Asp2(b). Hu-Asp1 is expressed most abundantly in pancreas and prostate tissues, while Hu-Asp2(a) and Hu-Asp2(b) are expressed most abundantly in pancreas and brain

5

10

15

20

25

30

tissues. The invention also provides isolated Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides, as well as fragments thereof which exhibit aspartyl protease activity.

In a preferred embodiment, the nucleic acid molecules comprise a polynucleotide having a nucleotide sequence selected from the group consisting of residues 1-1554 of SEQ ID NO. 1, encoding Hu-Asp1, residues 1-1503 of SEQ ID NO. 3, encoding Hu-Asp2(a), and residues 1-1428 of SEQ ID NO.5, encoding Hu-Asp2(b). In another aspect, the invention provides an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent conditions to a polynucleotide encoding Hu-Asp1, Hu-Asp2(a), Hu-Asp-2(b), or fragments thereof. European patent application EP 0 848 062 discloses a polypeptide referred to as "Asp 1," that bears substantial homology to Hu-Asp1, while international application WO 98/22597 discloses a polypeptide referred to as "Asp 2," that bears substantial homology to Hu-Asp2(a).

The present invention also provides vectors comprising the isolated nucleic acid molecules of the invention, host cells into which such vectors have been introduced, and recombinant methods of obtaining a Hu-Asp1, Hu-Asp2(a), or Hu-Asp2(b) polypeptide comprising culturing the above-described host cell and isolating the relevant polypeptide.

In another aspect, the invention provides isolated Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides, as well as fragments thereof. In a preferred embodiment, the Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides have the amino acid sequence given in SEQ ID NO. 2, SEQ ID NO. 4, or SEQ ID NO.6, respectively. The present invention also describes active forms of Hu-Asp2, methods for preparing such active forms, methods for preparing soluble forms, methods for measuring Hu-Asp2 activity, and substrates for Hu-Asp2 cleavage. The invention also describes antisense oligomers targeting the Hu-Asp1, Hu-Asp2(a) and Hu-Asp2(b) mRNA transcripts and the use of such antisense reagents to decrease such mRNA and consequently the production of the corresponding polypeptide. Isolated antibodies, both polyclonal and monoclonal, that binds specifically to any of the Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides of the invention are also provided.

The invention also provides a method for the identification of an agent that modulates the activity of any of Hu-Asp-1, Hu-Asp2(a), and Hu-Asp2(b). The inventions

5

10

15

20

25

30

describes methods to test such agents in cell-free assays to which Hu-Asp2 polypeptide is added, as well as methods to test such agents in human or other mammalian cells in which Hu-Asp2 is present.

Additional features and variations of the invention will be apparent to those skilled in the art from the entirety of this application, including the drawing and detailed description, and all such features are intended as aspects of the invention. Likewise, features of the invention described herein can be re-combined into additional embodiments that are also intended as aspects of the invention, irrespective of whether the combination of features is specifically mentioned above as an aspect or embodiment of the invention. Also, only such limitations which are described herein as critical to the invention should be viewed as such; variations of the invention lacking limitations which have not been described herein as critical are intended as aspects of the invention.

In addition to the foregoing, the invention includes, as an additional aspect, all embodiments of the invention narrower in scope in any way than the variations specifically mentioned above. Although the applicant(s) invented the full scope of the claims appended hereto, the claims appended hereto are not intended to encompass within their scope the prior art work of others. Therefore, in the event that statutory prior art within the scope of a claim is brought to the attention of the applicants by a Patent Office or other entity or individual, the applicant(s) reserve the right to exercise amendment rights under applicable patent laws to redefine the subject matter of such a claim to specifically exclude such statutory prior art or obvious variations of statutory prior art from the scope of such a claim. Variations of the invention defined by such amended claims also are intended as aspects of the invention.

BRIEF DESCRIPTION OF THE SEQUENCE LISTING

Sequence ID No. 1: Human Asp-1, nucleotide sequence.

Sequence ID No. 2: Human Asp-1, predicted amino acid sequence.

Sequence ID No. 3: Human Asp-2(a), nucleotide sequence.

Sequence ID No. 4: Human Asp-2(a), predicted amino acid sequence. The

Asp2(a) amino acid sequence includes a putative signal peptide comprising residues 1

to 21; and a putative pre-propeptide after the signal peptide that extends through residue 45 (as assessed by processing observed of recombinant Asp2(a) in CHO cells), and a putative propeptide that may extend to at least about residue 57, based on the observation of an observed GRR+GS (SEQ ID NO: 68) sequence which has characteristics of a protease recognition sequence. The Asp2(a) further includes a transmembrane domain comprising residues 455-477, a cytoplasmic domain comprising residues 478-501, and a putative alpha-helical spacer region, comprising residues 420-454, believed to be unnecessary for proteolytic activity, between the protease catalytic domain and the transmembrane domain.

10

15

20

25

30

5

Sequence ID No. 5: Human Asp-2(b), nucleotide sequence.

Sequence ID No. 6: Human Asp-2(b), predicted amino acid sequence. The Asp2(b) amino acid sequence includes a putative signal peptide, pre-propeptide, and propeptide as described above for Asp2(a). The Asp2(b) further includes a transmembrane domain comprising residues 430-452, a cytoplasmic domain comprising residues 453-476, and a putative alpha-helical spacer region, comprising residues 395-429, believed to be unnecessary for proteolytic activity, between the protease catalytic domain and the transmembrane domain.

Sequence ID No. 7: Murine Asp-2(a), nucleotide sequence.

Sequence ID No. 8: Murine Asp-2(a), predicted amino acid sequence. The proteolytic processing of murine Asp2(a) is believed to be analogous to the processing described above for human Asp2(a). In addition, a variant lacking amino acid residues 190-214 of SEQ ID NO: 8 is specifically contemplated as a murine Asp2(b) polypeptide.

Sequence ID No. 9: Human APP695, nucleotide sequence.

Sequence ID No.10: Human APP695, predicted amino acid sequence.

Sequence ID No.11: Human APP695-Sw, nucleotide sequence.

Sequence ID No.12: Human APP695-Sw. predicted amino acid sequence. In the APP695 isoform, the Sw mutation is characterized by a KM-NL alteration at positions 595-596 (compared to normal APP695).

Sequence ID No.13: Human APP695-VF, nucleotide sequence.

Sequence ID No.14: Human APP695-VF, predicted amino acid sequence. In the APP 695 isoform, the VF mutation is characterized by a V-F alteration at position 642 (compared to normal APP 695).

Sequence ID No.15: Human APP695-KK, nucleotide sequence.

5 Sequence ID No.16: Human APP695-KK, predicted amino acid sequence. (APP695 with two carboxy-terminal lysine residues.)

Sequence ID No.17: Human APP695-Sw-KK, nucleotide sequence.

Sequence ID No.18: Human APP695-Sw-KK, predicted amino acid sequence

Sequence ID No.19: Human APP695-VF-KK, nucleotide sequence

Sequence ID No.20: Human APP695-VF-KK, predicted amino acid sequence

Sequence ID No.21: T7-Human-pro-Asp-2(a)ΔTM, nucleotide sequence

Sequence ID No.22: T7-Human-pro-Asp-2(a)ΔTM, amino acid sequence

Sequence ID No.23: T7-Caspase-Human-pro-Asp-2(a) Δ TM, nucleotide sequence

Sequence ID No.24: T7-Caspase-Human-pro-Asp-2(a)ΔTM, amino acid sequence

Sequence ID No.25: Human-pro-Asp-2(a) Δ TM (low GC), nucleotide sequence

Sequence ID No.26: Human-pro-Asp-2(a)ΔTM, (low GC), amino acid

sequence

25

10

Sequence ID No.27: T7-Caspase-Caspase 8

cleavage-Human-pro-Asp-2(a)ΔTM, nucleotide sequence

Sequence ID No.28: T7-Caspase-Caspase 8

cleavage-Human-pro-Asp-2(a) \Delta TM, amino acid sequence

Sequence ID No.29: Human Asp-2(a)ΔTM, nucleotide sequence

Sequence ID No.30: Human Asp-2(a) \(\Delta TM \), amino acid sequence

Sequence ID No.31: Human Asp-2(a) ΔTM(His), nucleotide sequence

Sequence ID No. 32: Human Asp-2(a) Δ TM(His)₆, amino acid sequence

Sequence ID Nos. 33-49 are short synthetic peptide and oligonucleotide

sequences that are described below in the Detailed Description of the Invention.

Sequence ID No. 50: Human Asp2(b)ΔTM polynucleotide sequence.

Sequence ID No. 51: Human Asp2(b)ΔTM polypeptide sequence (exemplary variant of Human Asp2(b) lacking transmembrane and intracellular domains of Hu-Asp2(b) set forth in SEQ ID NO: 6.

Sequence ID No. 52: Human Asp2(b)ΔTM(His)₆ polynucleotide sequence.

Sequence ID No. 53: Human Asp2(b) Δ TM(His)₆ polypeptide sequence (Human Asp2(b) Δ TM with six histidine tag attached to C-terminus)

5

10

15

Sequence ID No. 54: Human APP770-encoding polynucleotide sequence.

Sequence ID No. 55: Human APP770 polypeptide sequence. To introduce the KM-NL Swedish mutation, residues KM at positions 670-71 are changed to NL. To introduce the V-F London mutation, the V residue at position 717 is changed to F.

Sequence ID No. 56: Human APP751 encoding polynucleotide sequence.

Sequence ID No. 57: Human APP751 polypeptide sequence (Human APP751 isoform).

Sequence ID No. 58: Human APP770-KK encoding polynucleotide sequence.

Sequence ID No. 59: Human APP770-KK polypeptide sequence. (Human APP770 isoform to which two C-terminal lysines have been added).

Sequence ID No. 60: Human APP751-KK encoding polynucleotide sequence.

Sequence ID No. 61: Human APP751-KK polypeptide sequence (Human

APP751 isoform to which two C-terminal lysines have been added).

Sequence ID No. 62-65: Various short peptide sequences described in detail in detailed description.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1: Figure 1 shows the nucleotide (SEQ ID NO:1) and predicted amino acid sequence (SEQ ID NO:2) of human Asp1.

Figure 2: Figure 2 shows the nucleotide (SEQ ID NO:3) and predicted amino acid sequence (SEQ ID NO:4) of human Asp2(a).

Figure 3: Figure 3 shows the nucleotide (SEQ ID NO:5) and predicted amino acid sequence (SEQ ID NO:6) of human Asp2(b). The predicted transmembrane domain of Hu-Asp2(b) is enclosed in brackets.

Figure 4: Figure 4 shows the nucleotide (SEQ ID No. 7) and predicted amino acid sequence (SEQ ID No. 8) of murine Asp2(a)

5

15

20

25

30

- Figure 5: Figure 5 shows the BestFit alignment of the predicted amino acid sequences of Hu-Asp2(a) (SEQ ID NO: 4) and murine Asp2(a) (SEQ ID NO: 8).
- Figure 6: Figure 6 shows the nucleotide (SEQ ID No. 21) and predicted amino acid sequence (SEQ ID No. 22) of T7-Human-pro-Asp-2(a)ΔTM
- Figure 7: Figure 7 shows the nucleotide (SEQ ID No. 23) and predicted amino acid sequence (SEQ ID No. 24) of T7-caspase-Human-pro-Asp-2(a)ΔTM
 - Figure 8: Figure 8 shows the nucleotide (SEQ ID No. 25) and predicted amino acid sequence (SEQ ID No. 26) of Human-pro-Asp-2(a) \(\Delta TM \) (low GC)
 - Figure 9: Western blot showing reduction of CTF99 production by HEK125.3 cells transfected with antisense oligomers targeting the Hu-Asp2 mRNA.
 - Figure 10: Western blot showing increase in CTF99 production in mouse Neuro-2a cells cotransfected with APP-KK with and without Hu-Asp2 only in those cells cotransfected with Hu-Asp2. A further increase in CTF99 production is seen in cells cotransfected with APP-Sw-KK with and without Hu-Asp2 only in those cells cotransfected with Hu-Asp2
 - Figure 11: Figure 11 shows the predicted amino acid sequence (SEQ ID No. 30) of Human-Asp2(a)ΔTM
 - Figure 12: Figure 11 shows the predicted amino acid sequence (SEQ ID No. 30) of Human-Asp2(a)ΔTM(His)₆

DETAILED DESCRIPTION OF THE INVENTION

A few definitions used in this invention follow, most definitions to be used are those that would be used by one ordinarily skilled in the art.

The term " β amyloid peptide" means any peptide resulting from beta secretase cleavage of APP. This includes peptides of 39, 40, 41, 42 and 43 amino acids, extending

from the β -secretase cleavage site to 39, 40, 41, 42 and 43 amino acids C-terminal to the β -secretase cleavage site. β amyloid peptide also includes sequences 1-6, SEQ ID NOs. 1-6 of US 5,750,349, issued 12 May 1998 (incorporated into this document by reference). A β -secretase cleavage fragment disclosed here is called CTF-99, which extends from β -secretase cleavage site to the carboxy terminus of APP.

When an isoform of APP is discussed then what is meant is any APP polypeptide, including APP variants (including mutations), and APP fragments that exists in humans such as those described in US 5,766,846, col 7, lines 45-67, incorporated into this document by reference.

10

15

20

25

30

5

The term "\beta-amyloid precursor protein" (APP) as used herein is defined as a polypeptide that is encoded by a gene of the same name localized in humans on the long arm of chromosome 21 and that includes "βAP – here "β-amyloid protein" see above, within its carboxyl third. APP is a glycosylated, single-membrane spanning protein expressed in a wide variety of cells in many mammalian tissues. Examples of specific isotypes of APP which are currently known to exist in humans are the 695 amino acid polypeptide described by Kang et. al. (1987) Nature 325:733-736 which is designated as the "normal" APP (SEQ ID NOs: 9-10); the 751 amino acid polypeptide described by Ponte et al. (1988) Nature 331:525-527 (1988) and Tanzi et al. (1988) Nature 331:528-530 (SEQ ID NOs: 56-57); and the 770-amino acid polypeptide described by Kitaguchi et. al. (1988) Nature 331:530-532 (SEQ ID NOs: 54-55). Examples of specific variants of APP include point mutation which can differ in both position and phenotype (for review of known variant mutation see Hardy (1992) Nature Genet. 1:233-234). All references cited here incorporated by reference. The term "APP fragments" as used herein refers to fragments of APP other than those which consist solely of βAP or βAP fragments. That is, APP fragments will include amino acid sequences of APP in addition to those which form intact \(\beta AP \) or a fragment of BAP.

When the term "any amino acid" is used, the amino acids referred to are to be selected from the following, three letter and single letter abbreviations - which may also be used, are provided as follows:

Alanine, Ala, A; Arginine, Arg, R; Asparagine, Asn, N; Aspartic acid, Asp, D; Cysteine, Cys, C; Glutamine, Gln, Q; Glutamic Acid, Glu, E; Glycine, Gly, G; Histidine, His, H; Isoleucine, Ile, I; Leucine, Leu, L; Lysine, Lys, K; Methionine, Met, M; Phenylalanine, Phe, F; Proline, Pro, P; Serine, Ser, S; Threonine, Thr, T; Tryptophan, Trp, W; Tyrosine, Tyr, Y; Valine, Val, V; Aspartic acid or Asparagine, Asx, B; Glutamic acid or Glutamine, Glx, Z; Any amino acid, Xaa, X.

5

10

15

20

25

30

The present invention describes a method to scan gene databases for the simple active site motif characteristic of aspartyl proteases. Eukaryotic aspartyl proteases such as pepsin and renin possess a two-domain structure which folds to bring two aspartyl residues into proximity within the active site. These are embedded in the short tripeptide motif DTG, or more rarely, DSG. Most aspartyl proteases occur as proenzyme whose N-terminus must be cleaved for activation. The DTG or DSG active site motif appears at about residue 65-70 in the proenzyme (prorenin, pepsinogen), but at about residue 25-30 in the active enzyme after cleavage of the N-terminal prodomain. The limited length of the active site motif makes it difficult to search collections of short, expressed sequence tags (EST) for novel aspartyl proteases. EST sequences typically average 250 nucleotides or less, and so would encode 80-90 amino acid residues or less. That would be too short a sequence to span the two active site motifs. The preferred method is to scan databases of hypothetical or assembled protein coding sequences. The present invention describes a computer method to identify candidate aspartyl proteases in protein sequence databases. The method was used to identify seven candidate aspartyl protease sequences in the Caenorhabditis elegans genome. These sequences were then used to identify by homology search Hu-Asp1 and two alternative splice variants of Hu-Asp2, designated herein as Hu-Asp2(a) and Hu-Asp2(b).

In a major aspect of the invention disclosed here we provide new information about APP processing. Pathogeneic processing of the amyloid precursor protein (APP) via the A β pathway requires the sequential action of two proteases referred to as β -secretase and γ -secretase. Cleavage of APP by the β -secretase and γ -secretase generates the N-terminus and C-terminus of the A β peptide, respectively. Because

over production of the A β peptide, particularly the A $\beta_{1.42}$, has been implicated in the initiation of Alzheimer's disease, inhibitors of either the β -secretase and/or the γ -secretase have potential in the treatment of Alzheimer's disease. Despite the importance of the β -secretase and γ -secretase in the pathogenic processing of APP, molecular definition of these enzymes has not been accomplished to date. That is, it was not known what enzymes were required for cleavage at either the β -secretase or the γ -secretase cleavage site. The sites themselves were known because APP was known and the A $\beta_{1.42}$, peptide was known, see US 5,766,846 and US 5,837,672, (incorporated by reference, with the exception to reference to "soluble" peptides). But what enzyme was involved in producing the A $\beta_{1.42}$, peptide was unknown.

5

10

15

20

25

30

Alignment of the amino acid sequences of Hu-Asp2 with other known aspartyl proteases reveals a similar domain organization. All of the sequences contain a signal sequence followed by a pro-segment and the catalytic domain containing 2 copies of the aspartyl protease active site motif (DTG/DSG) separated by approximately 180 amino acid residues. Comparison of the processing site for proteolytic removal of the pro-segment in the mature forms of pepsin A, pepsin C, cathepsin D, cathepsin E and renin reveals that the mature forms of these enzymes contain between 31-35 amino acid residues upstream of the first DTG motif. Inspection of this region in the Hu-Asp-2 amino acid sequence indicates a preferred processing site within the sequence GRR IGS (SEQ ID NO: 68) as proteolytic processing of pro-protein precursors commonly occurs at site following dibasic amino acid pairs (eg. RR). Also, processing at this site would yield a mature enzyme with 35 amino acid residues upstream of the first DTG, consistent with the processing sites for other aspartyl proteases. In the absence of self-activation of Hu-Asp2 or a knowledge of the endogenous protease that processes Hu-Asp2 at this site, a recombinant form was engineered by introducing a recognition site for the PreSission protease (LEVLFQ+GP; SEQ ID NO: 62) into the expression plasmids for bacterial, insect cell, and mammalian cell expression of pro-Hu-Asp2. In each case, the Gly residue in P1' position corresponds to the Gly residue 35 amino acids upstream of the first DTG motif in Hu-Asp2.

The present invention involves the molecular definition of several novel human aspartyl proteases and one of these, referred to as Hu-Asp-2(a) and Hu-Asp2(b), has been characterized in detail. Previous forms of asp1 and asp 2 have been disclosed, see EP 0848062 A2 and EP 0855444A2, inventors David Powel et al., assigned to Smith Kline Beecham Corp. (incorporated by reference). Herein are disclosed old and new forms of Hu-Asp 2. For the first time they are expressed in active form, their substrates are disclosed, and their specificity is disclosed. Prior to this disclosure cell or cell extracts were required to cleave the β-secretase site, now purified protein can be used in assays, also described here. Based on the results of (1) antisense knock out experiments, (2) transient transfection knock in experiments, and (3) biochemical experiments using purified recombinant Hu-Asp-2, we demonstrate that Hu-Asp-2 is the β -secretase involved in the processing of APP. Although the nucleotide and predicted amino acid sequence of Hu-Asp-2(a) has been reported, see above, see EP 0848062 A2 and EP 0855444A2, no functional characterization of the enzyme was disclosed. Here the authors characterize the Hu-Asp-2 enzyme and are able to explain why it is a critical and essential enzyme required in the formation of $A\beta_{1,42}$, peptide and possible a critical step in the development of AD.

In another embodiment the present invention also describes a novel splice variant of Hu-Asp2, referred to as Hu-Asp-2(b), that has never before been disclosed.

20

25

5

10

15

In another embodiment, the invention provides isolated nucleic acid molecules comprising a polynucleotide encoding a polypeptide selected from the group consisting of human aspartyl protease 1 (Hu-Asp1) and two alternative splice variants of human aspartyl protease-2 (Hu-Asp2), designated herein as Hu-Asp2(a) and Hu-Asp2(b). As used herein, all references to "Hu-Asp2" should be understood to refer to both Hu-Asp2(a) and Hu-Asp2(b). Hu-Asp1 is expressed most abundantly in pancreas and prostate tissues, while Hu-Asp2(a) and Hu-Asp2(b) are expressed most abundantly in pancreas and brain tissues. The invention also provides isolated Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides, as well as fragments thereof which exhibit aspartyl protease activity.

The predicted amino acid sequences of Hu-Asp1, Hu-Asp2(a) and Hu-Asp2(b) share significant homology with previously identified mammalian aspartyl proteases such as pepsinogen A, pepsinogen B, cathepsin D, cathepsin E, and renin. P.B.Szecs, *Scand. J. Clin. Lab. Invest.* 52:(Suppl. 210 5-22 (1992)). These enzymes are characterized by the presence of a duplicated DTG/DSG sequence motif. The Hu-Asp1 and HuAsp2 polypeptides disclosed herein also exhibit extremely high homology with the ProSite consensus motif for aspartyl proteases extracted from the SwissProt database.

5

10

15

20

25

30

The nucleotide sequence given as residues 1-1554 of SEQ ID NO:1 corresponds to the nucleotide sequence encoding Hu-Asp1, the nucleotide sequence given as residues 1-1503 of SEQ ID NO:3 corresponds to the nucleotide sequence encoding Hu-Asp2(a), and the nucleotide sequence given as residues 1-1428 of SEQ ID NO:5 corresponds to the nucleotide sequence encoding Hu-Asp2(b). The isolation and sequencing of DNA encoding Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) is described below in Examples 1 and 2.

As is described in Examples 1 and 2, automated sequencing methods were used to obtain the nucleotide sequence of Hu-Asp1, Hu-Asp2(a), and Hu-Asp-2(b). The Hu-Asp nucleotide sequences of the present invention were obtained for both DNA strands, and are believed to be 100% accurate. However, as is known in the art, nucleotide sequence obtained by such automated methods may contain some errors. Nucleotide sequences determined by automation are typically at least about 90%, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of a given nucleic acid molecule. The actual sequence may be more precisely determined using manual sequencing methods, which are well known in the art. An error in sequence which results in an insertion or deletion of one or more nucleotides may result in a frame shift in translation such that the predicted amino acid sequence will differ from that which would be predicted from the actual nucleotide sequence of the nucleic acid molecule, starting at the point of the mutation. The Hu-Asp DNA of the present invention includes cDNA, chemically synthesized DNA, DNA isolated by PCR, genomic DNA, and combinations thereof. Genomic

Hu-Asp DNA may be obtained by screening a genomic library with the Hu-Asp2 cDNA described herein, using methods that are well known in the art, or with oligonucleotides chosen from the Hu-Asp2 sequence that will prime the polymerase chain reaction (PCR). RNA transcribed from Hu-Asp DNA is also encompassed by the present invention.

5

10

15

20

25

30

Due to the degeneracy of the genetic code, two DNA sequences may differ and yet encode identical amino acid sequences. The present invention thus provides isolated nucleic acid molecules having a polynucleotide sequence encoding any of the Hu-Asp polypeptides of the invention, wherein said polynucleotide sequence encodes a Hu-Asp polypeptide having the complete amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or fragments thereof.

Also provided herein are purified Hu-Asp polypeptides, both recombinant and non-recombinant. Most importantly, methods to produce Hu-Asp2 polypeptides in active form are provided. These include production of Hu-Asp2 polypeptides and variants thereof in bacterial cells, insect cells, and mammalian cells, also in forms that allow secretion of the Hu-Asp2 polypeptide from bacterial, insect or mammalian cells into the culture medium, also methods to produce variants of Hu-Asp2 polypeptide incorporating amino acid tags that facilitate subsequent purification. In a preferred embodiment of the invention the Hu-Asp2 polypeptide is converted to a proteolytically active form either in transformed cells or after purification and cleavage by a second protease in a cell-free system, such active forms of the Hu-Asp2 polypeptide beginning with the N-terminal sequence TOHGIR (SEO ID NO: 69) or ETDEEP (SEQ ID NO: 70). The sequence TQHGIR (SEQ ID NO: 69) represents the amino-terminus of Asp2(a) or Asp2(b) beginning with residue 22 of SEQ ID NO: 4 or 6, after cleavage of a putative 21 residue signal peptide. Recombinant Asp2(a) expressed in and purified from insect cells was observed to have this amino terminus, presumably as a result of cleavage by a signal peptidase. The sequence ETDEEP (SEO ID NO: 70) represents the amino-terminus of Asp2(a) or Asp2(b) beginning with residue 46 of SEQ ID NO: 4 or 6, as observed when Asp2(a) has been recombinantly produced in CHO cells (presumably after cleavage by both a rodent

signal peptidase and another rodent peptidase that removes a propertide sequence). The Asp2(a) produced in the CHO cells possesses β -secretase activity, as described in greater detail in Examples 11 and 12. Variants and derivatives, including fragments, of Hu-Asp proteins having the native amino acid sequences given in SEO ID Nos: 2, 4, and 6 that retain any of the biological activities of Hu-Asp are also within the scope of the present invention. Of course, one of ordinary skill in the art will readily be able to determine whether a variant, derivative, or fragment of a Hu-Asp protein displays Hu-Asp activity by subjecting the variant, derivative, or fragment to a standard aspartyl protease assay. Fragments of Hu-Asp within the scope of this invention include those that contain the active site domain containing the amino acid sequence DTG, fragments that contain the active site domain amino acid sequence DSG. fragments containing both the DTG and DSG active site sequences, fragments in which the spacing of the DTG and DSG active site sequences has been lengthened, fragments in which the spacing has been shortened. Also within the scope of the invention are fragments of Hu-Asp in which the transmembrane domain has been removed to allow production of Hu-Asp2 in a soluble form. In another embodiment of the invention, the two halves of Hu-Asp2, each containing a single active site DTG or DSG sequence can be produced independently as recombinant polypeptides, then combined in solution where they reconstitute an active protease.

20

5

10

15

Thus, the invention provides a purified polypeptide comprising a fragment of a mammalian Asp2 protein, wherein said fragment lacks the Asp2 transmembrane domain of said Asp2 protein, and wherein the polypeptide and the fragment retain the β -secretase activity of said mammalian Asp2 protein. In a preferred embodiment, the purified polypeptide comprises a fragment of a human Asp2 protein that retains the β -secretase activity of the human Asp2 protein from which it was derived. Examples include:

25

a purified polypeptide that comprises a fragment of Asp2(a) having the amino acid sequence set forth in SEQ ID NO: 4, wherein the polypeptide lacks transmembrane domain amino acids 455 to 477 of SEQ ID NO: 4;

a purified polypeptide as described in the preceding paragraph that further lacks cytoplasmic domain amino acids 478 to 501 of SEQ ID NO: 4;

a purified polypeptide as described in either of the preceding paragraphs that further lacks amino acids 420-454 of SEQ ID NO: 4, which constitute a putative alpha helical region between the catalytic domain and the transmembrane domain that is believed to be unnecessary for β -secretase activity;

a purified polypeptide that comprises an amino acid sequence that includes amino acids 58 to 419 of SEQ ID NO: 4, and that lacks amino acids 22 to 57 of SEQ ID NO: 4;

a purified polypeptide that comprises an amino acid sequence that includes amino acids 46 to 419 of SEQ ID NO: 4, and that lacks amino acids 22 to 45 of SEQ ID NO: 4;

a purified polypeptide that comprises an amino acid sequence that includes amino acids 22 to 454 of SEQ ID NO: 4.

a purified polypeptide that comprises a fragment of Asp2(b) having the amino acid sequence set forth in SEQ ID NO: 6, and wherein said polypeptide lacks transmembrane domain amino acids 430 to 452 of SEQ ID NO: 6;

a purified polypeptide as described in the preceding paragraph that further lacks cytoplasmic domain amino acids 453 to 476 of SEQ ID NO: 6;

a purified polypeptide as described in either of the preceding two paragraphs that further lacks amino acids 395-429 of SEQ ID NO: 4, which constitute a putative alpha helical region between the catalytic domain and the transmembrane domain that is believed to be unnecessary for β -secretase activity;

a purified polypeptide comprising an amino acid sequence that includes amino acids 58 to 394 of SEQ ID NO: 4, and that lacks amino acids 22 to 57 of SEQ ID NO: 4;

15

10

5

20

25

a purified polypeptide comprising an amino acid sequence that includes amino acids 46 to 394 of SEQ ID NO: 4, and that lacks amino acids 22 to 45 of SEQ ID NO: 4; and

a purified polypeptide comprising an amino acid sequence that includes amino acids 22 to 429 of SEQ ID NO: 4.

Also included as part of the invention is a purified polynucleotide comprising a nucleotide sequence that encodes such polypeptides; a vector comprising a polynucleotide that encodes such polypeptides; and a host cell transformed or transfected with such a polynucleotide or vector.

5

10

15

20

25

30

Hu-Asp variants may be obtained by mutation of native Hu-Asp-encoding nucleotide sequences, for example. A Hu-Asp variant, as referred to herein, is a polypeptide substantially homologous to a native Hu-Asp polypeptide but which has an amino acid sequence different from that of native Hu-Asp because of one or more deletions, insertions, or substitutions in the amino acid sequence. The variant amino acid or nucleotide sequence is preferably at least about 80% identical, more preferably at least about 90% identical, and most preferably at least about 95% identical, to a native Hu-Asp sequence. Thus, a variant nucleotide sequence which contains, for example, 5 point mutations for every one hundred nucleotides, as compared to a native Hu-Asp gene, will be 95% identical to the native protein. The percentage of sequence identity, also termed homology, between a native and a variant Hu-Asp sequence may also be determined, for example, by comparing the two sequences using any of the computer programs commonly employed for this purpose,

Alterations of the native amino acid sequence may be accomplished by any of a number of known techniques. For example, mutations may be introduced at particular locations by procedures well known to the skilled artisan, such as oligonucleotide-directed mutagenesis, which is described by Walder *et al.* (*Gene 42*:133 (1986)); Bauer *et al.* (*Gene 37*:73 (1985)); Craik (*BioTechniques*, January

such as the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix,

Genetics Computer Group, University Research Park, Madison Wisconsin), which

uses the algorithm of Smith and Waterman (Adv. Appl. Math. 2: 482-489 (1981)).

1985, pp. 12-19); Smith et al. (Genetic Engineering: Principles and Methods, Plenum Press (1981)); and U.S. Patent Nos. 4,518,584 and 4,737,462.

5

10

15

20

25

30

Hu-Asp variants within the scope of the invention may comprise conservatively substituted sequences, meaning that one or more amino acid residues of a Hu-Asp polypeptide are replaced by different residues that do not alter the secondary and/or tertiary structure of the Hu-Asp polypeptide. Such substitutions may include the replacement of an amino acid by a residue having similar physicochemical properties, such as substituting one aliphatic residue (Ile, Val, Leu or Ala) for another, or substitution between basic residues Lys and Arg, acidic residues Glu and Asp, amide residues Gln and Asn, hydroxyl residues Ser and Tyr, or aromatic residues Phe and Tyr. Further information regarding making phenotypically silent amino acid exchanges may be found in Bowie *et al.*, *Science 247*:1306-1310 (1990). Other Hu-Asp variants which might retain substantially the biological activities of Hu-Asp are those where amino acid substitutions have been made in areas outside functional regions of the protein.

In another aspect, the invention provides an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent conditions to a portion of the nucleic acid molecules described above, *e.g.*, to at least about 15 nucleotides, preferably to at least about 20 nucleotides, more preferably to at least about 30 nucleotides, and still more preferably to at least about from 30 to at least about 100 nucleotides, of one of the previously described nucleic acid molecules. Such portions of nucleic acid molecules having the described lengths refer to, *e.g.*, at least about 15 contiguous nucleotides of the reference nucleic acid molecule. By stringent hybridization conditions is intended overnight incubation at about 42°C for about 2.5 hours in 6 X SSC/0.1% SDS, followed by washing of the filters four times for 15 minutes in 1.0 X SSC at 65°C, 0.1% SDS.

Fragments of the Hu-Asp encoding nucleic acid molecules described herein, as well as polynucleotides capable of hybridizing to such nucleic acid molecules may be used as a probe or as primers in a polymerase chain reaction (PCR). Such probes may be used, e.g., to detect the presence of Hu-Asp nucleic acids in *in vitro* assays, as well

as in Southern and northern blots. Cell types expressing Hu-Asp may also be identified by the use of such probes. Such procedures are well known, and the skilled artisan will be able to choose a probe of a length suitable to the particular application. For PCR, 5' and 3' primers corresponding to the termini of a desired Hu-Asp nucleic acid molecule are employed to isolate and amplify that sequence using conventional techniques.

Other useful fragments of the Hu-Asp nucleic acid molecules are antisense or sense oligonucleotides comprising a single stranded nucleic acid sequence capable of binding to a target Hu-Asp mRNA (using a sense strand), or Hu-Asp DNA (using an antisense strand) sequence. In a preferred embodiment of the invention these Hu-Asp antisense oligonucleotides reduce Hu-Asp mRNA and consequent production of Hu-Asp polypeptides.

In another aspect, the invention includes Hu-Asp polypeptides with or without associated native pattern glycosylation. Both Hu-Asp1 and Hu-Asp2 have canonical acceptor sites for Asn-linked sugars, with Hu-Asp1 having two of such sites, and Hu-Asp2 having four. Hu-Asp expressed in yeast or mammalian expression systems (discussed below) may be similar to or significantly different from a native Hu-Asp polypeptide in molecular weight and glycosylation pattern. Expression of Hu-Asp in bacterial expression systems will provide non-glycosylated Hu-Asp.

20

25

5

10

15

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. Hu-Asp polypeptides may be recovered and purified from tissues, cultured cells, or recombinant cell cultures by well-known methods, including ammonium sulfate or ethanol precipitation, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, and high performance liquid chromatography (HPLC). In a preferred embodiment, an amino acid tag is added to the Hu-Asp polypeptide using genetic engineering techniques that are well known to practitioners of the art which include addition of six histidine amino acid residues to allow purification by binding to nickel immobilized on a suitable support, epitopes for

30

polyclonal or monoclonal antibodies including but not limited to the T7 epitope, the myc epitope, and the V5a epitope, and fusion of Hu-Asp2 to suitable protein partners including but not limited to glutathione-S-transferase or maltose binding protein. In a preferred embodiment these additional amino acid sequences are added to the C-terminus of Hu-Asp but may be added to the N-terminus or at intervening positions within the Hu-Asp2 polypeptide.

5

10

15

20

25

30

The present invention also relates to vectors comprising the polynucleotide molecules of the invention, as well as host cell transformed with such vectors. Any of the polynucleotide molecules of the invention may be joined to a vector, which generally includes a selectable marker and an origin of replication, for propagation in a host. Because the invention also provides Hu-Asp polypeptides expressed from the polynucleotide molecules described above, vectors for the expression of Hu-Asp are preferred. The vectors include DNA encoding any of the Hu-Asp polypeptides described above or below, operably linked to suitable transcriptional or translational regulatory sequences, such as those derived from a mammalian, microbial, viral, or insect gene. Examples of regulatory sequences include transcriptional promoters, operators, or enhancers, mRNA ribosomal binding sites, and appropriate sequences which control transcription and translation. Nucleotide sequences are operably linked when the regulatory sequence functionally relates to the DNA encoding Hu-Asp. Thus, a promoter nucleotide sequence is operably linked to a Hu-Asp DNA sequence if the promoter nucleotide sequence directs the transcription of the Hu-Asp sequence.

Selection of suitable vectors to be used for the cloning of polynucleotide molecules encoding Hu-Asp, or for the expression of Hu-Asp polypeptides, will of course depend upon the host cell in which the vector will be transformed, and, where applicable, the host cell from which the Hu-Asp polypeptide is to be expressed. Suitable host cells for expression of Hu-Asp polypeptides include prokaryotes, yeast, and higher eukaryotic cells, each of which is discussed below.

The Hu-Asp polypeptides to be expressed in such host cells may also be fusion proteins which include regions from heterologous proteins. Such regions may be included to allow, *e.g.*, secretion, improved stability, or facilitated purification of the

polypeptide. For example, a sequence encoding an appropriate signal peptide can be incorporated into expression vectors. A DNA sequence for a signal peptide (secretory leader) may be fused inframe to the Hu-Asp sequence so that Hu-Asp is translated as a fusion protein comprising the signal peptide. A signal peptide that is functional in the intended host cell promotes extracellular secretion of the Hu-Asp polypeptide. Preferably, the signal sequence will be cleaved from the Hu-Asp polypeptide upon secretion of Hu-Asp from the cell. Nonlimiting examples of signal sequences that can be used in practicing the invention include the yeast Ifactor and the honeybee melatin leader in sf9 insect cells.

10

15

5

In a preferred embodiment, the Hu-Asp polypeptide will be a fusion protein which includes a heterologous region used to facilitate purification of the polypeptide. Many of the available peptides used for such a function allow selective binding of the fusion protein to a binding partner. For example, the Hu-Asp polypeptide may be modified to comprise a peptide to form a fusion protein which specifically binds to a binding partner, or peptide tag. Nonlimiting examples of such peptide tags include the 6-His tag, thioredoxin tag, hemaglutinin tag, GST tag, and OmpA signal sequence tag. As will be understood by one of skill in the art, the binding partner which recognizes and binds to the peptide may be any molecule or compound including metal ions (e.g., metal affinity columns), antibodies, or fragments thereof, and any protein or peptide which binds the peptide, such as the FLAG tag.

20

25

30

Suitable host cells for expression of Hu-Asp polypeptides includes prokaryotes, yeast, and higher eukaryotic cells. Suitable prokaryotic hosts to be used for the expression of Hu-Asp include bacteria of the genera *Escherichia, Bacillus, and Salmonella*, as well as members of the genera *Pseudomonas, Streptomyces*, and *Staphylococcus*. For expression in, *e.g., E. coli*, a Hu-Asp polypeptide may include an N-terminal methionine residue to facilitate expression of the recombinant polypeptide in a prokaryotic host. The N-terminal Met may optionally then be cleaved from the expressed Hu-Asp polypeptide. Other N-terminal amino acid residues can be added to the Hu-Asp polypeptide to facilitate expression in Escherichia coli including but not limited to the T7 leader sequence, the T7-caspase 8

leader sequence, as well as others leaders including tags for purification such as the 6-His tag (Example 9). Hu-Asp polypeptides expressed in E. coli may be shortened by removal of the cytoplasmic tail, the transmembrane domain, or the membrane proximal region. Hu-Asp polypeptides expressed in E. coli may be obtained in either a soluble form or as an insoluble form which may or may not be present as an inclusion body. The insoluble polypeptide may be rendered soluble by guanidine HCl, urea or other protein denaturants, then refolded into a soluble form before or after purification by dilution or dialysis into a suitable aqueous buffer. If the inactive proform of the Hu-Asp was produced using recombinant methods, it may be rendered active by cleaving off the prosegment with a second suitable protease such as human immunodeficiency virus protease.

5

10

15

20

25

Expression vectors for use in prokaryotic hosts generally comprises one or more phenotypic selectable marker genes. Such genes generally encode, *e.g.*, a protein that confers antibiotic resistance or that supplies an auxotrophic requirement. A wide variety of such vectors are readily available from commercial sources. Examples include pSPORT vectors, pGEM vectors (Promega), pPROEX vectors (LTI, Bethesda, MD), Bluescript vectors (Stratagene), pET vectors (Novagen) and pQE vectors (Qiagen).

Hu-Asp may also be expressed in yeast host cells from genera including Saccharomyces, Pichia, and Kluveromyces. Preferred yeast hosts are S. cerevisiae and P. pastoris. Yeast vectors will often contain an origin of replication sequence from a 2T yeast plasmid, an autonomously replicating sequence (ARS), a promoter region, sequences for polyadenylation, sequences for transcription termination, and a selectable marker gene. Vectors replicable in both yeast and E. coli (termed shuttle vectors) may also be used. In addition to the above-mentioned features of yeast vectors, a shuttle vector will also include sequences for replication and selection in E. coli. Direct secretion of Hu-Asp polypeptides expressed in yeast hosts may be accomplished by the inclusion of nucleotide sequence encoding the yeast I-factor leader sequence at the 5' end of the Hu-Asp-encoding nucleotide sequence.

Insect host cell culture systems may also be used for the expression of Hu-Asp polypeptides. In a preferred embodiment, the Hu-Asp polypeptides of the invention are expressed using an insect cell expression system (*see* Example 10). Additionally, a baculovirus expression system can be used for expression in insect cells as reviewed by Luckow and Summers, *Bio/Technology* 6:47 (1988).

5

10

15

20

25

30

In another preferred embodiment, the Hu-Asp polypeptide is expressed in mammalian host cells. Nonlimiting examples of suitable mammalian cell lines include the COS7 line of monkey kidney cells (Gluzman *et al.*, *Cell* 23:175 (1981)), human embyonic kidney cell line 293, and Chinese hamster ovary (CHO) cells. Preferably, Chinese hamster ovary (CHO) cells are used for expression of Hu-Asp proteins (Example 11).

The choice of a suitable expression vector for expression of the Hu-Asp polypeptides of the invention will of course depend upon the specific mammalian host cell to be used, and is within the skill of the ordinary artisan. Examples of suitable expression vectors include pcDNA3 (Invitrogen) and pSVL (Pharmacia Biotech). A preferred vector for expression of Hu-Asp polypeptides is pcDNA3.1-Hygro (Invitrogen). Expression vectors for use in mammalian host cells may include transcriptional and translational control sequences derived from viral genomes. Commonly used promoter sequences and enhancer sequences which may be used in the present invention include, but are not limited to, those derived from human cytomegalovirus (CMV), Adenovirus 2, Polyoma virus, and Simian virus 40 (SV40). Methods for the construction of mammalian expression vectors are disclosed, for example, in Okayama and Berg (Mol. Cell. Biol. 3:280 (1983)); Cosman et al. (Mol. Immunol. 23:935 (1986)); Cosman et al. (Nature 312:768 (1984)); EP-A-0367566; and WO 91/18982.

The polypeptides of the present invention may also be used to raise polyclonal and monoclonal antibodies, which are useful in diagnostic assays for detecting Hu-Asp polypeptide expression. Such antibodies may be prepared by conventional techniques. See, for example, *Antibodies: A Laboratory Manual*, Harlow and Land (eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1988);

Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses, Kennet et al. (eds.), Plenum Press, New York (1980). Synthetic peptides comprising portions of Hu-Asp containing 5 to 20 amino acids may also be used for the production of polyclonal or monoclonal antibodies after linkage to a suitable carrier protein including but not limited to keyhole limpet hemacyanin (KLH), chicken ovalbumin, or bovine serum albumin using various cross-linking reagents including carbodimides, glutaraldehyde, or if the peptide contains a cysteine,

N-methylmaleimide. A preferred peptide for immunization when conjugated to KLH contains the C-terminus of Hu-Asp1 or Hu-Asp2 comprising

QRRPRDPEVVNDESSLVRHRWK (SEQ ID NO: 2, residues 497-518) or

LRQQHDDFADDISLLK (SEQ ID NO:4, residues 486-501), respectively. See SEQ

5

10

15

20

25

30

ID Nos. 33-34.

The Hu-Asp nucleic acid molecules of the present invention are also valuable for chromosome identification, as they can hybridize with a specific location on a human chromosome. Hu-Asp1 has been localized to chromosome 21, while Hu-Asp2 has been localized to chromosome 11q23.3-24.1. There is a current need for identifying particular sites on the chromosome, as few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for marking chromosomal location. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. The relationship between genes and diseases that have been mapped to the same chromosomal region can then be identified through linkage analysis, wherein the coinheritance of physically adjacent genes is determined. Whether a gene appearing to be related to a particular disease is in fact the cause of the disease can then be determined by comparing the nucleic acid sequence between affected and unaffected individuals.

In another embodiment, the invention relates to a method of assaying Hu-Asp function, specifically Hu-Asp2 function which involves incubating in solution the Hu-Asp polypeptide with a suitable substrate including but not limited to a synthetic peptide containing the β -secretase cleavage site of APP, preferably one containing the

5

10

15

20

25

30

mutation found in a Swedish kindred with inherited AD in which KM is changed to NL, such peptide comprising the sequence SEVNLDAEFR (SEQ ID NO: 63) in an acidic buffering solution, preferably an acidic buffering solution of pH5.5 (see Example 12) using cleavage of the peptide monitored by high performance liquid chromatography as a measure of Hu-Asp proteolytic activity. Preferred assays for proteolytic activity utilize internally quenched peptide assay substrates. Such suitable substrates include peptides which have attached a paired flurophore and quencher including but not limited to 7-amino-4-methyl coumarin and dinitrophenol. respectively, such that cleavage of the peptide by the Hu-Asp results in increased fluorescence due to physical separation of the flurophore and quencher. Other paired flurophores and quenchers include bodipy-tetramethylrhodamine and QSY-5 (Molecular Probes, Inc.). In a variant of this assay, biotin or another suitable tag may be placed on one end of the peptide to anchor the peptide to a substrate assay plate and a flurophore may be placed at the other end of the peptide. Useful flurophores include those listed above as well as Europium labels such as W8044 (EG&g Wallac, Inc.). Cleavage of the peptide by Asp2 will release the flurophore or other tag from the plate, allowing compounds to be assayed for inhibition of Asp2 proteolytic cleavage as shown by an increase in retained fluorescence. Preferred colorimetric assays of Hu-Asp proteolytic activity utilize other suitable substrates that include the P2 and P1 amino acids comprising the recognition site for cleavage linked to o-nitrophenol through an amide linkage, such that cleavage by the Hu-Asp results in an increase in optical density after altering the assay buffer to alkaline pH.

In another embodiment, the invention relates to a method for the identification of an agent that increases the activity of a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b), the method comprising

- (a) determining the activity of said Hu-Asp polypeptide in the presence of a test agent and in the absence of a test agent; and
- (b) comparing the activity of said Hu-Asp polypeptide determined in the presence of said test agent to the activity of said Hu-Asp polypeptide determined in the absence of said test agent;

whereby a higher level of activity in the presence of said test agent than in the absence of said test agent indicates that said test agent has increased the activity of said Hu-Asp polypeptide. Such tests can be performed with Hu-Asp polypeptide in a cell free system and with cultured cells that express Hu-Asp as well as variants or isoforms thereof.

5

10

15

20

25

30

In another embodiment, the invention relates to a method for the identification of an agent that decreases the activity of a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b), the method comprising

- (a) determining the activity of said Hu-Asp polypeptide in the presence of a test agent and in the absence of a test agent; and
- (b) comparing the activity of said Hu-Asp polypeptide determined in the presence of said test agent to the activity of said Hu-Asp polypeptide determined in the absence of said test agent;

whereby a lower level of activity in the presence of said test agent than in the absence of said test agent indicates that said test agent has decreased the activity of said Hu-Asp polypeptide. Such tests can be performed with Hu-Asp polypeptide in a cell free system and with cultured cells that express Hu-Asp as well as variants or isoforms thereof.

In another embodiment, the invention relates to a novel cell line (HEK125.3 cells) for measuring processing of amyloid β peptide (A β) from the amyloid protein precursor (APP). The cells are stable transformants of human embryonic kidney 293 cells (HEK293) with a bicistronic vector derived from pIRES-EGFP (Clontech) containing a modified human APP cDNA, an internal ribosome entry site and an enhanced green fluorescent protein (EGFP) cDNA in the second cistron. The APP cDNA was modified by adding two lysine codons to the carboxyl terminus of the APP coding sequence. This increases processing of A β peptide from human APP by 2-4 fold. This level of A β peptide processing is 60 fold higher than is seen in nontransformed HEK293 cells. HEK125.3 cells will be useful for assays of compounds that inhibit A β peptide processing. This invention also includes addition of two lysine residues to the C-terminus of other APP isoforms including the 751 and

770 amino acid isoforms, to isoforms of APP having mutations found in human AD including the Swedish KM-NL and V717-F mutations, to C-terminal fragments of APP, such as those beginning with the β -secretase cleavage site, to C-terminal fragments of APP containing the β -secretase cleavage site which have been operably linked to an N-terminal signal peptide for membrane insertion and secretion, and to C-terminal fragments of APP which have been operably linked to an N-terminal signal peptide for membrane insertion and a reporter sequence including but not limited to green fluorescent protein or alkaline phosphatase, such that β -secretase cleavage releases the reporter protein from the surface of cells expressing the polypeptide.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

15

5

10

Example 1

Development of a Search Algorithm Useful for the Identification of Aspartyl Proteases, and Identification of C. elegans Aspartyl Protease Genes in Wormpep 12

Materials and Methods:

Classical aspartyl proteases such as pepsin and renin possess a two-domain structure which folds to bring two aspartyl residues into proximity within the active site. These are embedded in the short tripeptide motif DTG, or more rarely, DSG. The DTG or DSG active site motif appears at about residue 25-30 in the enzyme, but at about 65-70 in the proenzyme (prorenin, pepsinogen). This motif appears again about 150-200 residues downstream. The proenzyme is activated by cleavage of the N-terminal prodomain. This pattern exemplifies the double domain structure of the modern day aspartyl enzymes which apparently arose by gene duplication and divergence. Thus;

 NH_2 -----Y----- $D^{Y+25}TG$ ------C

where X denotes the beginning of the enzyme, following the N-terminal prodomain, and Y denotes the center of the molecule where the gene repeat begins again.

In the case of the retroviral enzymes such as the HIV protease, they represent only a half of the two-domain structures of well-known enzymes like pepsin, cathepsin D, renin, etc. They have no prosegment, but are carved out of a polyprotein precursor containing the *gag* and *pol* proteins of the virus. They can be represented by:

5

10

15

20

This "monomer" only has about 100 aa, so is extremely parsimonious as compared to the other aspartyl protease "dimers" which have of the order of 330 or so aa, not counting the N-terminal prodomain.

The limited length of the eukaryotic aspartyl protease active site motif makes it difficult to search EST collections for novel sequences. EST sequences typically average 250 nucleotides, and so in this case would be unlikely to span both aspartyl protease active site motifs. Instead, we turned to the *C. elegans* genome. The *C. elegans* genome is estimated to contain around 13,000 genes. Of these, roughly 12,000 have been sequenced and the corresponding hypothetical open reading frame (ORF) has been placed in the database Wormpep12. We used this database as the basis for a whole genome scan of a higher eukaryote for novel aspartyl proteases, using an algorithm that we developed specifically for this purpose. The following AWK script for locating proteins containing two DTG or DSG motifs was used for the search, which was repeated four times to recover all pairwise combinations of the aspartyl motif.

```
BEGIN{RS=">"} /* defines ">" as record separator for FASTA format */

{
    pos = index($0,"DTG") /*finds "DTG" in record*/

25 if (pos>0) {
        rest = substr($0,pos+3) /*get rest of record after first DTG*/
        pos2 = index(rest,"DTG") /*find second DTG*/
        if (pos2>0) printf ("%s%s\n",">",$0)} /*report hits*/

}
30 }
```

The AWK script shown above was used to search Wormpep12, which was downloaded from ftp.sanger.ac.uk/pub/databases/wormpep, for sequence entries

containing at least two DTG or DSG motifs. Using AWK limited each record to 3000 characters or less. Thus, 35 or so larger records were eliminated manually from Wormpep12 as in any case these were unlikely to encode aspartyl proteases.

Results and Discussion:

5

The Wormpep 12 database contains 12,178 entries, although some of these (<10%) represent alternatively spliced transcripts from the same gene. Estimates of the number of genes encoded in the *C. elegans* genome is on the order of 13,000 genes, so Wormpep12 may be estimated to cover greater than 90% of the *C. elegans* genome.

10

15

Eukaryotic aspartyl proteases contain a two-domain structure, probably arising from ancestral gene duplication. Each domain contains the active site motif D(S/T)G located from 20-25 amino acid residues into each domain. The retroviral (e.g., HIV protease) or retrotransposon proteases are homodimers of subunits which are homologous to a single eukaryotic aspartyl protease domain. An AWK script was used to search the Wormpep12 database for proteins in which the D(S/T)G motif occurred at least twice. This identified >60 proteins with two DTG or DSG motifs. Visual inspection was used to select proteins in which the position of the aspartyl domains was suggestive of a two-domain structure meeting the criteria described above.

20

25

In addition, the PROSITE eukaryotic and viral aspartyl protease active site pattern PS00141 was used to search Wormpep12 for candidate aspartyl proteases. (Bairoch A., Bucher P., Hofmann K., The PROSITE database: its status in 1997, *Nucleic Acids Res. 24*:217-221(1997)). This generated an overlapping set of Wormpep12 sequences. Of these, seven sequences contained two DTG or DSG motifs and the PROSITE aspartyl protease active site pattern. Of these seven, three were found in the same cosmid clone (F21F8.3, F21F8.4, and F21F8.7) suggesting that they represent a family of proteins that arose by ancestral gene duplication. Two other ORFs with extensive homology to F21F8.3, F21F8.4 and F21F8.7 are present in the same gene cluster (F21F8.2 and F21F8.6), however, these contain only a single DTG motif. Exhaustive BLAST searches with these seven sequences against

Wormpep12 failed to reveal additional candidate aspartyl proteases in the *C. elegans* genome containing two repeats of the DTG or DSG motif.

BLASTX search with each *C. elegans* sequence against SWISS-PROT, GenPep and TREMBL revealed that R12H7.2 was the closest worm homologue to the known mammalian aspartyl proteases, and that T18H9.2 was somewhat more distantly related, while CEASP1, F21F8.3, F21F8.4, and F21F8.7 formed a subcluster which had the least sequence homology to the mammalian sequences.

Discussion:

5

10

15

20

25

30

APP, the presentilins, and p35, the activator of cdk5, all undergo intracellular proteolytic processing at sites which conform to the substrate specificity of the HIV protease. Dysregulation of a cellular aspartyl protease with the same substrate specificity, might therefore provide a unifying mechanism for causation of the plaque and tangle pathologies in AD. Therefore, we sought to identify novel human aspartyl proteases. A whole genome scan in *C. elegans* identified seven open reading frames that adhere to the aspartyl protease profile that we had identified. These seven aspartyl proteases probably comprise the complete complement of such proteases in a simple, multicellular eukaryote. These include four closely related aspartyl proteases unique to *C. elegans* which probably arose by duplication of an ancestral gene. The other three candidate aspartyl proteases (T18H9.2, R12H7.2 and C11D2.2) were found to have homology to mammalian gene sequences.

Example 2

Identification of Novel Human Aspartyl Proteases Using Database Mining by Genome Bridging

Materials and Methods:

Exhaustive homology searches of EST databases with the CEASP1, F21F8.3, F21F8.4, and F21F8.7 sequences failed to reveal any novel mammalian homologues. TBLASTN searches with R12H7.2 showed homology to cathepsin D, cathepsin E,

pepsinogen A, pepsinogen C and renin, particularly around the DTG motif within the active site, but also failed to identify any additional novel mammalian aspartyl proteases. This indicates that the *C. elegans* genome probably contains only a single lysosomal aspartyl protease which in mammals is represented by a gene family that arose through duplication and consequent modification of an ancestral gene.

TBLASTN searches with T18H9.2, the remaining *C. elegans* sequence, identified several ESTs which assembled into a contig encoding a novel human aspartyl protease (Hu-ASP1). As is described above in Example 1, BLASTX search with the Hu-ASP1 contig against SWISS-PROT revealed that the active site motifs in the sequence aligned with the active sites of other aspartyl proteases. Exhaustive, repetitive rounds of BLASTN searches against LifeSeq, LifeSeqFL, and the public EST collections identified 102 EST from multiple cDNA libraries that assembled into a single contig. The 51 sequences in this contig found in public EST collections also have been assembled into a single contig (THC213329) by The Institute for Genome Research (TIGR). The TIGR annotation indicates that they failed to find any hits in the database for the contig. Note that the TIGR contig is the reverse complement of the LifeSeq contig that we assembled. BLASTN search of Hu-ASP1 against the rat and mouse EST sequences in ZooSeq revealed one homologous EST in each database (Incyte clone 700311523 and IMAGE clone 313341, GenBank accession number W10530, respectively).

TBLASTN searches with the assembled DNA sequence for Hu-ASP1 against both LifeSeqFL and the public EST databases identified a second, related human sequence (Hu-Asp2) represented by a single EST (2696295). Translation of this partial cDNA sequence reveals a single DTG motif which has homology to the active site motif of a bovine aspartyl protease, NM1.

BLAST searches, contig assemblies and multiple sequence alignments were performed using the bioinformatics tools provided with the LifeSeq, LifeSeqFL and LifeSeq Assembled databases from Incyte. Predicted protein motifs were identified using either the ProSite dictionary (Motifs in GCG 9) or the Pfam database.

25

5

10

15

Full-length cDNA cloning of Hu-Asp1

5

10

15

20

30

The open reading frame of *C. elegans* gene T18H9.2CE was used to query Incyte LifeSeq and LifeSeq-FL databases and a single electronic assembly referred to as 1863920CE1 was detected. The 5' most cDNA clone in this contig, 1863920, was obtained from Incyte and completely sequenced on both strands. Translation of the open reading frame contained within clone 1863920 revealed the presence of the duplicated aspartyl protease active site motif (DTG/DSG) but the 5' end was incomplete. The remainder of the Hu-Asp1 coding sequence was determined by 5' Marathon RACE analysis using a human placenta Marathon ready cDNA template (Clontech). A 3'-antisense oligonucleotide primer specific for the 5' end of clone 1863920 was paired with the 5'-sense primer specific for the Marathon ready cDNA synthetic adaptor in the PCR. Specific PCR products were directly sequenced by cycle sequencing and the resulting sequence assembled with the sequence of clone 1863920 to yield the complete coding sequence of Hu-Asp-1 (SEQ ID No. 1).

Several interesting features are present in the primary amino acid sequence of Hu-Asp1 (Figure 1, SEQ ID No. 2). The sequence contains a signal peptide (residues 1-20 in SEQ ID No. 2), a pro-segment, and a catalytic domain containing two copies of the aspartyl protease active site motif (DTG/DSG). The spacing between the first and second active site motifs is about 200 residues which should correspond to the expected size of a single, eukaryotic aspartyl protease domain. More interestingly, the sequence contains a predicted transmembrane domain (residues 469-492 in SEQ ID No.2) near its C-terminus which suggests that the protease is anchored in the membrane. This feature is not found in any other aspartyl protease.

25 Cloning of a full-length Hu-Asp-2 cDNAs:

As is described above in Example 1, genome wide scan of the *Caenorhabditis elegans* database WormPep12 for putative aspartyl proteases and subsequent mining of human EST databases revealed a human ortholog to the *C. elegans* gene T18H9.2 referred to as Hu-Asp1. The assembled contig for Hu-Asp1 was used to query for human paralogs using the BLAST search tool in human EST databases and a single

5

10

15

20

25

30

significant match (2696295CE1) with approximately 60% shared identity was found in the LifeSeq FL database. Similar queries of either gb105PubEST or the family of human databases available from TIGR did not identify similar EST clones. cDNA clone 2696295, identified by single pass sequence analysis from a human uterus cDNA library, was obtained from Incyte and completely sequence on both strands. This clone contained an incomplete 1266 bp open-reading frame that encoded a 422 amino acid polypeptide but lacked an initiator ATG on the 5' end. Inspection of the predicted sequence revealed the presence of the duplicated aspartyl protease active site motif DTG/DSG, separated by 194 amino acid residues. Subsequent queries of later releases of the LifeSeq EST database identified an additional ESTs, sequenced from a human astrocyte cDNA library (4386993), that appeared to contain additional 5' sequence relative to clone 2696295. Clone 4386993 was obtained from Incyte and completely sequenced on both strands. Comparative analysis of clone 4386993 and clone 2696295 confirmed that clone 4386993 extended the open-reading frame by 31 amino acid residues including two in-frame translation initiation codons. Despite the presence of the two in-frame ATGs, no in-frame stop codon was observed upstream of the ATG indicating that the 4386993 may not be full-length. Furthermore, alignment of the sequences of clones 2696295 and 4386993 revealed a 75 base pair insertion in clone 2696295 relative to clone 4386993 that results in the insertion of 25 additional amino acid residues in 2696295. The remainder of the Hu-Asp2 coding sequence was determined by 5' Marathon RACE analysis using a human hippocampus Marathon ready cDNA template (Clontech). A 3'-antisense oligonucleotide primer specific for the shared 5'-region of clones 2696295 and 4386993 was paired with the 5'-sense primer specific for the Marathon ready cDNA synthetic adaptor in the PCR. Specific PCR products were directly sequenced by cycle sequencing and the resulting sequence assembled with the sequence of clones 2696295 and 4386993 to yield the complete coding sequence of Hu-Asp2(a) (SEQ ID No. 3) and Hu-Asp2(b) (SEQ ID No. 5), respectively.

Several interesting features are present in the primary amino acid sequence of Hu-Asp2(a) (Figure 2 and SEQ ID No. 4) and Hu-Asp-2(b) (Figure 3, SEQ ID No. 6).

Both sequences contain a signal peptide (residues 1-21 in SEQ ID No. 4 and SEQ ID No. 6), a pro-segment, and a catalytic domain containing two copies of the aspartyl protease active site motif (DTG/DSG). The spacing between the first and second active site motifs is variable due to the 25 amino acid residue deletion in Hu-Asp-2(b) and consists of 168-*versus*-194 amino acid residues, for Hu-Asp2(b) and Hu-Asp-2(a), respectively. More interestingly, both sequences contains a predicted transmembrane domain (residues 455-477 in SEQ ID No.4 and 430-452 in SEQ ID No. 6) near their C-termini which indicates that the protease is anchored in the membrane. This feature is not found in any other aspartyl protease except Hu-Asp1.

10

15

5

Example 3

Molecular cloning of mouse Asp2 cDNA and genomic DNA.

Cloning and characterization of murine Asp2 cDNA.

The murine ortholog of Hu-Asp2 was cloned using a combination of cDNA library screening, PCR, and genomic cloning. Approximately 500,000 independent clones from a mouse brain cDNA library were screened using a ³²P-labeled coding sequence probe prepared from Hu-Asp2. Replicate positives were subjected to DNA sequence analysis and the longest cDNA contained the entire 3' untranslated region and 47 amino acids in the coding region. PCR amplification of the same mouse brain cDNA library with an antisense oligonucleotide primer specific for the 5'-most cDNA sequence determined above and a sense primer specific for the 5' region of human Asp2 sequence followed by DNA sequence analysis gave an additional 980 bp of the coding sequence. The remainder of the 5' sequence of murine Asp-2 was derived from genomic sequence (see below).

25

30

20

Isolation and sequence analysis of the murine Asp-2 gene.

A murine EST sequence encoding a portion of the murine Asp2 cDNA was identified in the GenBank EST database using the BLAST search tool and the Hu-Asp2 coding sequence as the query. Clone g3160898 displayed 88% shared identity to the human sequence over 352 bp. Oligonucleotide primer pairs specific for

this region of murine Asp2 were then synthesized and used to amplify regions of the murine gene. Murine genomic DNA, derived from strain 129/SvJ, was amplified in the PCR (25 cycles) using various primer sets specific for murine Asp2 and the products analyzed by agarose gel electrophoresis. The primer set Zoo-1 and Zoo-4 amplified a 750 bp fragment that contained approximately 600 bp of intron sequence based on comparison to the known cDNA sequence. This primer set was then used to screen a murine BAC library by PCR, a single genomic clone was isolated and this cloned was confirmed contain the murine Asp2 gene by DNA sequence analysis. Shotgun DNA sequencing of this Asp2 genomic clone and comparison to the cDNA sequences of both Hu-Asp2 and the partial murine cDNA sequences defined the full-length sequence of murine Asp2 (SEQ ID No. 7). The predicted amino acid sequence of murine Asp2 (SEQ ID No. 8) showed 96.4% shared identity (GCG BestFit algorithm) with 18/501 amino acid residue substitutions compared to the human sequence (Figure 4). The proteolytic processing of murine Asp2(a) is believed to be analogous to the processing described above for human Asp2(a). In addition, a variant lacking amino acid residues 190-214 of SEQ ID NO: 8 is specifically contemplated as a murine Asp2(b) polypeptide. All forms of murine Asp2(b) gene and protein are intended as aspects of the invention.

20 Example 4

Tissue Distribution of Expression of Hu-Asp2 Transcripts

Materials and Methods:

5

10

15

25

30

The tissue distribution of expression of Hu-Asp-2 was determined using multiple tissue Northern blots obtained from Clontech (Palo Alto, CA). Incyte clone 2696295 in the vector pINCY was digested to completion with EcoRI/NotI and the 1.8 kb cDNA insert purified by preparative agarose gel electrophoresis. This fragment was radiolabeled to a specific activity > 1 X 10⁹ dpm/µg by random priming in the presence of [α -³²P-dATP] (>3000 Ci/mmol, Amersham, Arlington Heights, IL) and Klenow fragment of DNA polymerase I. Nylon filters containing denatured, size fractionated poly A⁺ RNAs isolated from different human tissues were hybridized

with 2 x 10⁶ dpm/ml probe in ExpressHyb buffer (Clontech, Palo Alto, CA) for 1 hour at 68 °C and washed as recommended by the manufacture. Hybridization signals were visualized by autoradiography using BioMax XR film (Kodak, Rochester, NY) with intensifying screens at -80 °C.

5

10

15

20

Results and Discussion:

Limited information on the tissue distribution of expression of Hu-Asp-2 transcripts was obtained from database analysis due to the relatively small number of ESTs detected using the methods described above (< 5). In an effort to gain further information on the expression of the Hu-Asp2 gene, Northern analysis was employed to determine both the size(s) and abundance of Hu-Asp2 transcripts. PolyA⁺ RNAs isolated from a series of peripheral tissues and brain regions were displayed on a solid support following separation under denaturing conditions and Hu-Asp2 transcripts were visualized by high stringency hybridization to radiolabeled insert from clone 2696295. The 2696295 cDNA probe visualized a constellation of transcripts that migrated with apparent sizes of 3.0kb, 4.4 kb and 8.0 kb with the latter two transcript being the most abundant.

Across the tissues surveyed, Hu-Asp2 transcripts were most abundant in pancreas and brain with lower but detectable levels observed in all other tissues examined except thymus and PBLs. Given the relative abundance of Hu-Asp2 transcripts in brain, the regional expression in brain regions was also established. A similar constellation of transcript sizes were detected in all brain regions examined [cerebellum, cerebral cortex, occipital pole, frontal lobe, temporal lobe and putamen] with the highest abundance in the medulla and spinal cord.

25

30

Example 5

Northern Blot Detection of HuAsp-1 and HuAsp-2 Transcripts in Human Cell Lines

A variety of human cell lines were tested for their ability to produce Hu-Asp1 and Asp2 mRNA. Human embryonic kidney (HEK-293) cells, African green monkey (Cos-7) cells, Chinese hamster ovary (CHO) cells, HELA cells, and the

neuroblastoma cell line IMR-32 were all obtained from the ATCC. Cells were cultured in DME containing 10% FCS except CHO cells which were maintained in α-MEM/10% FCS at 37 °C in 5% CO₂ until they were near confluence. Washed monolayers of cells (3 X 10⁷) were lysed on the dishes and poly A⁺ RNA extracted using the Qiagen Oligotex Direct mRNA kit. Samples containing 2 μg of poly A⁺ RNA from each cell line were fractionated under denaturing conditions (glyoxal-treated), transferred to a solid nylon membrane support by capillary action, and transcripts visualized by hybridization with random-primed labeled (³²P) coding sequence probes derived from either Hu-Asp1 or Hu-Asp2. Radioactive signals were detected by exposure to X-ray film and by image analysis with a PhosphorImager.

5

10

15

20

25

The Hu-Asp1 cDNA probe visualized a similar constellation of transcripts (2.6 kb and 3.5 kb) that were previously detected is human tissues. The relative abundance determined by quantification of the radioactive signal was Cos-7 > HEK 292 = HELA > IMR32.

The Hu-Asp2 cDNA probe also visualized a similar constellation of transcripts compared to tissue (3.0 kb, 4.4 kb, and 8.0 kb) with the following relative abundance; HEK 293 > Cos 7 > IMR32 > HELA.

Example 6

Modification of APP to increase $A\beta$ processing for in vitro screening

Human cell lines that process $A\beta$ peptide from APP provide a means to screen in cellular assays for inhibitors of β - and γ -secretase. Production and release of $A\beta$ peptide into the culture supernatant is monitored by an enzyme-linked immunosorbent assay (EIA). Although expression of APP is widespread and both neural and non-neuronal cell lines process and release $A\beta$ peptide, levels of endogenous APP processing are low and difficult to detect by EIA. $A\beta$ processing can be increased by expressing in transformed cell lines mutations of APP that enhance $A\beta$ processing. We made the serendipitous observation that addition of two lysine residues to the carboxyl terminus of APP695 increases $A\beta$ processing still further. This allowed us

to create a transformed cell line that releases $A\beta$ peptide into the culture medium at the remarkable level of 20,000 pg/ml.

Materials And Methods

Materials:

5

10

30

Human embryonic kidney cell line 293 (HEK293 cells) were obtained internally. The vector pIRES-EGFP was purchased from Clontech. Oligonucleotides for mutation using the polymerase chain reaction (PCR) were purchased from Genosys. A plasmid containing human APP695 (SEQ ID No. 9 [nucleotide] and SEQ ID No. 10 [amino acid]) was obtained from Northwestern University Medical School. This was subcloned into pSK (Stratagene) at the *Not*1 site creating the plasmid pAPP695.

The Swedish mutation (K670N, M671L) was introduced into pAPP695 using

Mutagenesis protocol:

the Stratagene Quick Change Mutagenesis Kit to create the plasmid pAPP695NL 15 (SEQ ID No. 11 [nucleotide] and SEQ ID No. 12 [amino acid]). To introduce a di-lysine motif at the C-terminus of APP695, the forward primer #276 5' GACTGACCACTCGACCAGGTTC (SEQ ID No. 47) was used with the "patch" primer #274 5' CGAATTAAATTCCAGCACACTGGCTACTTCTTGTTCTGCATCTCAAAGAAC 20 (SEQ ID No. 48) and the flanking primer #275 CGAATTAAATTCCAGCACACTGGCTA (SEQ ID No. 49) to modify the 3' end of the APP695 cDNA (SEQ ID No. 15 [nucleotide] and SEQ ID No. 16 [amino acid]). This also added a BstX1 restriction site that will be compatible with the BstX1 site in the multiple cloning site of pIRES-EGFP. PCR amplification was performed with a 25 Clontech HF Advantage cDNA PCR kit using the polymerase mix and buffers supplied by the manufacturer. For "patch" PCR, the patch primer was used at 1/20th the molar concentration of the flanking primers. PCR amplification products were purified using a QIAquick PCR purification kit (Qiagen). After digestion with restriction enzymes, products were separated on 0.8% agarose gels and then excised

DNA fragments were purified using a OIAquick gel extraction kit (Qiagen).

To reassemble a modified APP695-Sw cDNA, the 5' Not1-Bgl2 fragment of the APP695-Sw cDNA and the 3' Bgl2-BstX1 APP695 cDNA fragment obtained by PCR were ligated into pIRES-EGFP plasmid DNA opened at the Not1 and BstX1 sites. Ligations were performed for 5 minutes at room temperature using a Rapid DNA Ligation kit (Boehringer Mannheim) and transformed into Library Efficiency DH5a Competent Cells (GibcoBRL Life Technologies). Bacterial colonies were screened for inserts by PCR amplification using primers #276 and #275. Plasmid DNA was purified for mammalian cell transfection using a QIAprep Spin Miniprep kit (Qiagen). The construct obtained was designated pMG125.3 (APPSW-KK, SEQ ID No. 17 [nucleotide] and SEQ ID No. 18 [amino acid]).

Mammalian Cell Transfection:

5

10

15

20

25

30

HEK293 cells for transfection were grown to 80% confluence in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum. Cotransfections were performed using LipofectAmine (Gibco-BRL) with 3 μg pMG125.3 DNA and 9 μg pcDNA3.1 DNA per 10 x 10⁶ cells. Three days posttransfection, cells were passaged into medium containing G418 at a concentration of 400 μg/ml. After three days growth in selective medium, cells were sorted by their fluorescence. Clonal Selection of 125.3 cells by FACS:

Cell samples were analyzed on an EPICS Elite ESP flow cytometer (Coulter, Hialeah, FL) equipped with a 488 nm excitation line supplied by an air-cooled argon laser. EGFP emission was measured through a 525 nm band-pass filter and fluorescence intensity was displayed on a 4-decade log scale after gating on viable cells as determined by forward and right angle light scatter. Single green cells were separated into each well of one 96 well plate containing growth medium without G418. After a four day recovery period, G418 was added to the medium to a final concentration of 400 µg/ml. After selection, 32% of the wells contained expanding clones. Wells with clones were expanded from the 96 well plate to a 24 well plate and then a 6 well plate with the fastest growing colonies chosen for expansion at each passage. The final cell line selected was the fastest growing of the final six passaged. This clone, designated 125.3, has been maintained in G418 at 400 ug/ml with passage

every four days into fresh medium. No loss of $A\beta$ production of EGFP fluorescence has been seen over 23 passages.

 $A\beta$ EIA Analysis (Double Antibody Sandwich ELISA for $hA\beta$ 1-40/42):

5

10

15

20

25

30

Cell culture supernatants harvested 48 hours after transfection were analyzed in a standard Aß EIA as follows. Human Aß 1-40 or 1-42 was measured using monoclonal antibody (mAb) 6E10 (Senetek, St. Louis, MO) and biotinylated rabbit antiserum 162 or 164 (New York State Institute for Basic Research, Staten Island, NY) in a double antibody sandwich ELISA. The capture antibody 6E10 is specific to an epitope present on the N-terminal amino acid residues 1-16 of hAβ. The conjugated detecting antibodies 162 and 164 are specific for hAß 1-40 and 1-42, respectively. Briefly, a Nunc Maxisorp 96 well immunoplate was coated with 100 μl/well of mAb 6E10 (5μg/ml) diluted in 0.1M carbonate-bicarbonate buffer, pH 9.6 and incubated at 4°C overnight. After washing the plate 3x with 0.01M DPBS (Modified Dulbecco's Phosphate Buffered Saline (0.008M sodium phosphate, 0.002M potassium phosphate, 0.14M sodium chloride, 0.01 M potassium chloride, pH 7.4) from Pierce, Rockford, II) containing 0.05% of Tween-20 (DPBST), the plate was blocked for 60 minutes with 200 µl of 10% normal sheep serum (Sigma) in 0.01M DPBS to avoid non-specific binding. Human A\beta 1-40 or 1-42 standards 100 \mul/well (Bachem, Torrance, CA) diluted, from a 1mg/ml stock solution in DMSO, in culture medium was added after washing the plate, as well as 100 μl/well of sample, e.g., conditioned medium of transfected cells.

The plate was incubated for 2 hours at room temperature and 4°C overnight. The next day, after washing the plate, 100 μl/well biotinylated rabbit antiserum 162 1:400 or 164 1:50 diluted in DPBST + 0.5% BSA was added and incubated at room temperature for 1hour, 15 minutes. Following washes, 100 μl/well neutravidin-horseradish peroxidase (Pierce, Rockford, II) diluted 1:10,000 in DPBST was applied and incubated for 1 hour at room temperature. After the last washes 100 μl/well of o-phenylnediamine dihydrochloride (Sigma Chemicals, St. Louis, MO) in 50mM citric acid/100mM sodium phosphate buffer (Sigma Chemicals, St. Louis, MO), pH 5.0, was added as substrate and the color development was monitored at

450nm in a kinetic microplate reader for 20 minutes using Soft max Pro software. All standards and samples were run in triplicates. The samples with absorbance values falling within the standard curve were extrapolated from the standard curves using Soft max Pro software and expressed in pg/ml culture medium.

5 Results:

Addition of two lysine residues to the carboxyl terminus of APP695 greatly increases Aβ processing in HEK293 cells as shown by transient expression (Table 1). Addition of the di-lysine motif to APP695 increases Aβ processing to that seen with the APP695 containing the Swedish mutation. Combining the di-lysine motif with the Swedish mutation further increases processing by an additional 2.8 fold.

Cotransformation of HEK293 cells with pMG125.3 and pcDNA3.1 allowed dual selection of transformed cells for G418 resistance and high level expression of EGFP. After clonal selection by FACS, the cell line obtained, produces a remarkable 20,000 pg A β peptide per ml of culture medium after growth for 36 hours in 24 well plates. Production of A β peptide under various growth conditions is summarized in Table 2.

20

10

15

25

TABLE 1

Release of Aβ peptide into the culture medium 48 hours after transient transfection of HEK293 cells with the indicated vectors containing wildtype or modified APP. Values tabulated are mean + SD and P-value for pairwise comparison using Student's t-test assuming unequal variances.

APP Construct	Aβ 1-40 peptide (pg/ml)	Fold Increase	P-valı
pIRES-EGFP vector	147 + 28	1.0	
wt APP695 (142.3)	194 + 15	1.3	0.051
wt APP695-KK (124.1)	424 + 34	2.8	3 x 10
APP695-Sw (143.3)	457 + 65	3.1	2 x 10
APP695-SwKK (125.3)	1308 + 98	8.9	3 x 10

TABLE 2
Release of Aβ peptide from HEK125.3 cells under various growth conditions.

5	Type of Culture	Volume of	Duration of	Αβ 1-40	Αβ 1-42
,	Plate	Medium	Culture	(pg/ml)	(pg/ml)
·	24 well plate	400 ul	36 hr	28,036	1,439

10

Example 7

Antisense oligomer inhibition of Abeta processing in HEK125.3 cells

15

The sequences of Hu-Asp1 and Hu-Asp2 were provided to Sequitur, Inc (Natick, MA) for selection of targeted sequences and design of 2nd generation chimeric antisense oligomers using prorietary technology (Sequitur Ver. D Pat pending #3002). Antisense oligomers Lot# S644, S645, S646 and S647 were targeted against Asp1. Antisense oligomers Lot# S648, S649, S650 and S651 were targeted against Asp2. Control antisense oligomers Lot# S652, S653, S655, and S674 were targeted against an irrelevant gene and antisense oligomers Lot #S656, S657, S658, and S659 were targeted against a second irrelevant gene.

20

For transfection with the antisense oligomers, HEK125.3 cells were grown to about 50% confluence in 6 well plates in Minimal Essential Medium (MEM) supplemented with 10% fetal calf serum. A stock solution of oligofectin G (Sequitur Inc., Natick, MA) at 2 mg/ml was diluted to 50 µg/ml in serum free MEM. Separately, the antisense oligomer stock solution at 100 µM was diluted to 800 nM in Opti-MEM (GIBCO-BRL, Grand Island, NY). The diluted stocks of oligofectin G and antisense oligomer were then mixed at a ratio of 1:1 and incubated at room temperature. After 15 minutes incubation, the reagent was diluted 10 fold into MEM

30

25

containing 10% fetal calf serum and 2 ml was added to each well of the 6 well plate after first removing the old medium. After transfection, cells were grown in the continual presence of the oligofectin G/antisense oligomer. To monitor A β peptide release, 400 μ l of conditioned medium was removed periodically from the culture well and replaced with fresh medium beginning 24 hours after transfection. A β peptides in the conditioned medium were assayed via immunoprecipitation and Western blotting. Data reported are from culture supernatants harvested 48 hours after transfection.

5

10

15

The 16 different antisense oligomers obtained from Sequitur Inc. were transfected separately into HEK125.3 cells to determine their affect on A β peptide processing. Only antisense oligomers targeted against Asp2 significantly reduced Abeta processing by HEK125.3 cells. Both A β (1-40) and A β (1-42) were inhibited by the same degree. In Table 3, percent inhibition is calculated with respect to untransfected cells. Antisense oligomer reagents giving greater than 50% inhibition are marked with an asterisk. For ASP2, 4 of 4 antisense oligomers gave greater than 50% inhibition with an average inhibition of 62% for A β 1-40 processing and 60% for A β 1-42 processing.

 $\label{eq:TABLE 3} \textbf{Inhibition of } A\beta \text{ peptide release from HEK125.3 cells treated with antisense} \\$ oligomers.

5	Gene Targeted	Antisense Oligomer	Abeta (1-40)	Abeta (1-42)
	Asp2-1	S648	71%*	67%*
10	Asp2-2	S649	83%*	76%*
	Asp2-3	S650	46%*	50%*
	Asp2-4	S651	47%*	46%*
15	Con1-1	S652	13%	18%
	Con1-2	S653	35%	30%
20	Con1-3	S655	9%	18%
	Con1-4	S674	29%	18%
	Con2-1	S656	12%	18%
25	Con2-2	S657	16%	19%
	Con2-3	S658	8%	35%
30	Con2-4	S659	3%	18%

Since HEK293 cells derive from kidney, the experiment was extended to human IMR-32 neuroblastoma cells which express all three APP isoforms and which release Aβ peptides into conditioned medium at measurable levels. [See Neill *et al.*,

J. NeuroSci. Res., (1994) 39: 482-93; and Asami-Odaka et al., Biochem., (1995) 34:10272-8.] Essentially identical results were obtained in the neuroblastoma cells as the HEK293 cells. As shown in Table 3B, the pair of Asp2 antisense oligomers reduced Asp2 mRNA by roughly one-half, while the pair of reverse control oligomers lacked this effect (Table 3B).

Table 3B

Reduction of A β 40 and A β 42 in human neuroblastoma IMR-32 cells and mouse neuroblastoma Neuro-2A cells treated with Asp2 antisense and control oligomers as indicated. Oligomers were transfected in quadruplicate cultures. Values tabulated are normalized against cultures treated with oligofectin- G^{TM} only (mean + SD, ** p<0.001 compared to reverse control oligomer).

		IMR-32 cells		Neuro-2A cells		
	Asp2 mRNA	Αβ40	Αβ42	Αβ40	Αβ42	
Asp2-1A	-75%	-49 + 2%**	-42 + 14%**	-70 + 7%**	-67 + 2%**	
Asp2-1R	0.16	-0 + 3%	21.26	-9 + 15%	1.05	
Asp2-2A	-39%	-43 + 3%**	-44 +18%**	-61 +12%**	-61 +12%**	
Asp2-2R	0.47	12.2	19.22	6.15	-8 + 10%	

20

25

5

10

15

Together with the reduction in Asp2 mRNA there was a concomitant reduction in the release of Aβ40 and Aβ42 peptides into the conditioned medium. Thus, Asp2 functions directly or indirectly in a human kidney and a human neuroblastoma cell line to facilitate the processing of APP into Aβ peptides. Molecular cloning of the mouse Asp2 cDNA revealed a high degree of homology to human (>96% amino acid identity, see Example 3), and indeed, complete nucleotide identity at the sites targeted by the Asp2-1A and Asp2-2A antisense oligomers. Similar results were obtained in mouse Neuro-2a cells engineered to express APP-Sw-KK. The Asp2 antisense

oligomers reduced release of $A\beta$ peptides into the medium while the reverse control oligomers did not (Table 3B). Thus, the three antisense experiments with HEK293, IMR-32 and Neuro-2a cells indicate that Asp2 acts directly or indirectly to facilitate $A\beta$ processing in both somatic and neural cell lines.

5

10

15

Example 8

Demonstration of Hu-Asp2 β-Secretase Activity in Cultured Cells

Several mutations in APP associated with early onset Alzheimer's disease have been shown to alter A β peptide processing. These flank the – and C-terminal cleavage sites that release A β from APP. These cleavage sites are referred to as the β -secretase and γ -secretase cleavage sites, respectively. Cleavage of APP at the β -secretase site creates a C-terminal fragment of APP containing 99 amino acids of 11,145 daltons molecular weight. The Swedish KM-NL mutation immediately upstream of the β -secretase cleavage site causes a general increase in production of both the 1-40 and 1-42 amino acid forms of A β peptide. The London VF mutation (V717-F in the APP770 isoform) has little effect on total A β peptide production, but appears to preferentially increase the percentage of the longer 1-42 amino acid form of A β peptide by affecting the choice of β -secretase cleavage site used during APP processing. Thus, we sought to determine if these mutations altered the amount and type of A β peptide produced by cultured cells cotransfected with a construct directing expression of Hu-Asp2.

25

20

Two experiments were performed which demonstrate Hu-Asp2 β -secretase activity in cultured cells. In the first experiment, treatment of HEK125.3 cells with antisense oligomers directed against Hu-Asp2 transcripts as described in Example 7 was found to decrease the amount of the C-terminal fragment of APP created by β -secretase cleavage (CTF99) (Figure 9). This shows that Hu-Asp2 acts directly or indirectly to facilitate β -secretase cleavage. In the second experiment, increased expression of Hu-Asp2 in transfected mouse Neuro2A cells is shown to increase accumulation of the CTF99 β -secretase cleavage fragment (Figure 10). This increase is seen most easily when a mutant APP-KK clone containing a C-terminal di-lysine

motif is used for transfection. A further increase is seen when Hu-Asp2 is cotransfected with APP-Sw-KK containing the Swedish mutation KM ¬NL. The Swedish mutation is known to increase cleavage of APP by the β-secretase.

A second set of experiments demonstrate Hu-Asp2 facilitates γ -secretase activity in cotransfection experiments with human embryonic kidney HEK293 cells. Cotransfection of Hu-Asp2 with an APP-KK clone greatly increases production and release of soluble A β 1-40 and A β 1-42 peptides from HEK293 cells. There is a proportionately greater increase in the release of A β 1-42. A further increase in production of A β 1-42 is seen when Hu-Asp2 is cotransfected with APP-VF (SEQ ID No. 13 [nucleotide] and SEQ ID No. 14 [amino acid]) or APP-VF-KK SEQ ID No. 19 [nucleotide] and SEQ ID No. 20 [amino acid]) clones containing the London mutation V717-F. The V717-F mutation is known to alter cleavage specificity of the APP γ -secretase such that the preference for cleavage at the A β 42 site is increased. Thus, Asp2 acts directly or indirectly to facilitate γ -secretase processing of APP at the β 42 cleavage site.

Materials

5

10

15

20

25

Antibodies 6E10 and 4G8 were purchased from Senetek (St. Louis, MO). Antibody 369 was obtained from the laboratory of Paul Greengard at the Rockefeller University. Antibody C8 was obtained from the laboratory of Dennis Selkoe at the Harvard Medical School and Brigham and Women's Hospital.

APP Constructs used

The APP constructs used for transfection experiments comprised the following APP: wild-type APP695 (SEQ ID No. 9 and No. 10)

APP-Sw: APP695 containing the Swedish KM¬NL mutation (SEQ ID No. 11 and No. 12, wherein the lysine (K) at residue 595 of APP695 is changed to asparagine (N) and the methionine (M) at residue 596 of APP695 is changed to leucine (L).),

APP-VF: APP695 containing the London V→F mutation (SEQ ID Nos. 13 & 14) (Affected residue 717 of the APP770 isoform corresponds with residue 642 of the

APP695 isoform. Thus, APP-VF as set in SEQ ID NO: 14 comprises the APP695 sequence, wherein the valine (V) at residue 642 is changed to phenylalanine (F).)

APP-KK: APP695 containing a C-terminal KK motif (SEQ ID Nos. 15 & 16), APP-Sw-KK: APP695-Sw containing a C-terminal KK motif (SEQ ID No. 17 & 18),

APP-VF-KK: APP695-VF containing a C-terminal KK motif (SEQ ID Nos. 19 & 20).

5

10

15

20

25

30

These were inserted into the vector pIRES-EGFP (Clontech, Palo Alto CA) between the *Not*1 and *BstX*1 sites using appropriate linker sequences introduced by PCR.

Transfection of antisense oligomers or plasmid DNA constructs in HEK293 cells, HEK125.3 cells and Neuro-2A cells,

Human embryonic kidney HEK293 cells and mouse Neuro-2a cells were transfected with expression constructs using the Lipofectamine Plus reagent from Gibco/BRL. Cells were seeded in 24 well tissue culture plates to a density of 70-80% confluence. Four wells per plate were transfected with 2 μ g DNA (3:1, APP:cotransfectant), 8 μ l Plus reagent, and 4 μ l Lipofectamine in OptiMEM. OptiMEM was added to a total volume of 1 ml, distributed 200 μ l per well and incubated 3 hours. Care was taken to hold constant the ratios of the two plasmids used for cotransfection as well as the total amount of DNA used in the transfection. The transfection media was replaced with DMEM, 10%FBS, NaPyruvate, with antibiotic/antimycotic and the cells were incubated under normal conditions (37°C, 5% CO₂) for 48 hours. The conditioned media were removed to polypropylene tubes and stored at -80°C until assayed for the content of A β 1-40 and A β 1-42 by EIA as described in the preceding examples. Transfection of antisense oligomers into HEK125.3 cells was as described in Example 7.

Preparation of cell extracts, Western blot protocol

Cells were harvested after being transfected with plasmid DNA for about 60 hours. First, cells were transferred to 15-ml conical tube from the plate and

centrifuged at 1,500 rpm for 5 minutes to remove the medium. The cell pellets were washed once with PBS. We then lysed the cells with lysis buffer (10 mM HEPES, pH 7.9, 150 mM NaCl, 10% glycerol, 1 mM EGTA, 1 mM EDTA, 0.1 mM sodium vanadate and 1% NP-40). The lysed cell mixtures were centrifuged at 5000 rpm and the supernatant was stored at -20°C as the cell extracts. Equal amounts of extracts from HEK125.3 cells transfected with the Asp2 antisense oligomers and controls were precipitated with antibody 369 that recognizes the C-terminus of APP and then CTF99 was detected in the immunoprecipitate with antibody 6E10. The experiment was repeated using C8, a second precipitating antibody that also recognizes the C-terminus of APP. For Western blot of extracts from mouse Neuro-2a cells cotransfected with Hu-Asp2 and APP-KK, APP-Sw-KK, APP-VF-KK or APP-VF, equal amounts of cell extracts were electrophoresed through 4-10% or 10-20% Tricine gradient gels (NOVEX, San Diego, CA). Full length APP and the CTF99 β-secretase product were detected with antibody 6E10.

15 Results

5

10

20

25

30

Transfection of HEK125.3 cells with Asp2-1 or Asp2-2 antisense oligomers reduces production of the CTF β-secretase product in comparison to cells similarly transfected with control oligomers having the reverse sequence (Asp2-1 reverse & Asp2-2 reverse), see Figure 9. Correspondingly, cotransfection of Hu-Asp2 into mouse Neuro-2a cells with the APP-KK construct increased the formation of CTF99. (See Fig. 10.) This was further increased if Hu-Asp2 was coexpressed with APP-Sw-KK, a mutant form of APP containing the Swedish KM-NL mutation that increases β-secretase processing.

Effects of Asp2 on the production of Ab peptides from endogenously expressed APP isoforms were assessed in HEK293 cells transfected with a construct expressing Asp2 or with the empty vector after selection of transformants with the antibiotic G418. A β 40 production was increased in cells transformed with the Asp2 construct in comparison to those transformed with the empty vector DNA. A β 40 levels in conditioned medium collected from the Asp2 transformed and control cultures was 424 ± 45 pg/ml and 113 ± 58 pg/ml, respectively (p<0.001). A β 42

release was below the limit of detection by the EIA, while the release of sAPP α was unaffected, 112 ± 8 ng/ml versus 111 ± 40 ng/ml. This further indicates that Asp2 acts directly or indirectly to facilitate the processing and release of A β from endogenously expressed APP.

5

Co-transfection of Hu-Asp2 with APP has little effect on A β 40 production but increases A β 42 production above background (Table 4). Addition of the di-lysine motif to the C-terminus of APP increases A β peptide processing about two fold, although A β 40 and A β 42 production remain quite low (352 pg/ml and 21 pg/ml, respectively). Cotransfection of Asp2 with APP-KK further increases both A β 40 and A β 42 production.

10

15

The APP V717 \rightarrow F mutation has been shown to increase γ -secretase processing at the A β 42 cleavage site. Cotransfection of Hu-Asp2 with the APP-VF or APP-VF-KK constructs increased A β 42 production (a two fold increase with APP-VF and a four-fold increase with APP-VF-KK, Table 4), but had mixed effects on A β 40 production (a slight decrease with APP-VF, and a two fold increase with APP-VF-KK in comparison to the pcDNA cotransfection control. Thus, the effect of Asp2 on A β 42 production was proportionately greater leading to an increase in the ratio of A β 42/total Ab. Indeed, the ratio of A β 42/total A β reaches a very high value of 42% in HEK293 cells cotransfected with Hu-Asp2 and APP-VF-KK.

20

25

Table 4

Results of cotransfecting Hu-Asp2 or pcDNA plasmid DNA with various APP constructs containing the V717→F mutation that modifies γ-secretase processing.

Cotransfection with Asp2 consistently increases the ratio of Aβ42/total Aβ. Values tabulated are Aβ peptide pg/ml.

		pcDNA		Asp2		
		Cotransfection		Cotransfection		
	Αβ40	Αβ42	Aβ42/Tot al	Αβ40	Αβ42	Aβ42
1.00	100.1			100 10		
APP	192 <u>+</u> 1 8	<4	<2%	188 <u>+</u> 40	8 <u>+</u> 10	3.9
APP-VF	118 <u>+</u> 1	15 <u>+</u> 19	11.5%	85 <u>+</u> 7	24 <u>+</u> 12	22.4
APP-KK	352 <u>+</u> 2 4	21 <u>+</u> 6	5.5%	1062 <u>+</u> 101	226 <u>+</u> 4 9	17.5
APP-VF-K K	230 <u>+</u> 3	88 <u>+</u> 24	27.7%	491 <u>+</u> 35	355 <u>+</u> 3	42%

Example 9

Bacterial expression of human Asp2(a)

Expression of recombinant Hu-Asp2(a) in E. coli.

Hu-Asp2(a) can be expressed in *E. coli* after addition of N-terminal sequences such as a T7 tag (SEQ ID No. 21 and No. 22) or a T7 tag followed by a caspase 8 leader sequence (SEQ ID No. 23 and No. 24). Alternatively, reduction of the GC content of the 5' sequence by site directed mutagenesis can be used to increase the yield of Hu-Asp2 (SEQ ID No. 25 and No. 26). In addition, Asp2(a) can be engineered with a proteolytic cleavage site (SEQ ID No. 27 and No. 28). To produce a soluble protein after expression and refolding, deletion of the transmembrane domain and cytoplasmic tail, or deletion of the membrane proximal region, transmembrane domain, and cytoplasmic tail is preferred. Any materials (vectors, host cells, etc.) and methods described herein to express Hu-Asp2(a) should in principle be equally effective for expression of Hu-Asp2(b).

15 Methods

5

10

PCR with primers containing appropriate linker sequences was used to assemble fusions of Asp2(a) coding sequence with N-terminal sequence modifications including a T7 tag (SEQ ID Nos. 21 and 22) or a T7-caspase 8 leader (SEQ ID Nos. 23 and 24). These constructs were cloned into the expression vector pet23a(+) [Novagen] in which a T7 promoter directs expression of a T7 tag preceding a 20 sequence of multiple cloning sites. To clone Hu-Asp2 sequences behind the T7 leader of pet23a+, the following oligonucleotides were used for amplification of the selected Hu-Asp2(a) sequence: #553=GTGGATCCACCCAGCACGGCATCCGGCTG (SEQ ID No. 35), #554=GAAAGCTTTCATGACTCATCTGTCTGTGGAATGTTG (SEQ 25 ID No. 36) which placed BamHI and HindIII sites flanking the 5' and 3' ends of the insert, respectively. The Asp2(a) sequence was amplified from the full length Asp2(a) cDNA cloned into pcDNA3.1 using the Advantage-GC cDNA PCR [Clontech] following the manufacturer's supplied protocol using annealing & extension at 68°C in a two-step PCR cycle for 25 cycles. The insert and vector were cut with BamHI and 30 HindIII, purified by electrophoresis through an agarose gel, then ligated using the

Rapid DNA Ligation kit [Boerhinger Mannheim]. The ligation reaction was used to transform the *E. coli* strain JM109 (Promega) and colonies were picked for the purification of plasmid (Qiagen,Qiaprep minispin) and DNA sequence analysis. For inducible expression using induction with isopropyl b-D-thiogalactopyranoside (IPTG), the expression vector was transferred into *E. coli* strain BL21 (Statagene). Bacterial cultures were grown in LB broth in the presence of ampicillin at 100 ug/ml, and induced in log phase growth at an OD600 of 0.6-1.0 with 1 mM IPTG for 4 hour at 37°C. The cell pellet was harvested by centrifugation.

5

20

25

Nos. 23 and 24), the construct created above containing the T7-Hu-Asp2 sequence (SEQ ID Nos. 21 and 22) was opened at the BamH1 site, and then the phosphorylated caspase 8 leader oligonucleotides

#559=GATCGATGACTATCTCTGACTCTCCGCGTGAACAGGACG (SEQ ID No. 37), #560=GATCCGTCCTGTTCACGCGGAGAGTCAGAGATAGTCATC (SEQ ID No. 38) were annealed and ligated to the vector DNA. The 5' overhang for each set of oligonucleotides was designed such that it allowed ligation into the BamHI site but not subsequent digestion with BamHI. The ligation reaction was transformed into

In order to reduce the GC content of the 5' terminus of asp2(a), a pair of antiparallel oligos were designed to change degenerate codon bases in 15 amino acid positions from G/C to A/T (SEQ ID Nos. 25 and 26). The new nucleotide sequence at the 5' end of asp2 did not change the encoded amino acid and was chosen to optimize *E. Coli* expression. The sequence of the sense linker is 5'

JM109 as above for analysis of protein expression after transfer to E. coli strain BL21.

CGGCATCCGGCTGCCCCTGCGTAGCGGTCTGGGTGGTGCTCCACTGGGTCT GCGTCTGCCCCGGGAGACCGACGAA G 3' (SEQ ID No. 39). The sequence of the antisense linker is: 5'

CTTCGTCGGTCTCCCGGGGCAGACGCAGACCCAGTGGAGCACCACCAGA CCGCTACGCAGGGCAGCCGGATGCCG 3' (SEQ ID No. 40). After annealing the phosphorylated linkers together in 0.1 M NaCl-10 mM Tris, pH 7.4 they were

30 ligated into unique Cla I and Sma I sites in Hu-Asp2 in the vector pTAC. For

inducible expression using induction with isopropyl b-D-thiogalactopyranoside (IPTG), bacterial cultures were grown in LB broth in the presence of ampicillin at 100 ug/ml, and induced in log phase growth at an OD600 of 0.6-1.0 with 1 mM IPTG for 4 hour at 37°C. The cell pellet was harvested by centrifugation.

5

To create a vector in which the leader sequences can be removed by limited proteolysis with caspase 8 such that this liberates a Hu-Asp2 polypeptide beginning with the N-terminal sequence GSFV (SEQ ID Nos. 27 and 28), the following procedure was followed. Two phosphorylated oligonucleotides containing the caspase 8 cleavage site IETD, #571=5'

10

GATCGATGACTATCTCTGACTCTCCGCTGGACTCTGGTATCGAAACCGACG (SEQ ID No. 41) and #572=

GATCCGTCGGTTTCGATACCAGAGTCCAGCGGAGAGTCAGAGATAGTCAT C (SEQ ID No. 42) were annealed and ligated into pET23a+ that had been opened with BamHI. After transformation into JM109, the purified vector DNA was recovered and orientation of the insert was confirmed by DNA sequence analysis.

15

20

25

The following oligonucleotides were used for amplification of the selected Hu-Asp2(a) sequence: #573=5'AAGGATCCTTTGTGGAGATGGTGGACAACCTG, (SEQ ID No. 43) #554=GAAAGCTTTCATGACTCATCTGTCTGTGGAATGTTG (SEQ ID No. 44) which placed BamHI and HindIII sites flanking the 5' and 3' ends of the insert, respectively. The Hu-Asp2(a) sequence was amplified from the full length Hu-Asp2(a) cDNA cloned into pcDNA3.1 using the Advantage-GC cDNA PCR [Clontech] following the manufacturer's supplied protocol using annealing & extension at 68°C in a two-step PCR cycle for 25 cycles. The insert and vector were cut with BamHI and HindIII, purified by electrophoresis through an agarose gel, then ligated using the Rapid DNA Ligation kit [Boerhinger Mannheim]. The ligation reaction was used to transform the *E. coli* strain JM109 [Promega] and colonies were picked for the purification of plasmid (Qiagen,Qiaprep minispin) and DNA sequence analysis. For inducible expression using induction with isopropyl b-D-thiogalactopyranoside (IPTG), the expression vector was transferred into *E. coli* strain BL21 (Statagene). Bacterial cultures were grown in LB broth in the presence of

ampicillin at 100 ug/ml, and induced in log phase growth at an OD600 of 0.6-1.0 with 1 mM IPTG for 4 hour at 37°C. The cell pellet was harvested by centrifugation.

To assist purification, a 6-His tag can be introduced into any of the above constructs following the T7 leader by opening the construct at the BamHI site and then ligating in the annealed, phosphorylated oligonucleotides containing the six histidine sequence #565=GATCGCATCATCACCATCACCATG (SEQ ID No. 45), #566=GATCCATGGTGATGGTGATGATGC (SEQ ID No. 46). The 5' overhang for each set of oligonucleotides was designed such that it allowed ligation into the BamHI site but not subsequent digestion with BamHI.

Preparation of Bacterial Pellet:

5

10

15

20

25

36.34g of bacterial pellet representing 10.8L of growth was dispersed into a total volume of 200ml using a 20mm tissue homogenizer probe at 3000 to 5000 rpm in 2M KCl, 0.1M Tris, 0.05M EDTA, 1mM DTT. The conductivity adjusted to about 193mMhos with water. After the pellet was dispersed, an additional amount of the KCl solution was added, bringing the total volume to 500 ml. This suspension was homogenized further for about 3 minutes at 5000 rpm using the same probe. The mixture was then passed through a Rannie high-pressure homogenizer at 10,000psi.

In all cases, the pellet material was carried forward, while the soluble fraction was discarded. The resultant solution was centrifuged in a GSA rotor for 1 hour at 12,500 rpm. The pellet was resuspended in the same solution (without the DTT) using the same tissue homogenizer probe at 2,000 rpm. After homogenizing for 5 minutes at 3000 rpm, the volume was adjusted to 500ml with the same solution, and spun for 1 hour at 12,500 rpm. The pellet was then resuspended as before, but this time the final volume was adjusted to 1.5L with the same solution prior to homogenizing for 5 minutes. After centrifuging at the same speed for 30 minutes, this procedure was repeated. The pellet was then resuspended into about 150ml of cold water, pooling the pellets from the six centrifuge tubes used in the GSA rotor. The pellet has homogenized for 5 minutes at 3,000 rpm, volume adjusted to 250ml with cold water, then spun for 30 minutes. Weight of the resultant pellet was 17.75g.

Summary: Lysis of bacterial pellet in KCl solution, followed by centrifugation in a GSA rotor was used to initially prepare the pellet. The same solution was then used an additional three times for resuspension/homogenization. A final water wash/homogenization was then performed to remove excess KCl and EDTA.

- 5 Solublization of Recombinant Hu-Asp2(a):
 - A ratio of 9-10ml/gram of pellet was utilized for solubilizing the rHuAsp2L from the pellet previously described. 17.75g of pellet was thawed, and 150ml of 8M guanidine HCl, 5mM β ME, 0.1% DEA, was added. 3M Tris was used to titrate the pH to 8.6. The pellet was initially resuspended into the guanidine solution using a 20 mm tissue
- homogenizer probe at 1000 rpm. The mixture was then stirred at 4°C for 1 hour prior to centrifugation at 12,500 rpm for 1 hour in GSA rotor. The resultant supernatant was then centrifuged for 30 minutes at 40,000 x g in an SS-34 rotor. The final supernatant was then stored at -20°C, except for 50 ml.
- 15 Immobilized Nickel Affinity Chromatography of Solubilized Recombinant Hu-Asp2(a):
 The following solutions were utilized:
 - A) 6M Guanidine HCl, 0.1M NaP, pH 8.0, 0.01M Tris, 5mM βME, 0.5mM Imidazole
- 20 A') 6M Urea, 20mM NaP, pH 6.80, 50mM NaCl
 - B') 6M Urea, 20mM NaP, pH 6.20, 50mM NaCl, 12mM Imidazole
 - C') 6M Urea, 20mM NaP, pH 6.80, 50mM NaCl, 300mM Imidazole Note: Buffers A' and C' were mixed at the appropriate ratios to give intermediate concentrations of Imidazole.
- The 50ml of solubilized material was combined with 50ml of buffer A prior to adding to 100-125ml Qiagen Ni-NTA SuperFlow (pre-equilibrated with buffer A) in a 5 x 10cm Bio-Rad econo column. This was shaken gently overnight at 4°C in the cold room.

Chromatography Steps:

Drained the resultant flow through.

Washed with 50ml buffer A (collecting into flow through fraction)
Washed with 250ml buffer A (wash 1)

Washed with 250ml buffer A (wash 2)

Washed with 250ml buffer A'

Washed with 250ml buffer B'

Washed with 250ml buffer A'

5 Eluted with 250ml 75mM Imidazole

Eluted with 250ml 150mM Imidazole (150-1)

Eluted with 250ml 150mM Imidazole (150-2)

Eluted with 250ml 300mM Imidazole (300-1)

Eluted with 250ml 300mM Imidazole (300-2)

Eluted with 250ml 300mM Imidazole (300-3)

Chromatography Results:

The Hu-Asp(a) eluted at 75mM Imidazole through 300mM Imidazole. The 75mM fraction, as well as the first 150mM Imidazole (150-1) fraction contained contaminating proteins as visualized on Coomassie Blue stained gels. Therefore, fractions 150-2 and 300-1 will be utilized for refolding experiments since they contained the greatest amount of protein as visualized on a Coomassie Blue stained gel.

Refolding Experiments of Recombinant Hu-Asp2(a):

20 Experiment 1:

Forty ml of 150-2 was spiked with 1M DTT, 3M Tris, pH 7.4 and DEA to a final concentration of 6mM, 50mM, and 0.1% respectively. This was diluted suddenly (while stirring) with 200ml of (4°C) cold 20mM NaP, pH 6.8, 150mM NaCl. This dilution gave a final Urea concentration of 1M. This solution remained clear, even if allowed to set open to the air at room temperature (RT) or at 4°C.

After setting open to the air for 4-5 hours at 4°C, this solution was then dialyzed overnight against 20mM NaP, pH 7.4, 150mM NaCl, 20% glycerol. This method effectively removes the urea in the solution without precipitation of the protein.

25

Experiment 2:

Some of the 150-2 eluate was concentrated 2x on an Amicon Centriprep, 10,000 MWCO, then treated as in Experiment 1. This material also stayed in solution, with no visible precipitation.

5 Experiment 3:

10

15

20

25

30

89ml of the 150-2 eluate was spiked with 1M DTT, 3M Tris, pH 7.4 and DEA to a final concentration of 6mM, 50mM, and 0.1% respectively. This was diluted suddenly (while stirring) with 445ml of (4°C) cold 20mM NaP, pH 6.8, 150mM NaCl. This solution appeared clear, with no apparent precipitation. The solution was removed to RT and stirred for 10 minutes prior to adding MEA to a final concentration of 0.1mM. This was stirred slowly at RT for 1 hour. Cystamine and CuSO₄ were then added to final concentrations of 1mM and 10 μM respectively. The solution was stirred slowly at RT for 10 minutes prior to being moved to the 4°C cold room and shaken slowly overnight, open to the air.

The following day, the solution (still clear, with no apparent precipitation) was centrifuged at 100,000 x g for 1 hour. Supernatants from multiple runs were pooled, and the bulk of the stabilized protein was dialyzed against 20mM NaP, pH 7.4, 150mM NaCl, 20% glycerol. After dialysis, the material was stored at -20°C.

Some (about 10 ml) of the protein solution (still in 1M Urea) was saved back for biochemical analyses, and frozen at -20°C for storage.

Example 10

Expression of Hu-Asp2 and Derivatives in Insect Cells

Any materials (vectors, host cells, etc.) and methods that are useful to express Hu-Asp2(a) should in principle be equally effective for expression of Hu-Asp2(b). *Expression by baculovirus infection*.

The coding sequence of Hu-Asp2(a) and Hu-ASp2(b) and several derivatives were engineered for expression in insect cells using the PCR. For the full-length sequence, a 5'-sense oligonucleotide primer that modified the translation initiation site to fit the Kozak consensus sequence was paired with a 3'-antisense primer that

contains the natural translation termination codon in the Hu-Asp2 sequence. PCR amplification of the pcDNA3.1(hygro)/Hu-Asp2(a) template was used to prepare two derivatives of Hu-Asp2(a) or Hu-Asp(b) that delete the C-terminal transmembrane domain (SEQ ID Nos. 29-30 and 50-51, respectively) or delete the transmembrane domain and introduce a hexa-histidine tag at the C-terminus (SEQ ID Nos. 31-32 and 52-53) respectively, were also engineered using PCR. The same 5'-sense oligonucleotide primer described above was paired with either a 3'-antisense primer that (1) introduced a translation termination codon after codon 453 (SEQ ID No. 3) or (2) incorporated a hexa-histidine tag followed by a translation termination codon in the PCR using pcDNA3.1(hygro)/Hu-Asp-2(a) as the template. In all cases, the PCR reactions were performed amplified for 15 cycles using PwoI DNA polymerase (Boehringer-Mannheim) as outlined by the supplier. The reaction products were digested to completion with BamHI and NotI and ligated to BamHI and NotI digested baculovirus transfer vector pVL1393 (Invitrogen). A portion of the ligations was used to transform competent E. coli DH5 cells followed by antibiotic selection on LB-Amp. Plasmid DNA was prepared by standard alkaline lysis and banding in CsCl to yield the baculovirus transfer vectors pVL1393/Asp2(a), pVL1393/Asp2(a)\DeltaTM and pVL1393/Asp2(a)ΔTM(His)₆. Creation of recombinant baculoviruses and infection of sf9 insect cells was performed using standard methods.

20 Expression by transfection

5

10

15

25

30

Transient and stable expression of Hu-Asp2(a)ΔTM and Hu-Asp2(a)ΔTM(His)₆ in High 5 insect cells was performed using the insect expression vector pIZ/V5-His. The DNA inserts from the expression plasmids vectors pVL1393/Asp2(a), pVL1393/Asp2(a)ΔTM and pVL1393/Asp2(a)ΔTM(His)₆ were excised by double digestion with *BamH*I and *Not*I and subcloned into *BamH*I and *Not*I digested pIZ/V5-His using standard methods. The resulting expression plasmids, referred to as pIZ/Hu-Asp2ΔTM and pIZ/Hu-Asp2ΔTM(His)₆, were prepared as described above.

For transfection, High 5 insect cells were cultured in High Five serum free medium supplemented with $10 \mu g/ml$ gentamycin at $27 \, ^{\circ}\text{C}$ in sealed flasks.

Transfections were performed using High five cells, High five serum free media supplemented with 10 µg/ml gentamycin, and InsectinPlus liposomes (Invitrogen, Carlsbad, CA) using standard methods.

For large scale transient transfections, 1.2×10^7 high five cells were plated in a 150 mm tissue culture dish and allowed to attach at room temperature for 15-30 minutes. During the attachment time the DNA/liposome mixture was prepared by mixing 6 ml of serum free media, $60 \mu g$ Hu-Asp2(a) Δ TM/pIZ (+/- His) DNA and 120 μ l of Insectin Plus and incubating at room temperature for 15 minutes. The plating media was removed from the dish of cells and replaced with the DNA/liposome mixture for 4 hours at room temperature with constant rocking at 2 rpm. An additional 6 ml of media was added to the dish prior to incubation for 4 days at 27 °C in a humid incubator. Four days post transfection the media was harvested, clarified by centrifugation at 500 x g, assayed for Hu-Asp2(a) expression by Western blotting. For stable expression, the cells were treated with 50 μ g/ml Zeocin and the surviving pool used to prepared clonal cells by limiting dilution followed by analysis of the expression level as noted above.

Purification of Hu-Asp2(a) Δ TM and Hu-Asp2(a) Δ TM(His)₆

5

10

15

20

25

Removal of the transmembrane segment from Hu-Asp2(a) resulted in the secretion of the polypeptide into the culture medium. Following protein production by either baculovirus infection or transfection, the conditioned medium was harvested, clarified by centrifugation, and dialyzed against Tris-HCl (pH 8.0). This material was then purified by successive chromatography by anion exchange (Tris-HCl, pH 8.0) followed by cation exchange chromatography (Acetate buffer at pH 4.5) using NaCl gradients. The elution profile was monitored by (1) Western blot analysis and (2) by activity assay using the peptide substrate described in Example 12. For the Hu-Asp2(a)ΔTM(His)₆, the conditioned medium was dialyzed against Tris buffer (pH 8.0) and purified by sequential chromatography on IMAC resin followed by anion exchange chromatography.

Amino-terminal sequence analysis of the purified Hu-Asp2(a) Δ TM(His)₆ protein revealed that the signal peptide had been cleaved [TQHGIRLPLR, corresponding to SEQ ID NO: 32, residues 22-3].

5

15

20

25

30

Example 11

Expression of Hu-Asp2(a) and Hu-Asp(b) in CHO cells

The materials (vectors, host cells, etc.) and methods described herein for expression of Hu-Asp2(a) are intended to be equally applicable for expression of Hu-Asp2(b).

10 Heterologous expression of Hu-Asp-2(a) in CHO-K1 cells

The entire coding sequence of Hu-Asp2(a) was cloned into the mammalian expression vector pcDNA3.1(+)Hygro (Invitrogen, Carlsbad, CA) which contains the CMV immediate early promoter and bGH polyadenylation signal to drive over expression. The expression plasmid, pcDNA3.1(+)Hygro/Hu-Asp2(a), was prepared by alkaline lysis and banding in CsCl and completely sequenced on both strands to verify the integrity of the coding sequence.

Wild-type Chinese hamster ovary cells (CHO-K1) were obtained from the ATCC. The cells were maintained in monolayer cultures in α-MEM containing 10% FCS at 37°C in 5% CO₂. Two 100 mm dishes of CHO-K1 cells (60% confluent) were transfected with pcDNA3.1(+)/Hygro alone (mock) or pcDNA3.1(+)/Hygro/Hu-Asp2(a) or pcDNA3.1(+)/Hygro/Hu-Asp2(b) using the cationic liposome DOTAP as recommended by the supplier (Roche, Indianapolis, IN). The cells were treated with the plasmid DNA/liposome mixtures for 15 hours and then the medium replaced with growth medium containing 500 Units/ml hygromycin B. In the case of pcDNA3.1(+)/Hygro/Hu-Asp2(a) or (b) transfected CHO-K1cells, individual hygromycin B-resistant cells were cloned by limiting dilution. Following clonal expansion of the individual cell lines, expression of Hu-Asp2(a) or Hu-Asp2(b) protein was assessed by Western blot analysis using a polyclonal rabbit antiserum raised against recombinant Hu-Asp2 prepared by expression in *E. coli*. Near confluent dishes of each cell line were harvested by scraping into PBS and the cells

recovered by centrifugation. The cell pellets were resuspended in cold lysis buffer (25 mM Tris-HCl (pH 8.0)/5 mM EDTA) containing protease inhibitors and the cells lysed by sonication. The soluble and membrane fractions were separated by centrifugation (105,000 x g, 60 min) and normalized amounts of protein from each fraction were then separated by SDS-PAGE. Following electrotransfer of the separated polypeptides to PVDF membranes, Hu-Asp-2(a) or Hu-Asp2(b) protein was detected using rabbit anti-Hu-Asp2 antiserum (1/1000 dilution) and the antibody-antigen complexes were visualized using alkaline phosphatase conjugated goat anti-rabbit antibodies (1/2500). A specific immunoreactive protein with an apparent Mr value of 65 kDa was detected in pcDNA3.1(+)Hygro/Hu-Asp2 transfected cells and not mock-transfected cells. Also, the Hu-Asp2 polypeptide was only detected in the membrane fraction, consistent with the presence of a signal peptide and single transmembrane domain in the predicted sequence. Based on this analysis, clone #5 had the highest expression level of Hu-Asp2(a) protein and this production cell lines was scaled up to provide material for purification.

Purification of recombinant Hu-Asp-2(a) from CHO-K1/Hu-Asp2 clone #5

In a typical purification, clone #5 cell pellets derived from 20 150 mm dishes of confluent cells, were used as the starting material. The cell pellets were resuspended in 50 ml cold lysis buffer as described above. The cells were lysed by polytron homogenization (2 x 20 sec) and the lysate centrifuged at 338,000 x g for 20 minutes. The membrane pellet was then resuspended in 20 ml of cold lysis buffer containing 50 mM β -octylglucoside followed by rocking at 4 °C for 1 hour. The detergent extract was clarified by centrifugation at 338,000 x g for 20 minutes and the supernatant taken for further analysis.

25

30

5

10

15

20

The β -octylglucoside extract was applied to a Mono Q anion exchange column that was previously equilibrated with 25 mM Tris-HCl (pH 8.0)/50 mM β -octylglucoside. Following sample application, the column was eluted with a linear gradient of increasing NaCl concentration (0-1.0 M over 30 minutes) and individual fractions assayed by Western blot analysis and for β -secretase activity (see below). Fractions containing both Hu-Asp-2(a) immunoreactivity and β -secretase activity

-79-

were pooled and dialyzed against 25 mM NaOAc (pH 4.5)/50 mM β-octylglucoside. Following dialysis, precipitated material was removed by centrifugation and the soluble material chromatographed on a MonoS cation exchange column that was previously equilibrated in 25 mM NaOAc (pH 4.5)/ 50 mM β-octylglucoside. The column was cluted using a linear gradient of increasing NaCl concentration (0-1.0 M over 30 minutes) and individual fractions assayed by Western blot analysis and for β-secretase activity. Fractions containing both Hu-Asp2 immunoreactivity and β-secretase activity were combined and determined to be >95% pure by SDS-PAGE/Coomassie Blue staining.

The same methods were used to express and purify Hu-Asp2(b).

Example 12

Assay of Hu-Asp2 β -secretase activity using peptide substrates

β-secretase assay

5

10

15

20

25

30

Recombinant human Asp2(a) prepared in CHO cells and purified as described in Example 11 was used to assay Asp2(a) proteolytic activity directly. Activity assays for Asp2(a) were performed using synthetic peptide substrates containing either the wild-type APP β-secretase site (SEVKM DAEFR; SEQ ID NO: 64), the Swedish KM-NL mutation (SEVNL DAEFR; SEQ ID NO: 63), or the Aβ40 and 42 y-secretase sites (RRGGVV I IA I TVIVGER; SEQ ID NO: 65). Reactions were performed in 50 mM 2-[N-morpholino]ethane-sulfonate ("Na-MES," pH 5.5) containing 1% β-octylglucoside, 70 mM peptide substrate, and recombinant Asp2(a) (1-5 µg protein) for various times at 37°C. The reaction products were quantified by RP-HPLC using a linear gradient from 0-70 B over 30 minutes (A=0.1% TFA in water, B=0.1%TFA/10%water/90%AcCN). The elution profile was monitored by absorbance at 214 nm. In preliminary experiments, the two product peaks which eluted before the intact peptide substrate, were confirmed to have the sequence DAEFR (SEQ ID NO: 72) and SEVNL (SEQ ID NO: 73) using both Edman sequencing and MADLI-TOF mass spectrometry. Percent hydrolysis of the peptide substrate was calculated by comparing the integrated peak areas for the two product

peptides and the starting material derived from the absorbance at 214 nm. The sequence of cleavage/hydrolysis products was confirmed using Edman sequencing and MADLI-TOF mass spectrometry.

The behavior of purified Asp2(a) in the proteolysis assays was consistent with the prior anti-sense studies which indicated that Asp2(a) possesses β -secretase activity. Maximal proteolysis was seen with the Swedigh β -secretase peptide, which, after 6 hours, was about 10-fold higher than wild type APP.

5

10

15

20

25

30

The specificity of the protease cleavage reaction was determined by performing the β -secretase assay in the presence of 8 μ M pepstatin A and the presence of a cocktail of protease inhibitors (10 μ M leupeptin, 10 μ M E64, and 5 mM EDTA). Proteolytic activity was insensitive to both the pepstatin and the cocktail, which are inhibitors of cathepsin D (and other aspartyl proteases), serine proteases, cysteinyl proteases, and metalloproteases, respectively.

Hu-Asp2(b) when similarly expressed in CHO cells and purified using identical conditions for extraction with β -octylglucoside and sequential chromatography over Mono Q and Mono S also cleaves the Swedish β -secretase peptide in proteolysis assays using identical assay conditions.

Collectively, this data establishes that both forms of Asp2 (Hu-Asp2(a) and Hu-Asp2(b)) act directly in cell-free assays to cleave synthetic APP peptides at the β-secretase site, and that the rate of cleavage is greatly increased by the Swedish KM→NL mutation that is associated with Alzheimer's disease.

An alternative β -secretase assay utilizes internally quenched fluorescent substrates to monitor enzyme activity using fluorescence spectroscopy in a single sample or multiwell format. Each reaction contained 50 mM Na-MES (pH 5.5), peptide substrate MCA-EVKMDAEF[K-DNP] (SEQ ID NO: 71; BioSource International) (50 μ M) and purified Hu-Asp-2 enzyme. These components were equilibrated to 37 °C for various times and the reaction initiated by addition of substrate. Excitation was performed at 330 nm and the reaction kinetics were monitored by measuring the fluorescence emission at 390 nm. To detect compounds that modulate Hu-Asp-2 activity, the test compounds were added during the

preincubation phase of the reaction and the kinetics of the reaction monitored as described above. Activators are scored as compounds that increase the rate of appearance of fluorescence while inhibitors decrease the rate of appearance of fluorescence.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples.

Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the invention. The entire disclosure of all publications cited herein are hereby incorporated by reference.

What is claimed is:

5

10

15

20

1. A polypeptide comprising the amino acid sequence of a mammalian amyloid protein precursor (APP) or fragment thereof containing an APP cleavage site recognizable by a mammalian β -secretase, and further comprising two lysine residues at the carboxyl terminus of the amino acid sequence of the mammalian APP or APP fragment.

- 2. A polypeptide according to claim 1 comprising the amino acid sequence of a mammalian amyloid protein precursor (APP), and further comprising two lysine residues at the carboxyl terminus of the amino acid sequence of the mammalian amyloid protein precursor.
 - 3. A polypeptide according to claim 1 wherein the polypeptide further includes a marker.
 - 4. A polypeptide according to claim 3 wherein the marker comprises a reporter protein amino acid sequence attached to the APP amino acid sequence.
- 5. A polypeptide according to claim 4 wherein the reporter protein comprises an amino acid sequence of a fluorescing protein.
 - 6. A polypeptide according to claim 1, wherein the mammalian APP is a human APP.
- 7. A polypeptide according to claim 6, wherein the human APP comprises at least one variation selected from the group consisting of a Swedish KM→NL mutation and a London V717→F mutation.

8. A polypeptide according to claim 6, wherein the human APP is selected from the group consisting of: an APP695 isoform, an APP 751 isoform, and an APP770 isoform.

- 9. A polypeptide according to claim 1 wherein the APP protein or fragment thereof comprises the APP-Sw β-secretase peptide sequence NLDA.
- 10. A polypeptide according to claim 9 wherein the APP protein or fragment thereof comprises the APP-Sw β-secretase peptide sequence
 SEVNLDAEFR (SEQ ID NO: 63).
 - 11. A polypeptide according to claim 9 wherein the APP protein or fragment thereof further includes an APP transmembrane domain carboxy-terminal to the APP-Sw β-secretase peptide sequence.

15

- 12. A polypeptide according to claim 9 wherein the APP protein or fragment thereof comprises a chimeric APP, said chimeric APP including partial APP amino acid sequences from at least two species.
- 20 13. A polypeptide according to claim 12 wherein the chimeric APP includes amino acid sequence of a human APP and a rodent APP.
 - 14. A polynucleotide comprising a nucleotide sequence that encodes a polypeptide according to any one of claims 1.

25

- 15. A vector comprising a polynucleotide according to claim 14.
- 16. A vector according to claim 15 wherein said polynucleotide is operably linked to a promoter to promote expression of the polypeptide encoded by the polynucleotide in a host cell.

17. A host cell transformed or transfected with a polynucleotide according to claim 14 or a vector according to claim 15 or 16.

18. A host cell according to claim 17 that is a mammalian cell.

5

15

20

25

- 19. A polypeptide useful for assaying for modulators of β -secretase activity, said polypeptide comprising an amino acid sequence of the formula NH₂-X-Y-Z-KK-COOH;
- wherein X, Y, and Z each comprise an amino acid sequence of at least one amino acid;

wherein-NH₂-X comprises an amino-terminal amino acid sequence having at least one amino acid residue;

wherein Y comprises an amino acid sequence of a β -secretase recognition site of a mammalian amyloid protein precursor (APP); and

wherein Z-KK-COOH comprises a carboxy-terminal amino acid sequence ending in two lysine (K) residues.

- 20. A polypeptide according to claim 19 wherein the carboxyl-terminal amino acid sequence Z includes a hyrdrophobic domain that is a transmembrane domain in host cells that express the polypeptide.
- 21. A polypeptide according to claim 19 wherein the amino-terminal amino acid sequence X includes an amino acid sequence of a reporter protein.
- 22. A polypeptide according to claim 19 wherein the β-secretase recognition site Y comprises the human APP-Sw β-secretase peptide sequence NLDA.
- 23. A polynucleotide comprising a nucleotide sequence that encodes a polypeptide according to any one of claims 19-22.

24. A purified polypeptide comprising the murine Asp2 amino acid sequence set forth in SEQ ID NO: 8, or a fragment thereof that retains the β -secretase activity of said murine Asp2.

- 5 25. A polynucleotide comprising a nucleotide sequence that encodes the polypeptide of claim 24.
 - 26. A polynucleotide according to claim 25 comprising the nucleotide sequence set forth in SEQ ID NO: 7.

- 27. A purified murine Asp2(b) polypeptide comprising the amino acid sequence set for in SEQ ID NO: 8 from residues 1-189 and 215-501, but lacking residues 190-214.
- 15 28. A polynucleotide comprising a nucleotide sequence that encodes the murine Asp2(b) polypeptide according to claim 27.
 - 29. A vector comprising a polynucleotide according to claim 25.
- 20 30. A vector according to claim 29 wherein said polynucleotide is operably linked to a promoter to promote expression of the polypeptide encoded by the polynucleotide in a host cell.
- 31. A host cell transformed or transfected with a vector according to claim30.
 - 32. A host cell according to claim 31 that is a mammalian cell.
- 33. A host cell according to claim 31 that expresses the polypeptide on its surface.

34. A host cell according to claim 31, wherein the host cell is transfected with a nucleic acid comprising a nucleotide sequence that encodes an amyloid precursor protein (APP) that includes two carboxy-terminal lysine residues.

5

- 35. A host cell according to claim 34 that expresses the polypeptide and the APP on its surface.
- 36. A method of making a murine Asp2 polypeptide comprising steps of culturing a host cell of claim 61 in a culture medium under conditions in which the cell produces the polypeptide that is encoded by the polynucleotide.
 - 37. A method according to claim 36, further comprising a step of purifying the polypeptide from the cell or the culture medium.

15

- 38. A host cell transformed or transfected with a polynucleotide according to claim 25.
 - 39. A host cell according to claim 38 that is a mammalian cell.

20

- 40. A host cell according to claim 38 that expresses the polypeptide on its surface.
- 41. A host cell according to claim 38, wherein the host cell is transfected with a nucleic acid comprising a nucleotide sequence that encodes an amyloid precursor protein (APP) or fragment thereof containing a β-secretase cleavage site.
 - 42. A host cell according to claim 41 wherein the APP includes two carboxy-terminal lysine residues.

30

43. A host cell according to claim 41 wherein the APP comprises the Swedish mutation (K \rightarrow N, M \rightarrow L) adjacent to the β -secretase cleavage site.

- 44. A host cell according to claim 41 that expresses the polypeptide and the APP on its surface.
 - 45. A method of making a murine Asp2 polypeptide comprising steps of culturing a host cell of claim 38 in a culture medium under conditions in which the cell produces the polypeptide that is encoded by the polynucleotide.

10

- 46. A method according to claim 45, further comprising a step of purifying the polypeptide from the cell or the culture medium. –
- 47. A purified polypeptide comprising a fragment of a mammalian Asp2 protein, wherein said polypeptide lacks the Asp2 transmembrane domain of said Asp2 protein, and wherein the polypeptide and the fragment retain the β-secretase activity of said mammalian Asp2 protein.
- 48. A purified polypeptide according to claim 47 comprising a fragment of a human Asp2 protein that retains the β-secretase activity of said human Asp2 protein.
 - 49. A purified polypeptide according to claim 48, wherein said polypeptide comprises a fragment of Asp2(a) having the amino acid sequence set forth in SEQ ID NO: 4, and wherein said polypeptide lacks transmembrane domain amino acids 455 to 477 of SEQ ID NO: 4.
 - 50. A purified polypeptide according to claim 49, wherein said polypeptide further lacks cytoplasmic domain amino acids 478 to 501 of SEQ ID NO: 4.

51. A purified polypeptide according to claim 50, wherein said polypeptide further lacks amino acids 420-454 of SEQ ID NO: 4.

- 52. A purified polypeptide according to any one of claims 48-51, wherein said polypeptide comprises an amino acid sequence:
 - that includes amino acids 58 to 419 of SEQ ID NO: 4, and that lacks amino acids 22 to 57 of SEQ ID NO: 4.
- 53. A purified polypeptide according to any one of claims 48-51, wherein said polypeptide comprises an amino acid sequence:

that includes amino acids 46 to 419 of SEQ ID NO: 4, and that lacks amino acids 22 to 45 of SEQ ID NO: 4.

- 54. A purified polypeptide according to claim 49, wherein said polypeptide comprises an amino acid sequence that includes amino acids 22 to 454 of SEQ ID NO: 4.
 - 55. A purified polypeptide according to claim 47 comprising the amino acid sequence of human Asp-2(b) protein set forth as SEQ ID NO: 6, or fragments thereof that retain β-secretase activity.

· 20

- 56. A purified polypeptide according to claim 48, wherein said polypeptide comprises a fragment of Asp2(b) having the amino acid sequence set forth in SEQ ID NO: 6, and wherein said polypeptide lacks transmembrane domain amino acids 430 to 452 of SEQ ID NO: 6.
- 57. A purified polypeptide according to claim 56, wherein said polypeptide further lacks cytoplasmic domain amino acids 453 to 476 of SEQ ID NO: 6.

58. A purified polypeptide according to claim 57, wherein said polypeptide further lacks amino acids 395-429 of SEQ ID NO: 4.

59. A purified polypeptide according to any one of claims 56-58, wherein said polypeptide comprises an amino acid sequence:

5

20

25

that includes amino acids 58 to 394 of SEQ ID NO: 4, and that lacks amino acids 22 to 57 of SEQ ID NO: 4.

60. A purified polypeptide according to any one of claims 56-58, wherein said polypeptide comprises an amino acid sequence:

that includes amino acids 46 to 394 of SEQ ID NO: 4, and that lacks amino acids 22 to 45 of SEQ ID NO: 4.

- 61. A purified polypeptide according to claim 56, wherein said polypeptide comprises an amino acid sequence that includes amino acids 22 to 429 of SEQ ID NO: 6.
 - 62. A polypeptide comprising an amino acid sequence at least 95% identical to a fragment of a human Asp2 protein, wherein said polypeptide and said fragment lack a transmembrane domain and retain β-secretase activity of the human Asp2 protein.
 - 63. A purified polynucleotide comprising a nucleotide sequence that encodes the polypeptide of any one of claims 47-63.
 - 64. A polynulcleotide of claim 47 wherein the polypeptide comprises a fragment of human Asp2 protein.
- 65. A polynucleotide of claim 64 wherein the polypeptide comprises a fragment of Asp2(a) having the amino acid sequence set forth as SEQ ID NO: 4, and

wherein the polypeptide lacks the transmembrane domain amino acids 455-477 of SEQ ID NO: 4.

- 66. A polynucleotide of claim 64, wherein the polypeptide further lacks cytoplasmic domain amino acids 478-501 of SEQ ID NO: 4.
 - 67. A purified polynucleotide of claim 66, wherein said polypeptide further lacks amino acids 420-454 of SEQ ID NO: 4.
- 10 68. A polynucleotide of claim 65, wherein the polypeptide comprises an amino acid sequence:

that includes amino acids 58-419 of SEQ ID NO: 4, and that lacks amino acids 22-57 of SEQ ID NO: 4.

15 69. A polynucleotide of claim 65, wherein the polypeptide comprises an amino acid sequence:

that includes amino acids 46-419 of SEQ ID NO: 4, and that lacks amino acids 22-45 of SEQ ID NO: 4.

- 20 70. A polynucleotide of claim 65, wherein the polypeptide comprises an amino acid sequence that includes amino acids 22-454 of SEQ ID NO: 4.
 - 71. A polynucleotide of claim 64, wherein the polypeptide comprises a fragment of human Asp2(b) having the amino acid set forth in SEQ ID NO: 6, and wherein the polypeptide lacks transmembrane domain amino acids 430-452 of SEQ ID NO: 6.
 - 72. A polynucleotide of claim 71, wherein the polypeptide lacks cytoplasmic domain amino acids 453-476 of SEQ ID NO: 6.

25

73. A polynucleotide of claim 72, wherein the polypeptide further lacks amino acids 395-429 of SEQ ID NO: 6.

74. A polynucleotide of claim 71, wherein the polypeptide comprises an amino acid sequence:

5

10

that includes amino acids 58-394 of SEQ ID NO: 6, and that lacks amino acids 22 to 57 of SEQ ID NO: 6.

75. A polynucleotide of claim 71, wherein the polypeptide comprises an amino acid sequence:

that includes amino acids 46-394 of SEQ ID NO: 6, and that lacks amino acids 22-45 of SEQ ID NO: 6.

- 76. A polynucleotide of claim 71, wherein the polypeptide comprises an amino acid sequence that includes amino acids 22 to 429 of SEQ ID NO: 6.
 - 77. A vector comprising a polynucleotide according to claim 63.
- A host cell transformed or transfected with a polynucleotide according to claim 63.
 - 79. A host cell transformed or transfected with a vector of claim 77.
- 80. A polynucleotide comprising a nucleotide sequence that hybridizes under stringent conditions to a nucleic acid comprising the sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 6, wherein the nucleotide sequence encodes a polypeptide having β-secretase biological activity.
- 30 81. A vector comprising a polynucleotide of claim 80.

82. A host cell transformed or transfected with a polynucleotide of claim 80.

- 83. A method for assaying for modulators of β -secretase activity, comprising the steps of:
- (a) contacting a first composition with a second composition both in the presence and in the absence of a putative modulator compound, wherein the first composition comprises a mammalian β -secretase polypeptide or biologically active fragment thereof, and wherein the second composition comprises a substrate polypeptide having an amino acid sequence comprising a β -secretase cleavage site;
- (b) measuring cleavage of the substrate polypeptide in the presence and in the absence of the putative modulator compound; and
- (c) identifying modulators of β -secretase activity from a difference in cleavage in the presence versus in the absence of the putative modulator compound, wherein a modulator that is a β -secretase antagonist reduces such cleavage and a modulator that is a β -secretase agonist increases such cleavage.
- 84. A method according to claim 83, wherein the first composition comprises a purified human Asp2 polypeptide.
- 85. A method according to claim 83, wherein the first composition comprises a soluble fragment of a human Asp2 polypeptide that retains Asp2 β -secretase activity.
- 86. A method according to claim 85 wherein the soluble fragment is a fragment lacking an Asp2 transmembrane domain.
 - 87. A method according to claim 83, wherein the substrate polypeptide of the second composition comprises the amino acid sequence SEVNLDAEFR.

30

5

10

15

20

88. A method according to claim 83, wherein the substrate polypeptide of the second composition comprises the amino acid sequence EVKMDAEF.

- 89. A method according to claim 83, wherein the second composition comprises a polypeptide having an amino acid sequence of a human amyloid precursor protein (APP).
 - 90. A method according to claim 89, wherein the human amyloid precursor protein is selected from the group consisting of: APP695, APP751, and APP770.
 - 91. A method according to claim 90, wherein the human amyloid precursor protein includes at least on mutation selected from a KM→NL Swiss mutation and a V→F London mutation.
- 15 92. A method according to claim 89, wherein the polypeptide having an amino acid sequence of a human APP further comprises an amino acid sequence comprising a marker sequence attached amino-terminal to the amino acid sequence of the human amyloid precursor protein.
- 20 93. A method according to claim 89, wherein the polypeptide having an amino acid sequence of a human APP further comprises two lysine residues attached to the carboxyl terminus of the amino acid sequence of the human APP.
- 94. A method according to claim 82, wherein the second composition
 25 comprises a eukaryotic cell that expresses amyloid precursor protein (APP) or a fragment thereof containing a β-secretase cleavage site.
 - 95. A method according to claim 94, wherein the APP expressed by the host cell is an APP variant that includes two carboxyl-terminal lysine residues.

30

5

96. A method for identifying agents that inhibit the activity of human Asp2 aspartyl protease (Hu-Asp2), comprising the steps of:

- (a) contacting amyloid precursor protein (APP) and purified and isolated Hu-Asp2 in the presence and absence of a test agent;
- (b) determining the APP processing activity of the Hu-Asp2 in the presence and absence of the test agent; and
- (c) comparing the APP processing activity of the Hu-Asp2 polypeptide in the presence of the test agent to the activity in the absence of the test agent to identify an agent that inhibits the APP processing activity of Hu-Asp2, wherein reduced activity in the presence of the test agent identifies an agent that inhibits Hu-Asp2 activity.
- 97. A method according to claim 96, wherein the Hu-Asp2 comprises a polypeptide purified and isolated from a cell transformed or transfected with a polynucleotide comprising a nucleotide sequence that encodes the Hu-Asp2.
 - 98. A method according to claim 60 wherein the nucleotide sequence is selected from the group consisting of:
 - (a) a nucleotide sequence encoding the Hu-Asp2(a) amino acid sequence set forth in SEQ ID NO: 4;
 - (b) a nucleotide sequence encoding the Hu-Asp2(b) amino acid sequence set forth in SEQ ID NO: 6;
 - (c) a nucleotide sequence encoding a fragment of Hu-Asp2(a) (SEQ ID NO: 4) or Hu-Asp2(b) (SEQ ID NO: 6), wherein said fragment exhibits aspartyl protease activity characteristic of Hu-Asp2(a) or Hu-Asp2(b); and
 - (d) a nucleotide sequence of a polynucleotide that hybridizes under stringent hybridization conditions to the complement of a Hu-Asp2-encoding polynucleotide selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO:

30 5.

5

10

20

PCT/IB01/00797 WO 01/49097

99. A method according to claim 97 wherein the Hu-Asp2 comprises the Hu-Asp2(a) amino acid sequence set forth in SEQ ID NO: 4.

- 5 100. A method according to claim 97, wherein the Hu-Asp2 comprises the Hu-Asp2(b) amino acid sequence set forth in SEQ ID NO: 6.
 - 101. A method according to claim 97, wherein the Hu-Asp2 comprises a fragment of Hu-Asp2(a) (SEQ ID NO: 4) or Hu-Asp2(b) (SEQ ID NO: 6), wherein said fragment exhibits aspartyl protease activity characteristic of Hu-Asp2(a) or Hu-Asp2(b).
 - 102. A method according to claim 96, wherein the APP comprises the Swedish mutation $(K \rightarrow N, M \rightarrow L)$ adjacent to the β -secretase processing site.

15

10

- A method according to claim 96, further comprising a step of treating 103. Alzheimer's Disease with an agent identified as an inhibitor of Hu-Asp2 according to steps (a)-(c).
- 20
- A method for identifying agents that inhibit the activity of human Asp2 aspartyl protease (Hu-Asp2), comprising the steps of: contacting Hu-Asp2 and amyloid precursor protein (APP) in the

25

- presence and absence of a test agent, wherein the APP comprises a carboxyterminal di-lysine (KK) and wherein the contacting comprises growing a host cell that expresses the APP in the presence and absence of the test agent;
- determining the APP processing activity of the Hu-Asp2 in the (b) presence and absence of the test agent; and
- comparing the APP processing activity of the Hu-Asp2 polypeptide in (c) the presence of the test agent to the activity in the absence of the test agent to identify an agent that inhibits the activity of Hu-Asp2, wherein reduced

activity in the presence of the test agent identifies an agent that inhibits Hu-Asp2 activity.

105. A method according to claim 104, wherein the APP further comprises the Swedish mutation (K \rightarrow N, M \rightarrow L) adjacent to the β -secretase processing site.

5

10

15

- 106. A method according to claim 104, wherein the host cell has been transformed or transfected with a polynucleotide comprising a nucleotide sequence that encodes a Hu-Asp2, wherein said nucleotide sequence is selected from the group consisting of:
- (a) a nucleotide sequence encoding the Hu-Asp2(a) amino acid sequence set forth in SEQ ID NO: 4;
- (b) a nucleotide sequence encoding the Hu-Asp2(b) amino acid sequence set forth in SEQ ID NO: 6;
- (c) a nucleotide sequence encoding a fragment of Hu-Asp2(a) (SEQ ID NO: 4) or Hu-Asp2(b) (SEQ ID NO: 6), wherein said fragment exhibits aspartyl protease activity characteristic of Hu-Asp2(a) or Hu-Asp2(b); and
 - (d) a nucleotide sequence of a polynucleotide that hybridizes under stringent hybridization conditions to the complement of a Hu-Asp2-encoding polynucleotide selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 5.
- 107. A method according to claim 104, further comprising a step of treating Alzheimer's Disease with an agent identified as an inhibitor of Hu-Asp2 according to steps (a)-(c).
 - 108. A method for identifying agents that inhibit the activity of human Asp2 aspartyl protease (Hu-Asp2), comprising the steps of:
- (a) contacting Hu-Asp2 and amyloid precursor protein (APP) in the presence and absence of a test agent, wherein the contacting comprises

growing a host cell transformed or transfected with a polynucleotide comprising a nucleotide sequence encoding the Hu-Asp2 in the presence and absence of the test agent;

(b) determining the APP processing activity of the Hu-Asp2 in the presence and absence of the test agent; and

5

10

- (c) comparing the APP processing activity of the Hu-Asp2 polypeptide in the presence of the test agent to the activity in the absence of the test agent to identify an agent that inhibits the activity of Hu-Asp2, wherein reduced activity in the presence of the test agent identifies an agent that inhibits Hu-Asp2 activity.
- 109. A method according to claim 108, wherein the host cell expresses APP.
- 110. A method according to claim 109 wherein the determining step comprises measuring the production of amyloid beta peptide by the cell in the presence and absence of the test agent.
 - 111. A method according to claim 109, wherein the host cell expresses an APP having an amino acid sequence that includes a carboxy-terminal di-lysine.
 - 112. A method according to claim 109, wherein the host cell expresses an APP comprising the Swedish mutation (K \rightarrow N, M \rightarrow L) adjacent to the β -secretase processing site.
- 25 113. A method according to claim 108, wherein the host cell is a human embryonic kidney cell line 293 (HEK293) cell.

114. A method according to claim 108 wherein the nucleotide sequence is selected from the group consisting of:

- (a) a nucleotide sequence encoding the Hu-Asp2(a) amino acid sequence set forth in SEQ ID NO: 4;
- (b) a nucleotide sequence encoding the Hu-Asp2(b) amino acid sequence set forth in SEQ ID NO: 6;
- (c) a nucleotide sequence encoding a fragment of Hu-Asp2(a) (SEQ ID NO: 4) or Hu-Asp2(b) (SEQ ID NO: 6), wherein said fragment exhibits aspartyl protease activity characteristic of Hu-Asp2(a) or Hu-Asp2(b); and
- 10 (d) a nucleotide sequence of a polynucleotide that hybridizes under stringent hybridization conditions to the complement of a Hu-Asp2-encoding polynucleotide selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 5.
 - 115. A method according to claim 108, wherein the host cell comprises a vector that comprises the polynucleotide.
 - 116. A method according to claim 108 wherein the polynucleotide comprises a nucleotide sequence encoding the Hu-Asp2(a) amino acid sequence set forth in SEQ ID NO: 4.
 - 117. A method according to claim 108 wherein the polynucleotide comprises a nucleotide sequence encoding the Hu-Asp2(b) amino acid sequence set forth in SEQ ID NO: 6.

25

15

20

5

118. A method according to claim 108 wherein the polynucleotide comprises a nucleotide sequence encoding a polypeptide comprising a fragment of Hu-Asp2(a) (SEQ ID NO: 4) or Hu-Asp2(b) (SEQ ID NO: 6), wherein said fragment exhibits aspartyl protease activity characteristic of Hu-Asp2(a) or Hu-Asp2(b).

119. A method according to claim 108 wherein the Hu-Asp2 is encoded by a nucleotide sequence of a polynucleotide that hybridizes under stringent hybridization conditions to the complement of a Hu-Asp2-encoding polynucleotide selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 5.

5

10

15

20

- 120. A method according to claim 108, further comprising a step of treating Alzheimer's Disease with an agent identified as an inhibitor of Hu-Asp2 according to steps (a)-(c).
- 121. A method for identifying agents that modulate the activity of Asp2 aspartyl protease, comprising the steps of:
 - (a) contacting an Asp2 aspartyl protease and amyloid precursor protein (APP) in the presence and absence of a test agent, wherein the Asp2 aspartyl protease is encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions to the complement of a Hu-Asp2-encoding polynucleotide selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 5;
 - (b) determining the APP processing activity of the Asp2 aspartyl protease in the presence and absence of the test agent; and
- (c) comparing the APP processing activity of the Asp2 aspartyl protease in the presence of the test agent to the activity in the absence of the agent to identify agents that modulate the activity of the Asp2 aspartyl protease, wherein a modulator that is an Asp2 inhibitor reduces APP processing and a modulator that is an Asp2 agonist increases such processing.
- 25 122. A method according to claim 121, wherein the Asp2 aspartyl protease is purified and isolated.
 - 123. A method according to claim121, further comprising a step of treating Alzheimer's Disease with an agent identified as an inhibitor of Hu-Asp2 according to steps (a)-(c).

124. A method for identifying an agent that inhibits APP processing activity of human Asp2 aspartyl protease, comprising steps of:

- (a) contacting Hu-Asp2 with an APP substrate for the Hu-Asp2, in the presence and absence of a test agent;
- (b) determining the proteolytic processing of the APP substrate by the Hu-Asp2 in the presence and absence of the test agent; and
- (c) comparing the proteolytic processing of the APP substrate by the Hu-Asp2 in the presence and absence of the test agent to identify an agent that inhibits the APP processing activity of Hu-Asp2, wherein reduced proteolytic processing of the APP substrate by the Hu-Asp2 in the presence of the test agent identifies an agent that inhibits Hu-Asp2 activity.
- 125. A method according to claim 124, wherein the APP substrate is a peptide comprising a β-secretase cleavage site of APP.

15

10

5

126. A method according to claim 125, wherein the β -secretase cleavage site comprises the formula P2-P1-P1'-P2', wherein

P2 is an amino acid selected from K and N;

P1 is an amino acid selected from M and L;

P1' is the amino acid D; and

P2' is the amino acid A.

127. A method according to claim 125, wherein the peptide comprises the amino acid sequence KMDA (SEQ ID NO: 64, positions 4-7).

25

30

- 128. A method according to claim 126, wherein the peptide comprises the amino acid sequence EVKMDAEF (SEQ ID NO: 67).
- 129. A method according to claim 125, wherein the peptide comprises the amino acid sequence NLDA (SEQ ID NO: 66).

130. A method of reducing cellular production of amyloid beta $(A\beta)$ from amyloid precursor protein (APP), comprising step of transforming or transfecting cells with an anti-sense reagent capable of reducing Asp2 polypeptide production by reducing Asp2 transcription or translation in the cells, wherein reduced Asp2 polypeptide production in the cells correlates with reduced cellular processing of APP into A β .

- 131. A method according to claim 130, wherein the cell is a neural cell.
- 10

20

25

- 132. A method according to claim 130, wherein the anti-sense reagent comprises an oligonucleotide comprising a single stranded nucleic acid sequence capable of binding to a Hu-Asp mRNA.
- 133. A method according to claim 130, wherein the anti-sense reagent comprises an oligonucleotide comprising a single stranded nucleic acid sequence capable of binding to a Hu-Asp DNA.
 - 134. A method of reducing cellular production of amyloid beta (Aβ) from amyloid precursor protein (APP), comprising steps of:
 - (a) identifying mammalian cells that produce Aβ; and
 - (b) transforming or transfecting the cells with an anti-sense reagent capable of reducing Asp2 polypeptide production by reducing Asp2 transcription or translation in the cells, wherein reduced Asp2 polypeptide production in the cells correlates with reduced cellular processing of APP into Aβ.
 - 135. A method according to claim 134, wherein the cell is a neural cell.

136. A method according to claim 134, wherein the anti-sense reagent comprises an oligonucleotide comprising a single stranded nucleic acid sequence capable of binding to a Hu-Asp mRNA.

- 5 137. A method according to claim 133, wherein the anti-sense reagent comprises an oligonucleotide comprising a single stranded nucleic acid sequence capable of binding to a Hu-Asp DNA.
- 138. A method according to claim 133, wherein the identifying step comprises diagnosing Alzheimer's disease, where Alzheimer's disease correlates with the existence of cells that produce Aβ that forms amyloid plaques in the brain.
 - 139. A vector comprising a polynucleotide according to claim 22.
- 15 140. A host cell comprising a vector according to claim 139.
 - 141. A purified polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 8.
- 20 142. A polypeptide comprising an amino acid sequence at least 95% identical to a polypeptide according to any one of claims 42-61, wherein said polypeptide lacks a transmembrane domain and retains β-secretase activity of a human Asp2 protein.
- 25 143. A method according to claim 83, wherein the first composition comprises a human Asp2 polypeptide of any one of claims 1-13, 19-24, 26-27 or 47-62.

144. A method according to claim 124 wherein the Hu-Asp2 is purified and isolated.

- 145. A method according to claim 124, wherein the Hu-Asp2 is encoded by a nucleic acid that hybridizes under stringent hybridization conditions to the complement of a Hu-Asp2-encoding polynucleotide selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 5.
- 146. A method according to claim 124, wherein the Hu-Asp2 is selected from the group consisting of:
 - (a) Hu-Asp2(a) comprising the amino acid sequence set forth in SEQ ID NO: 4;
 - (b) Hu-Asp2(b) comprising the amino acid sequence set forth in SEQ ID NO: 6; and
 - (c) fragments of Hu-Asp2(a) (SEQ ID NO: 4) and Hu-Asp2(b) (SEQ ID NO: 6) that cleave the APP substrate at a β-secretase cleavage site.
 - 147. A method according to claim 87, wherein the Hu-Asp2 comprises an amino acid sequence at least 95% identical to an amino acid sequence selected from the group consisting of SEQ ID NOS: 4 and 6.
 - 148. A method according to claim 146, wherein the Hu-Asp2 comprises a soluble fragment of Hu-Asp2(a) or Hu-Asp2(b) that lacks an Asp2 transmembrane domain.

25

15

20

149. A method according to claim 148, wherein the Hu-Asp2 has an amino acid sequence consisting of a sequence-selected from the group consisting of SEQ ID NOS: 30, 32, 51, and 53.

150. A method according to claim 148, wherein the Hu-Asp2 comprises a fragment of Hu-Asp2(a) or Hu-Asp2(b), wherein the Hu-Asp 2 lacks amino acids 1-45 of SEQ ID NOS: 4 or 6.

FIGURE 1A

ATGGGCGCACTGGCCCGG GCGCTGCTGCTG CCTCTGCTGGCC CAGTGGCTCCTG CGCGCC M G A L A R A L L L P L L A Q W L L R A CCCCGG AGCTGGCCCCG CGCCCTTCACGC TGCCCCTCCGGG TGGCCGCGGCCA CGAAC A P E L A P A P F T L P L R V A A A T N CGCGTA GTTGCGCCCACC CCGGGACCCGGG ACCCCTGCCGAG CGCCACGCCGAC GGCTTG R V V A P T P G P G T P A E R H A D G L GCGCTCGCCCTGGAGCCT GCCCTGGCGTCC CCCGCGGGCGCC GCCAACTTCTTG GCCATG A L A L E P A L A S P A G A A N F L A M GTAGACAACCTGCAGGGG GACTCTGGCCGC GGCTACTACCTG GAGATGCTGATC GGGACC V D N L Q G D S G R G Y Y L E M L I G T CCCCCG CAGAAGCTACAG ATTCTCGTTGAC ACTGGAAGCAGT AACTTTGCCGTG GCAGGA PPQKLQILVDTGSSNFAVAG ACCCCG CACTCCTACATA GACACGTACTTT GACACAGAGAGG TCTAGCACATAC CGCTCC T P H S Y I D T Y F D T E R S S T Y R S AAGGGCTTTGACGTCACA GTGAAGTACACA CAAGGAAGCTGG ACGGGCTTCGTT GGGGAA K G F D V T V K Y T Q G S W T G F V G E D L V T I P K G F N T S F L V N I A T I TTTGAATCAGAGAATTTCTTTTTGCCTGGGATTAAATGGAATGGAATACTTGGCCTAGCT FESENFFLPGIKWNGILGLA TATGCCACACTTGCCAAG CCATCAAGTTCT CTGGAGACCTTC TTCGACTCCCTG GTGACA Y A T L A K P S S S L E T F F D S L V T CAAGCA AACATCCCCAAC GTTTTCTCCATG CAGATGTGTGGA GCCGGCTTGCCC GTTGCT Q A N I P N V F S M Q M C G A G L P V A GGATCTGGGACCAACGGA GGTAGTCTTGTC TTGGGTGGAATT GAACCAAGTTTG TATAAA G S G T N G G S L V L G G I E P S L Y K GGAGACATCTGGTATACC CCTATTAAGGAA GAGTGGTACTAC CAGATAGAAATT CTGAAA G D I W Y T P I K E E W Y Y Q I E I L K TTGGAA ATTGGAGGCCAA AGCCTTAATCTG GACTGCAGAGAG TATAACGCAGAC AAGGCC L E I G G Q S L N L D C R E Y N A D K A ATCGTGGACAGTGGCACC ACGCTGCTGCGC CTGCCCCAGAAG GTGTTTGATGCG GTGGTG I V D S G T T L L R L P Q K V F D A V V GAAGCT GTGGCCCGCGCA TCTCTGATTCCA GAATTCTCTGAT GGTTTCTGGACT GGGTCC E A V A R A S L I P E F S D G F W T G S CAGCTG GCGTGCTGGACG AATTCGGAAACA CCTTGGTCTTAC TTCCCTAAAATC TCCATC Q L A C W T N S E T P W S Y F P K I S I TACCTG AGAGATGAGAAC TCCAGCAGGTCA TTCCGTATCACA ATCCTGCCTCAG CTTTAC YLRDENSSRSFRITILPQLY ATTCAG CCCATGATGGGG GCCGGCCTGAAT TATGAATGTTAC CGATTCGGCATT TCCCCA I Q P M M G A G L N Y E C Y R F G I S P TCCACA AATGCGCTGGTG ATCGGTGCCACG GTGATGGAGGGC TTCTACGTCATC TTCGAC STNALVIGATVMEGFYVIFD AGAGCC CAGAAGAGGGTG GGCTTCGCAGCG AGCCCCTGTGCA GAAATTGCAGGT GCTGCA

FIGURE 1B

FIGURE 2A

ATGGCCCAAGCCCTGCCCTGGCTCCTGCTG TGGATGGGCGCG GGAGTGCTGCCT GCCCAC MAQALPWLLLWMGAGVLPAH GGCACCCAGCACGCATC CGGCTGCCCCTG CGCAGCGGCCTG GGGGGCGCCCCC CTGGGG G T Q H G I R L P L R S G L G G A P L G CTGCGGCTGCCCCGGGAG ACCGACGAAGAG CCCGAGGAGCCC GGCCGGAGGGGC AGCTTT L R L P R E T D E E P E E P G R R G S F GTGGAGATGGTGGACAAC CTGAGGGGCAAG TCGGGGCAGGGC TACTACGTGGAG ATGACC V E M V D N L R G K S G Q G Y Y V E M T GTGGGCAGCCCCCGCAG ACGCTCAACATC CTGGTGGATACA GGCAGCAGTAAC TTTGCA V G S P P Q T L N I L V D T G S S N F A GTGGGTGCTGCCCCCAC CCCTTCCTGCAT CGCTACTACCAG AGGCAGCTGTCC AGCACA V G A A P H P F L H R Y Y Q R Q L S S T TACCGGGACCTCCGGAAG GGTGTGTATGTG CCCTACACCCAG GGCAAGTGGGAA GGGGAG Y R D L R K G V Y V P Y T Q G K W E G E CTGGGCACCGACCTGGTA AGCATCCCCCAT GGCCCCAACGTC ACTGTGCGTGCC AACATT L G T D L V S I P H G P N V T V R A N I GCTGCCATCACTGAATCA GACAAGTTCTTC ATCAACGGCTCC AACTGGGAAGGC ATCCTG A A I T E S D K F F I N G S N W E G I L GGGCTGGCCTATGCTGAG ATTGCCAGGCTT TGTGGTGCTGGC TTCCCCCTCAAC CAGTCT G L A Y A E I A R L C G A G F P L N Q S GAAGTGCTGGCCTCTGTC GGAGGGAGCATG ATCATTGGAGGT ATCGACCACTCG CTGTAC EVLASVGGSMIIGGIDHSLY ACAGGCAGTCTCTGGTAT ACACCCATCCGG CGGGAGTGGTAT TATGAGGTGATC ATTGTG TGSLWYTPIRREWYYEVIIV CGGGTGGAGATCAATGGA CAGGATCTGAAA ATGGACTGCAAG GAGTACAACTAT GACAAG R V E I N G Q D L K M D C K E Y N Y D K AGCATTGTGGACAGTGGC ACCACCAACCTT CGTTTGCCCAAG AAAGTGTTTGAA GCTGCA SIVDSGTTNLRLPKKVFEAA GTCAAATCCATCAAGGCA GCCTCCTCCACG GAGAAGTTCCCT GATGGTTTCTGG CTAGGA V K S I K A A S S T E K F P D G F W L G GAGCAGCTGGTGTGCTGG CAAGCAGGCACC ACCCCTTGGAAC ATTTTCCCAGTC ATCTCA EQLVCWQAGTTPWNIFPVIS CTCTACCTAATGGGTGAG GTTACCAACCAG TCCTTCCGCATC ACCATCCTTCCG CAGCAA LYLMGEVTNQSFRITILPQQ TACCTG CGGCCAGTGGAA GATGTGGCCACG TCCCAAGACGAC TGTTACAAGTTT GCCATC

FIGURE 2B

FIGURE 3A

ATGGCC CAAGCCCTGCCC TGGCTCCTGCTG TGGATGGGCGCG GGAGTGCTGCCT GCCCAC MAQALPWLLLWMGAGVLPAH GGCACC CAGCACGGCATC CGGCTGCCCCTG CGCAGCGGCCTG GGGGGCGCCCCC CTGGGG G T Q H G I R L P L R S G L G G A P L G CTGCGGCTGCCCCGGGAG ACCGACGAAGAG CCCGAGGAGCCC GGCCGGAGGGGC AGCTTT L R L P R E T D E E P E E P G R R G S F GTGGAGATGGTGGACAAC CTGAGGGGCAAG TCGGGGCAGGGC TACTACGTGGAG ATGACC ${\tt V}$ E M V D N L R G K S G Q G Y Y V E M T GTGGGCAGCCCCCCGCAG ACGCTCAACATC CTGGTGGATACA GGCAGCAGTAAC TTTGCA V G S P P Q T L N I L V D T G S S N F A GTGGGTGCTGCCCCCAC CCCTTCCTGCAT CGCTACTACCAG AGGCAGCTGTCC AGCACA V G A A P H P F L H R Y Y Q R Q L S S T TACCGGGACCTCCGGAAG GGTGTGTATGTG CCCTACACCCAG GGCAAGTGGGAA GGGGAG Y R D L R K G V Y V P Y T Q G K W E G E CTGGGCACCGACCTGGTA AGCATCCCCCAT GGCCCCAACGTC ACTGTGCGTGCC AACATT L G T D L V S I P H G P N V T V R A N I GCTGCCATCACTGAATCA GACAAGTTCTTC ATCAACGGCTCC AACTGGGAAGGC ATCCTG A A I T E S D K F F I N G S N W E G I L GGGCTG GCCTATGCTGAG ATTGCCAGGCCT GACGACTCCCTG GAGCCTTTCTTT GACTCT G L A Y A E I A R P D D S L E P F F D S CTGGTA AAGCAGACCCAC GTTCCCAACCTC TTCTCCCTGCAG CTTTGTGGTGCT GGCTTC L V K Q T H V P N L F S L Q L C G A G F CCCCTCAACCAGTCTGAA GTGCTGGCCTCT GTCGGAGGGAGC ATGATCATTGGA GGTATC PLNQSEVLASVGGSMIIGGI GACCACTCGCTGTACACA GGCAGTCTCTGG TATACACCCATC CGGCGGGAGTGG TATTAT D H S L Y T G S L W Y T P I R R E W Y Y GAGGTCATCATTGTGCGG GTGGAGATCAAT GGACAGGATCTG AAAATGGACTGC AAGGAG E V I I V R V E I N G Q D L K M D C K E TACAACTATGACAAGAGC ATTGTGGACAGT GGCACCACCAAC CTTCGTTTGCCC AAGAAA Y N Y D K S I V D S G T T N L R L P K K GTGTTTGAAGCTGCAGTC AAATCCATCAAG GCAGCCTCCTCC ACGGAGAAGTTC CCTGAT V F E A A V K S I K A A S S T E K F P D

FIGURE 3B

GGTTTCTGGCTAGGAGAG CAGCTGGTGTGCTGGCAAGCAGGCACCACCCCTTGGAACATT G F W L G E Q L V C W Q A G T T P W N I TTCCCAGTCATCTCACTC TACCTAATGGGT GAGGTTACCAAC CAGTCCTTCCGC ATCACC F P V I S L Y L M G E V T N Q S F R I T ATCCTT CCGCAGCAATAC CTGCGGCCAGTG GAAGATGTGGCC ACGTCCCAAGAC GACTGT I L P Q Q Y L R P V E D V A T S Q D D C TACAAG TTTGCCATCTCA CAGTCATCCACG GGCACTGTTATG GGAGCTGTTATC ATGGAG Y K F A I S Q S S T G T V M G A V I M E GGCTTCTACGTTGTCTTT GATCGGGCCCGA AAACGAATTGGC TTTGCTGTCAGC GCTTGC G F Y V V F D R A R K R I G F A V S A C CATGTG CACGATGAGTTC AGGACGGCAGCG GTGGAAGGCCCT TTTGTCACCTTG GACATG H V H D E F R T A A V E G P F V T L D M GAAGAC TGTGGCTACAAC ATTCCACAGACA GATGAGTCAACC CTCATGACCATA GCCTAT E D C G Y N I P Q T D E S T L M T I A Y GTCATGGCTGCCATCTGC GCCCTCTTCATG CTGCCACTCTGC CTCATGGTGTGT CAGTGG $\begin{smallmatrix} V \end{smallmatrix} M \end{smallmatrix} A \end{smallmatrix} A \begin{smallmatrix} I \end{smallmatrix} C \end{smallmatrix} A \end{smallmatrix} L \begin{smallmatrix} F \end{smallmatrix} M \end{smallmatrix} L \end{smallmatrix} P \end{smallmatrix} L C \end{smallmatrix} L \end{smallmatrix} M \end{smallmatrix} V C Q W$ CGCTGC CTCCGCTGCCTG CGCCAGCAGCAT GATGACTTTGCT GATGACATCTCC CTGCTG RCLRCLRQQHDDFADDISLL AAGTGA GGAGGCCCATGG GCAGAAGATAGA GATTCCCCTGGA CCACACCTCCGT GGTTCA

FIGURE 4

ATGGCCCCAGCGCTGCA CTGGCTCCTGCT ATGGGTGGGCTC GGGAATGCTGCC TGCCCAG MAPALH W L L L W V G S G M L P A Q GGAACCCATCTCGGCAT CCGGCTGCCCCT TCGCAGCGGCCT GGCAGGGCCACC CCTGGGC G T H L G I R L P L R S G L A G P P L G CTGAGGCTGCCCCGGGA GACTGACGAGGA ATCGGAGGAGCC TGGCCGGAGAGG CAGCTTT L R L P R E T D E E S E E P G R R G S F GTGGAGATGGTGGACAA CCTGAGGGGAAA GTCCGGCCAGGG CTACTATGTGGAGATGACC VEMVDNLRGKSGQGYYVEMT GTAGG CAGCCCCCACA GACGCTCAACAT CCTGGTGGACAC GGGCAGTAGTAA CTTTGCA V G S P P Q T L N I L V D T G S S N F A GTGGGGGCTGCCCACA CCCTTTCCTGCA TCGCTACTACCA GAGGCAGCTGTC CAGCACA V G A A P H P F L H R Y Y Q R Q L S S T TATCG AGACCTCCGAAA GGGTGTGTATGT GCCCTACACCCA GGGCAAGTGGGA GGGGGAA Y R D L R K G V Y V P Y T Q G K W E G E CTGGG CACCGACCTGGT GAGCATCCCTCA TGGCCCCAACGT CACTGTGCGTGC CAACATT L G T D L V S I P H G P N V T V R A N I GCTGC CATCACTGAATC GGACAAGTTCTT CATCAATGGTTC CAACTGGGAGGG CATCCTA A A I T E S D K F F I N G S N W E G I L ${\tt GGGCTGGCCTATGCTGAGATTGCCAGGCCCGACGACTCTTTGGAGCCCTTCTTTGACTCC}$ G L A Y A E I A R P D D S L E P F F D S CTGGT GAAGCAGACCCA CATTCCCAACAT CTTTTCCCTGCA GCTCTGTGGCGC TGGCTTC L V K Q T H I P N I F S L Q L C G A G F CCCCT CAACCAGACCGA GGCACTGGCCTC GGTGGGAGGGAG CATGATCATTGG TGGTATC PLNQTEALAS V G G S M I I G G I GACCA CTCGCTATACAC GGGCAGTCTCTG GTACACACCCAT CCGGCGGGAGTG GTATTAT D H S L Y T G S L W Y T P I R R E W Y Y GAAGT GATCATTGTACG TGTGGAAATCAA TGGTCAAGATCT CAAGATGGACTG CAAGGAG E V I I V R V E I N G Q D L K M D C K E TACAA CTACGACAAGAG CATTGTGGACAG TGGGACCACCAA CCTTCGCTTGCC CAAGAAA Y N Y D K S I V D S G T T N L R L P K K GTATTTGAAGCTGCCGT CAAGTCCATCAA GGCAGCCTCCTC GACGGAGAAGTT CCCGGAT V F E A A V K S I K A A S S T E K F GGCTTTTGGCTAGGGGA GCAGCTGGTGTG CTGGCAAGCAGG CACGACCCCTTG GAACATT W L G E Q L V C W Q A G T T P W N I TTCCCAGTCATTTCACT TTACCTCATGGG TGAAGTCACCAA TCAGTCCTTCCG CATCACC F P V I S L Y L M G E V T N Q S F R I T ATCCTTCCTCAGCAATA CCTACGGCCGGT GGAGGACGTGGC CACGTCCCAAGA CGACTGT I L P Q Q Y L R P V E D V A T S Q D D C TACAA GTTCGCTGTCTC ACAGTCATCCAC GGGCACTGTTAT GGGAGCCGTCAT CATGGAA Y K F A V S Q S S T G T V M G A V I M E GGTTT CTATGTCGTCTT CGATCGAGCCCG AAAGCGAATTGG CTTTGCTGTCAG CGCTTGC G F Y V V F D R A R K R I G F A V S A C CATGT GCACGATGAGTT CAGGACGGCGC AGTGGAAGGTCC GTTTGTTACGGC AGACATG H V H D E F R T A A V E G P F V T A D M GAAGA CTGTGGCTACAA CATTCCCCAGAC AGATGAGTCAAC ACTTATGACCAT AGCCTAT E D C G Y N I P Q T D E S T L M T I A Y GTCATGGCGGCCATCTG CGCCCTCTTCAT GTTGCCACTCTG CCTCATGGTATG TCAGTGG V M A A I C A L F M L P L C L M V C Q W CGCTGCCTGCGTTGCCT GCGCCACCAGCA CGATGACTTTGC TGATGACATCTC CCTGCTC R C L R C L R H Q H D D F A D D I S L L AAGTA AGGAGGCTCGTG GGCAGATGATGG AGACGCCCCTGG ACCACATCTGGG TGGTTCC CTTTGGTCACATGAGTT GGAGCTATGGAT GGTACCTGTGGC CAGAGCACCTCA GGACCCT CACCA ACCTGCCAATGC TTCTGGCGTGAC AGAACAGAGAAA TCAGGCAAGCTG GATTACA GGGCTTGCACCTGTAGG ACACAGGAGAGG GAAGGAAGCAGC GTTCTGGTGGCA GGAATAT CCTTA GGCACCACAAC TTGAGTTGGAAA TTTTGCTGCTTG AAGCTTCAGCCC TGACCCT $\mathtt{CTGCC}\,\mathtt{CAGCATCCTTTA}\,\mathtt{GAGTCTCCAACC}\,\mathtt{TAAAGTATTCTT}\,\mathtt{TATGTCCTTCCA}\,\mathtt{GAAGTAC}$ TGGCGTCATACTCAGGC TACCCGGCATGT GTCCCTGTGGTA CCCTGGCAGAGA AAGGGCC AATCT CATTCCCTGCTG GCCAAAGTCAGC AGAAGAAGGTGA AGTTTGCCAGTT GCTTTAG TGATA GGGACTGCAGAC TCAAGCCTACAC TGGTACAAAGAC TGCGTCTTGAGA TAAACAA GAA

FIGURE 5

1	MAQALPWLLLWMGAGVLPAHGTQHGIRLPLRSGLGGAPLGLRLPRETDEE	50
1	MAPALHWLLLWVGSGMLPAQGTHLGIRLPLRSGLAGPPLGLRLPRETDEE	50
51	PEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFA	100
51	SEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFA	100
101	VGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPH	150
101	VGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPH	150
151	GPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDS	200
151		200
201	LVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLW	250
201	LVKQTHIPNIFSLQLCGAGFPLNQTEALASVGGSMIIGGIDHSLYTGSLW	250
251	YTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKK	300
251	YTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKK	300
301	VFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMG	350
301		350
351	EVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIME	400
351	EVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAVSQSSTGTVMGAVIME	400
401	GFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQT	450
401	GFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTADMEDCGYNIPQT	450
451	DESTLMTIAYVMAAICALFMLPLCLMVCQWRCLRCLRQQHDDFADDISLL	500
451	DESTLMTIAYVMAAICALFMLPLCLMVCQWRCLRCLRHQHDDFADDISLL	500
501	K 501	
501	K 501	

FIGURE 6A

ATGGCTAGC ATGACTGGTGGA CAGCAAATGGGT CGCGGATCCACC CAGCACGGCATC CGG $\texttt{M} \ \texttt{A} \ \texttt{S} \ \texttt{M} \ \texttt{T} \ \texttt{G} \ \texttt{G} \ \texttt{Q} \ \texttt{Q} \ \texttt{M} \ \texttt{G} \ \texttt{R} \ \texttt{G} \ \texttt{S} \ \texttt{T} \ \texttt{Q} \ \texttt{H} \ \texttt{G} \ \texttt{I} \ \texttt{R}$ CTGCCCTG CGCAGCGGCCTG GGGGGCGCCCC CTGGGGCTGCGG CTGCCCCGGGAG ACC L P L R S G L G G A P L G L R L P R E T GACGAAGAG CCCGAGGAGCCC GGCCGGAGGGGC AGCTTTGTGGAG ATGGTGGACAAC CTG D E E P E E P G R R G S F V E M V D N L AGGGGCAAG TCGGGGCAGGGC TACTACGTGGAG ATGACCGTGGGC AGCCCCCCGCAG ACG R G K S G O G Y Y V E M T V G S P P Q T CTCAACATC CTGGTGGATACA GGCAGCAGTAAC TTTGCAGTGGGT GCTGCCCCCAC CCC L N I L V D T G S S N F A V G A A P H P TTCCTGCAT CGCTACTACCAG AGGCAGCTGTCC AGCACATACCGG GACCTCCGGAAG GGC FLHRYYOROLSSTYRDLRKG GTGTATGTG CCCTACACCCAG GGCAAGTGGGAA GGGGAGCTGGGC ACCGACCTGGTA AGC V Y V P Y T Q G K W E G E L G T D L V S ATCCCCCAT GGCCCCAACGTC ACTGTGCGTGCC AACATTGCTGCC ATCACTGAATCA GAC I P H G P N V T V R A N I A A I T E S D AAGTTCTTC ATCAACGGCTCC AACTGGGAAGGC ATCCTGGGGCTG GCCTATGCTGAG ATT K F F I N G S N W E G I L G L A Y A E I GCCAGGCCT GACGACTCCCTG GAGCCTTTCTTT GACTCTCTGGTA AAGCAGACCCAC GTT ARPDDSLEPFFDSLVKQTHV CCCAACCTC TTCTCCCTGCAG CTTTGTGGTGCT GGCTTCCCCCTC AACCAGTCTGAA GTG PNLFSLQLCGAGFPLNQSEV CTGGCCTCT GTCGGAGGGAGC ATGATCATTGGA GGTATCGACCAC TCGCTGTACACA GGC L A S V G G S M I I G G I D H S L Y T G AGTCTCTGG TATACACCCATC CGGCGGGAGTGG TATTATGAGGTC ATCATTGTGCGG GTG S L W Y T P I R R E W Y Y E V I I V R V GAGATCAAT GGACAGGATCTG AAAATGGACTGC AAGGAGTACAAC TATGACAAGAGC ATT E I N G Q D L K M D C K E Y N Y D K S I GTGGACAGT GGCACCAAC CTTCGTTTGCCC AAGAAAGTGTTT GAAGCTGCAGTC AAA V D S G T T N L R L P K K V F E A A V K TCCATCAAG GCAGCCTCCTCC ACGGAGAAGTTC CCTGATGGTTTC TGGCTAGGAGAG CAG S I K A A S S T E K F P D G F W L G E Q CTGGTGTGC TGGCAAGCAGGC ACCACCCCTTGG AACATTTTCCCA GTCATCTCACTC TAC L V C W Q A G T T P W N I F P V I S L Y CTAATGGGT GAGGTTACCAAC CAGTCCTTCCGC ATCACCATCCTT CCGCAGCAATAC CTG

CGGCCAGTGG AAGATGTGGCCA CGTCCCAAGACG ACTGTTACAAGT TTGCCATCTCAC AG

FIGURE 6B

P Q T D E S *

FIGURE 7A

ATGGCTAGC ATGACTGGTGGA CAGCAAATGGGT CGCGGATCGATG ACTATCTCTGAC TCT MASMTGGQQMGRGSMTISDS CCGCGTGAA CAGGACGGATCC ACCCAGCACGGC ATCCGGCTGCCC CTGCGCAGCGGC CTG PREQDGSTQHGIRLPLRSGL GGGGGCGCC CCCCTGGGGCTG CGGCTGCCCCGG GAGACCGACGAA GAGCCCGAGGAG CCC G G A P L G L R L P R E T D E E P E E P GGCCGGAGG GGCAGCTTTGTG GAGATGGTGGAC AACCTGAGGGGC AAGTCGGGGCAG GGC G R R G S F V E M V D N L R G K S G Q G TACTACGTG GAGATGACCGTG GGCAGCCCCCG CAGACGCTCAAC ATCCTGGTGGAT ACA Y Y V E M T V G S P P Q T L N I L V D T GGCAGCAGT AACTTTGCAGTG GGTGCTGCCCCC CACCCCTTCCTG CATCGCTACTAC CAG G S S N F A V G A A P H P F L H R Y Y Q AGGCAGCTG TCCAGCACATAC CGGGACCTCCGG AAGGGCGTGTAT GTGCCCTACACC CAG R Q L S S T Y R D L R K G V Y V P Y T GGCAAGTGG GAAGGGGAGCTG GGCACCGACCTG GTAAGCATCCCC CATGGCCCCAAC GTC G K W E G E L G T D L V S I P H G P N V ACTGTGCGT GCCAACATTGCT GCCATCACTGAA TCAGACAAGTTC TTCATCAACGGC TCC T V R A N I A A I T E S D K F F I N G S ${\tt AACTGGGAA}\,{\tt GGCATCCTGGGG}\,{\tt CTGGCCTATGCT}\,{\tt GAGATTGCCAGG}\,{\tt CCTGACGACTCC}\,{\tt CTG}$ N W E G I L G L A Y A E I A R P D D S L GAGCCTTTC TTTGACTCTCTG GTAAAGCAGACC CACGTTCCCAAC CTCTTCTCCCTG CAG E P F F D S L V K Q T H V P N L F S L Q CTTTGTGGT GCTGGCTTCCCC CTCAACCAGTCT GAAGTGCTGGCC TCTGTCGGAGGG AGC L C G A G F P L N Q S E V L A S V G G S ATGATCATT GGAGGTATCGAC CACTCGCTGTAC ACAGGCAGTCTC TGGTATACACCC ATC MII G G I D H S L Y T G S L W Y T P I CGGCGGGAG TGGTATTATGAG GTCATCATTGTG CGGGTGGAGATC AATGGACAGGAT CTG R R E W Y Y E V I I V R V E I N G Q D L AAAATGGAC TGCAAGGAGTAC AACTATGACAAG AGCATTGTGGAC AGTGGCACCACC AAC $\begin{smallmatrix} K & M & D & C & K & E & Y & N & Y & D & K & S & I & V & D & S & G & T & T & N \\ \end{smallmatrix}$ CTTCGTTTG CCCAAGAAAGTG TTTGAAGCTGCA GTCAAATCCATC AAGGCAGCCTCC TCC L R L P K K V F E A A V K S I K A A S S ACGGAGAG TTCCCTGATGGT TTCTGGCTAGGA GAGCAGCTGGTG TGCTGGCAAGCA GGC TEKFPDGFWLGEQLVCWQAG ACCACCCCTT GGAACATTTTCC CAGTCATCTCAC TCTACCTAATGG GTGAGGTTACCA AC T T P W N I F P V I S L Y L M G E V T N

FIGURE 7B

CAGTCCTTCCGCATCACCATCC TTCCGCAGCAAT ACCTGCGGCCAG TGGAAGATGTGG CC Q S F R I T I L P Q Q Y L R P V E D V A

ACGTCCCAAG ACGACTGTTACA AGTTTGCCATCT CACAGTCATCCA CGGGCACTGTTA TG T S Q D D C Y K F A I S Q S S T G T V M

GGAGCTGTTA TCATGGAGGGCT TCTACGTTGTCT TTGATCGGGCCC GAAAACGAATTG GC G A V I M E G F Y V V F D R A R K R I G

TTTGCTGTCA GCGCTTGCCATG TGCACGATGAGT TCAGGACGGCAG CGGTGAAGGCC CT F A V S A C H V H D E F R T A A V E G P

TTTGTCACCT TGGACATGGAAG ACTGTGGCTACA ACATTCCACAGA CAGATGAGTCAT GA F V T L D M E D C G Y N I P Q T D E S *

FIGURE 8A

ATGACTCAGCATGG TATTCGTCTGCC ACTGCGTAGCGG TCTGGGTGGTGC TCCACTGGGT M T Q H G I R L P L R S G L G G A P L G L R L P R E T D E E P E E P G R R G S F GTGGAGATGGTGGA CAACCTGAGGGG CAAGTCGGGGCA GGGCTACTACGT GGAGATGACC V E M V D N L R G K S G Q G Y Y V E M T GTGGGCAGCCCCC GCAGACGCTCAA CATCCTGGTGGA TACAGGCAGCAG TAACTTTGCA V G S P P Q T L N I L V D T G S S N F A -GTGGGTGCTGCCCC CCACCCCTTCCT GCATCGCTACTA CCAGAGGCAGCT GTCCAGCACA V G A A P H P F L H R Y Y Q R Q L S S T TACCGGGACCTCCG GAAGGGCGTGTA TGTGCCCTACAC CCAGGGCAAGTG GGAAGGGGAG Y R D L R K G V Y V P Y T Q G K W E G E CTGGGCACCGACCT GGTAAGCATCCC CCATGGCCCCAA CGTCACTGTGCG TGCCAACATT LGTDLVSIPHGPNVTVRANI GCTGCCATCACTGA ATCAGACAAGTT CTTCATCAACGG CTCCAACTGGGA AGGCATCCTG A A I T E S D K F F I N G S N W E G I L GGGCTGGCCTATGC TGAGATTGCCAG GCCTGACGACTC CCTGGAGCCTTT CTTTGACTCT G L A Y A E I A R P D D S L E P F F D S CTGGTAAAGCAGAC CCACGTTCCCAA CCTCTTCTCCCT GCAGCTTTGTGG TGCTGGCTTC CC CCTCAACCAGTC TGAAGTGCTGGC CTCTGTCGGAGG GAGCATGATCAT TGGAGGTATC PLNQSEVLASVGGSMIIGGI -GA CCACTCGCTGTA CACAGGCAGTCT CTGGTATACACC CATCCGGCGGGA GTGGTATTAT D H S L Y T G S L W Y T P I R R E W Y Y GA GGTCATCATTGT GCGGGTGGAGAT CAATGGACAGGA TCTGAAAATGGA CTGCAAGGAG E V I I V R V E I N G Q D L K M D C K E TA CAACTATGACAA GAGCATTGTGGA CAGTGGCACCAC CAACCTTCGTTT GCCCAAGAAA Y N Y D K S I V D S G T T N L R L P K K GTGTTTGAAGCTGC AGTCAAATCCAT CAAGGCAGCCTC CTCCACGGAGAA GTTCCCTGAT V F E A A V K S I K A A S S T E K F P D GGTTTCTGGCTAGG AGAGCAGCTGGT GTGCTGGCAAGC AGGCACCACCCC TTGGAACATT G F W L G E Q L V C W Q A G T T P W N I TT CCCAGTCATCTC ACTCTACCTAAT GGGTGAGGTTAC CAACCAGTCCTT TCGCATCACC $\begin{smallmatrix} F & P & V & I & S & L & Y & L & M & G & E & V & T & N & Q & S & F & R & I & T \\ \end{smallmatrix}$ AT CCTTCCGCAGCA ATACCTGCGGCC AGTGGAAGATGT GGCCACGTCCCA AGACGACTGT I L P Q Q Y L R P V E D V A T S Q D D C -

FIGURE 8B

CATTAG H *

FIGURE 9




FIGURE 10




FIGURE 11

MAQALPWLLLWMGAGVLPAHGTQHGIRLPLRSGLGGAPLGLRLPRETDEE
PEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFA
VGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPH
GPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDS
LVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLW
YTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKK
VFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMG
EVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIME
GFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQT
DES

FIGURE 12

MAQALPWLLLWMGAGVLPAHGTQHGIRLPLRSGLGGAPLGLRLPRETDEE PEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFA VGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPH GPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDS LVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLW YTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKK VFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMG EVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIME GFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQT DESHHHHHH

- 1 -

SEQUENCE LISTING

```
<110> Beinkowski et al.
<120> ALZHEIMER'S DISEASE SECRETASE, APP SUBSTRATES THEREFOR, AND USES
      THEREFOR
<130> 28341/6280M
< 140 >
<141>
<150> 09/416,901
<151> 1999-10-13
<150> 60/155,493
<151> 1999-09-23
<150> 09/404,133
<151> 1999-09-23
<150> PCT/US99/20881
<151> 1999-09-23
<150> 60/101,594
<151> 1998-09-24
<160> 73
<170> PatentIn Ver. 2.0
<210> 1
<211> 1804
<212> DNA
<213> Homo sapiens
<400> 1
atgggegeae tggeeeggge getgetgetg eetetgetgg eeeagtgget eetgegegee 60
geoceggage tggeocege geoctteacg etgeocetec gggtggeoge ggccacgaac 120
egegtagttg egeceacece gggaceeggg acceetgeeg agegeeaege egacggettg 180
gegetegece tggageetge cetggegtee eeegegggeg eegecaactt ettggeeatg 240
gtagacaacc tgcagggga ctctggccgc ggctactacc tggagatgct gatcgggacc 300
cccccgcaga agctacagat tctcgttgac actggaagca gtaactttgc cgtggcagga 360
accocgcact cotacataga cacgtacttt gacacagaga ggtctagcac ataccgctcc 420
aagggetttg acgteacagt gaagtacaca caaggaaget ggacgggett egttggggaa 480
gacctegtea ceatececaa aggetteaat acttettte ttgteaacat tgecactatt 540
tttgaatcag agaatttett tttgeetggg attaaatgga atggaataet tggeetaget 600
tatgccacac ttgccaagcc atcaagttct ctggagacct tcttcgactc cctggtgaca 660
caaqcaaaca teeccaaegt ttteteeatg cagatgtgtg gageeggett geeegttget 720
ggatctggga ccaacggagg tagtcttgtc ttgggtggaa ttgaaccaag tttgtataaa 780
ggagacatet ggtatacece tattaaggaa gagtggtaet accagataga aattetgaaa 840
ttggaaattg gaggccaaag ccttaatctg gactgcagag agtataacgc agacaaggcc 900
ategtggaca gtggcaccac getgetgege etgececaga aggtgtttga tgeggtggtg 960
gaagetgtgg ceegegeate tetgatteea gaattetetg atggtttetg gaetgggtee 1020
cagetggegt getggaegaa tteggaaaca eettggtett aetteeetaa aateteeate 1080
tacetgagag atgagaacte cagcaggtea tteegtatea caateetgee teagetttae 1140
attcagccca tgatggggc cggcctgaat tatgaatgtt accgattcgg catttcccca 1200
tccacaaatg cgctggtgat cggtgccacg gtgatggagg gcttctacgt catcttcgac 1260
agageceaga agagggtggg ettegeageg ageceetgtg cagaaattge aggtgetgea 1320
gtgtctgaaa tttccgggcc tttctcaaca gaggatgtag ccagcaactg tgtccccgct 1380
cagtetttga gegageceat tttgtggatt gtgteetatg egeteatgag egtetgtgga 1440
 gecatectee tigiettaat egicetgeig eigetgeegt teeggigtea gegiegeeee 1500
```

PCT/IB01/00797 WO 01/49097

- 2 -

gcca agca	ggcc gccg ccag ctac	tg a gg a at g	.cctc .tcga .cctt	aagc tggt ctaq	a ac g gc a tt	catg gctt cact	aact tctc gtct	cag ctg ttt	ctat tgcc gatt	taa cac ctt	gaaa ccgt gatt	atca cttc ttca	ica t aa t iag c	ttcc ctct tttc	gaata agggc gttct aaatc aaaaa
<210 <211 <212 <213	> 51 > PF	RT.	apie	ns											
<400 Met	> 2 Gly	Ala	Leu	Ala 5	Arg	Ala	Leu	Leu	Leu 10	Pro	Leu	Leu	Ala	Gln 15	Trp
Leu	Leu	Arg	Ala 20	Ala	Pro	Glu	Leu	Ala 25	Pro	Ala	Pro	Phe	Thr 30	Leu	Pro
Leu	Arg	Val 35	Ala	Ala	Ala	Thr	Asn 40	Arg	Val	Val	Ala	Pro 45	Thr	Pro	Gly
Pro	Gly 50	Thr	Pro	Ala	Glu	Arg 55	His	Ala	Asp	Gly	Leu 60	Ala	Leu	Ala	Leu
Glu 65	Pro	Ala	Leu	Ala	Ser 70	Pro	Ala	Gly	Ala	Ala 75	Asn	Phe	Leu	Ala	Met 80
Val	Asp	Asn	Leu	Gln 85	Gly	Asp	Ser	Gly	Arg 90	Gly	Tyr	Tyr	Leu	Glu 95	Met
Leu	Ile	Gly	Thr 100	Pro	Pro	Gln	Lys	Leu 105	Gln	Ile	Leu	Val	Asp 110	Thr	Gly
Ser	Ser	Asn 115	Phe	Ala	Val	Ala	Gly 120	Thr	Pro	His	Ser	Tyr 125	Ile	Asp	Thr
Tyr	Phe 130	Asp	Thr	Glu	Arg	Ser 135	Ser	Thr	Tyr	Arg	Ser 140	Lys	Gly	Phe	Asp
Val 145	Thr	Val	Lys	Tyr	Thr 150	Gln	Gly	Ser	Trp	Thr 155	Gly	Phe	Val	Gly	Glu 160
Asp	Leu	Val	Thr	Ile 165	Pro	Lys	Gly	Phe	Asn 170	Thr	Ser	Phe	Leu	Val 175	Asn
Ile	Ala	Thr	Ile 180	Phe	Glu	Ser	Glu	Asn 185	Phe	Phe	Leu	Pro	Gly 190	Ile	Lys
Trp	Asn	Gly 195	Ile	Leu	Gly	Leu	Ala 200	Tyr	Ala	Thr	Leu	Ala 205	Lys	Pro	Ser
Ser	Ser 210		Glu	Thr	Phe	Phe 215	Asp	Ser	Leu	Val	Thr 220	Gln	Ala	Asn	Ile
Pro 225		. Val	Phe	Ser	Met 230	Gln	Met	Cys	Gly	Ala 235	Gly	Leu	Pro	Val	Ala 240
Gly	Ser	Gly	Thr	Asn 245		Gly	Ser	Leu	Val 250	Leu	Gly	Gly	Ile	Glu 255	Pro

PCT/IB01/00797 WO 01/49097

- 3 -

Ser Leu Tyr Lys Gly Asp Ile Trp Tyr Thr Pro Ile Lys Glu Glu Trp 265

Tyr Tyr Gln Ile Glu Ile Leu Lys Leu Glu Ile Gly Gly Gln Ser Leu

Asn Leu Asp Cys Arg Glu Tyr Asn Ala Asp Lys Ala Ile Val Asp Ser 295

Gly Thr Thr Leu Leu Arg Leu Pro Gln Lys Val Phe Asp Ala Val Val

Glu Ala Val Ala Arg Ala Ser Leu Ile Pro Glu Phe Ser Asp Gly Phe

Trp Thr Gly Ser Gln Leu Ala Cys Trp Thr Asn Ser Glu Thr Pro Trp 345

Ser Tyr Phe Pro Lys Ile Ser Ile Tyr Leu Arg Asp Glu Asn Ser Ser

Arg Ser Phe Arg Ile Thr Ile Leu Pro Gln Leu Tyr Ile Gln Pro Met

Met Gly Ala Gly Leu Asn Tyr Glu Cys Tyr Arg Phe Gly Ile Ser Pro 390

Ser Thr Asn Ala Leu Val Ile Gly Ala Thr Val Met Glu Gly Phe Tyr

Val Ile Phe Asp Arg Ala Gln Lys Arg Val Gly Phe Ala Ala Ser Pro

Cys Ala Glu Ile Ala Gly Ala Ala Val Ser Glu Ile Ser Gly Pro Phe

Ser Thr Glu Asp Val Ala Ser Asn Cys Val Pro Ala Gln Ser Leu Ser

Glu Pro Ile Leu Trp Ile Val Ser Tyr Ala Leu Met Ser Val Cys Gly 465

Ala Ile Leu Leu Val Leu Ile Val Leu Leu Leu Pro Phe Arg Cys 490 485

Gln Arg Arg Pro Arg Asp Pro Glu Val Val Asn Asp Glu Ser Ser Leu 505

Val Arg His Arg Trp Lys 515

<210> 3

<211> 2070

<212> DNA

<213> Homo sapiens

<400> 3

atggeccaag ceetgeeetg geteetgetg tggatggeg egggagtget geetgeeeac 60 ggcacccagc acggcatccg gctgcccctg cgcagcggcc tggggggcgc ccccctgggg 120 gtggagatgg tggacaacct gaggggcaag tcggggcagg gctactacgt ggagatgacc 240 - 4 -

```
qtqqqcaqcc cccqcaqac qctcaacatc ctgqtqqata cagqcagcaq taactttgca 300
qtqqtgctg cccccaccc cttcctgcat cgctactacc agaggcagct gtccagcaca 360
tacegggace teeggaaggg tgtgtatgtg cectacaeee agggcaagtg ggaaggggag 420
ctgggeaceg acetggtaag catececcat ggeeceaaeg teactgtgeg tgeeaacatt 480
gctgccatca ctgaatcaga caagttcttc atcaacggct ccaactggga aggcatcctg 540
qqqctqqcct atqctgagat tgccaggcct gacgactccc tggagccttt ctttgactct 600
ctggtaaagc agaccacgt teccaacete ttetecetge acetttgtgg tgetggette 660
ccctcaacc agtotgaagt gotggcotot gtoggaggga goatgatoat tggaggtato 720
gaccactege tgtacacagg cagtetetgg tatacaceca teeggeggga gtggtattat 780
gaggtcatca ttgtgcgggt ggagatcaat ggacaggatc tgaaaatgga ctgcaaggag 840
tacaactatg acaagagcat tgtggacagt ggcaccacca accttcgttt gcccaagaaa 900
gtgtttgaag ctgcagtcaa atccatcaag gcagcctcct ccacggagaa gttccctgat 960
ggtttctggc taggagagca gctggtgtgc tggcaagcag gcaccacccc ttggaacatt 1020
ttcccagtca tctcactcta cctaatgggt gaggttacca accagtcctt ccgcatcacc 1080
atcetteege ageaatacet geggeeagtg gaagatgtgg ccaegteeca agacgactgt 1140
tacaagtttg ccatctcaca gtcatccacg ggcactgtta tgggagctgt tatcatggag 1200
ggcttctacg ttgtctttga tcgggcccga aaacgaattg gctttgctgt cagcgcttgc 1260
catgtgcacg atgagttcag gacggcagcg gtggaaggcc cttttgtcac cttggacatg 1320
gaagactgtg getacaacat tecacagaca gatgagteaa ceeteatgac catageetat 1380
gtcatggctg ccatctgcgc cctcttcatg ctgccactct gcctcatggt gtgtcagtgg 1440
egetgeetee getgeetgeg eeageageat gatgaetttg etgatgaeat eteeetgetg 1500
aagtgaggag geceatggge agaagataga gatteeeetg gaccacacet cegtggttea 1560
ctttggtcac aagtaggaga cacagatggc acctgtggcc agagcacctc aggaccctcc 1620
ccacccacca aatgcctctg ccttgatgga gaaggaaaag gctggcaagg tgggttccag 1680
ggactgtacc tgtaggaaac agaaaagaga agaaagaagc actctgctgg cgggaatact 1740
cttggtcacc tcaaatttaa gtcgggaaat tctgctgctt gaaacttcag ccctgaacct 1800
gtactggcat cacacgcagg ttaccttggc gtgtgtccct gtggtaccct ggcagagaag 1920
agaccaagct tgtttccctg ctggccaaag tcagtaggag aggatgcaca gtttgctatt 1980
tgctttagag acagggactg tataaacaag cctaacattg gtgcaaagat tgcctcttga 2040
attaaaaaaa aaaaaaaaaa aaaaaaaaaa
<210> 4
<211> 501
<212> PRT
<213> Homo sapiens
Met Ala Gln Ala Leu Pro Trp Leu Leu Leu Trp Met Gly Ala Gly Val
Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser
Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp
Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val
Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr
Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser
Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr
                               105
           100
Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val
```

120

Tyr	Val 130	Pro	Tyr	Thr	Gln	Gly 135	Lys	Trp	Glu	Gly	Glu 140	Leu	Gly	Thr	Asp
Leu 145	Val	Ser	Ile	Pro	His 150	Gly	Pro	Asn	Val	Thr 155	Val	Arg	Ala	Asn	Ile 160
Ala	Ala	Ile	Thr	Glu 165	Ser	Asp	Lys	Phe	Phe 170	Ile	Asn	Gly	Ser	Asn 175	Trp
Glu	Gly	Ile	Leu 180	Gly	Leu	Ala	Tyr	Ala 185	Glu	Ile	Ala	Arg	Pro 190	Asp	Asp
Ser	Leu	Glu 195	Pro	Phe	Phe	Asp	Ser 200	Leu	Val	Lys	Gln	Thr 205	His	Val	Pro
Asn	Leu 210	Phe	Ser	Leu	His	Leu 215	Cys	Gly	Ala	Gly	Phe 220	Pro	Leu	Asn	Gln
Ser 225	Glu	Val	Leu	Ala	Ser 230	Val	Gly	Gly	Ser	Met 235	Ile	Ile	Gly	Gly	Ile 240
Asp	His	Ser	Leu	Tyr 245	Thr	Gly	Ser	Leu	Trp 250	Tyr	Thr	Pro	Ile	Arg 255	Arg
Glu	Trp	Tyr	Tyr 260	Glu	Val	Ile	Ile	Val 265	Arg	Val	Glu	Ile	Asn 270	Gly	Gln
Asp	Leu	Lys 275	Met	Asp	Cys	Lys	Glu 280	Tyr	Asn	Tyr	Asp	Lys 285	Ser	Ile	Val
Asp	Ser 290	Gly	Thr	Thr	Asn	Leu 295	Arg	Leu	Pro	Lys	Lys 300	Val	Phe	Glu	Ala
Ala 305	Val	Lys	Ser	Ile	Lys 310	Ala	Ala	Ser	Ser	Thr 315	Glu	Lys	Phe	Pro	Asp 320
Gly	Phe	Trp	Leu	Gly 325	Glu	Gln	Leu	Val	Cys 330	Trp	Gln	Ala	Gly	Thr 335	Thr
Pro	Trp	Asn	Ile 340	Phe	Pro	Val	Ile	Ser 345	Leu	Tyr	Leu	Met	Gly 350	Glu	Val
Thr	Asn	Gln 355	Ser	Phe	Arg	Ile	Thr 360	Ile	Leu	Pro	Gln	Gln 365	Tyr	Leu	Arg
Pro	Val 370	Glu	Asp	Val	Ala	Thr 375	Ser	Gln	Asp	Asp	Cys 380	Tyr	Lys	Phe	Ala
Ile 385	Ser	Gln	Ser	Ser	Thr 390	Gly	Thr	Val	Met	Gly 395	Ala	Val	Ile	Met	Glu 400
Gly	Phe	Tyr	Val	Val 405	Phe	Asp	Arg	Ala	Arg 410	Lys	Arg	Ile	Gly	Phe 415	Ala
Val	Ser	Ala	Cys 420	His	Val	His	Asp	Glu 425	Phe	Arg	Thr	Ala	Ala 430	Val	Glu
Gly	Pro	Phe 435	Val	Thr	Leu	Asp	Met 440	Glu	Asp	Cys	Gly	Tyr 445	Asn	Ile	Pro
Gln	Thr 450		Glu	Ser	Thr	Leu 455	Met	Thr	Ile	Ala	Tyr 460	Val	Met	Ala	Ala

-6-

Ile Cys Ala Leu Phe Met Leu Pro Leu Cys Leu Met Val Cys Gln Trp 475 470 465 Arg Cys Leu Arg Cys Leu Arg Gln Gln His Asp Asp Phe Ala Asp Asp 485 490 Ile Ser Leu Leu Lys <210> 5 <211> 1977 <212> DNA <213> Homo sapiens <400> 5 atggcccaag ccctgccctg gctcctgctg tggatggcg cgggagtgct gcctgcccac 60 ggcacccage acggcatecg getgeceetg egcageggee tgggggggege ceceetgggg 120 qtqqaqatqq tggacaacct gaggggcaag tcggggcagg gctactacgt ggagatgacc 240 gtgggcagcc ccccgcagac gctcaacatc ctggtggata caggcagcag taactttgca 300 gtgggtgctg ccccccaccc cttcctgcat cgctactacc agaggcagct gtccagcaca 360 taccqqqacc tccggaaggg tgtgtatgtg ccctacaccc agggcaagtg ggaaggggag 420 ctgggcaccg acctggtaag catcccccat ggccccaacg tcactgtgcg tgccaacatt 480 getgecatea etgaateaga caagttette ateaaegget eeaaetggga aggeateetg 540 gggctggcct atgctgagat tgccaggctt tgtggtgctg gcttccccct caaccagtct 600 gaaqtqctqq cctctqtcqq aqqqaqcatq atcattggag gtatcgacca ctcgctgtac 660 acaggcagtc tctggtatac acccatccgg cgggagtggt attatgaggt gatcattgtg 720 cgggtggaga tcaatggaca ggatctgaaa atggactgca aggagtacaa ctatgacaag 780 agcattgtgg acagtggcac caccaacctt cgtttgccca agaaagtgtt tgaagctgca 840 qtcaaatcca tcaaqqcaqc ctcctccacg gagaagttcc ctgatggttt ctggctagga 900 qaqcaqctqq tqtqctqqca aqcaggcacc accccttgga acattttccc agtcatctca 960 ctctacctaa tgggtgaggt taccaaccag tccttccgca tcaccatcct tccgcagcaa 1020 tacctgcggc cagtggaaga tgtggccacg tcccaagacg actgttacaa gtttgccatc 1080 tcacagtcat ccacgggcac tgttatggga gctgttatca tggagggctt ctacgttgtc 1140 tttgatcggg cccgaaaacg aattggcttt gctgtcagcg cttgccatgt gcacgatgag 1200 ttcaggacgg cagcggtgga aggccctttt gtcaccttgg acatggaaga ctgtggctac 1260 aacattccac agacagatga qtcaaccctc atgaccatag cctatgtcat ggctgccatc 1320 tgegeeetet teatgetgee actetgeete atggtgtgte agtggegetg ecteegetge 1380 ctgegccage ageatgatga etttgetgat gacatetece tgetgaagtg aggaggeeca 1440 tgggcagaag atagagattc ccctggacca cacctccgtg gttcactttg gtcacaagta 1500 ggagacacag atggcacctg tggccagagc acctcaggac cctccccacc caccaaatgc 1560 ctctqccttq atqqaqaagg aaaaggctgg caaggtgggt tccagggact gtacctgtag 1620 gaaacagaaa agagaagaaa gaagcactct gctggcggga atactcttgg tcacctcaaa 1680 tttaagtegg gaaattetge tgettgaaac tteageeetg aacetttgte caccatteet 1740 ttaaattctc caacccaaag tattcttctt ttcttagttt cagaagtact ggcatcacac 1800 gcaggttacc ttggcgtgtg tccctgtggt accctggcag agaagagacc aagcttgttt 1860 ccctgctggc caaagtcagt aggagaggat gcacagtttg ctatttgctt tagagacagg 1920 gactgtataa acaagcctaa cattggtgca aagattgcct cttgaaaaaa aaaaaaa <210> 6 <211> 476 <212> PRT <213> Homo sapiens <400> 6 Met Ala Gln Ala Leu Pro Trp Leu Leu Leu Trp Met Gly Ala Gly Val Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser

Gly	Leu	Gly 35	Gly	Ala	Pro	Leu	Gly 40	Leu	Arg	Leu	Pro	Arg 45	Glu	Thr	Asp
Glu	Glu 50	Pro	Glu	Glu	Pro	Gly 55	Arg	Arg	Gly	Ser	Phe 60	Val	Glu	Met	Val
Asp 65	Asn	Leu	Arg	Gly	Lys 70	Ser	Gly	Gln	Gly	Tyr 75	Tyr	Val	Glu	Met	Thr 80
Val	Gly	Ser	Pro	Pro 85	Gln	Thr	Leu	Asn	Ile 90	Leu	Val	Asp	Thr	Gly 95	Ser
Ser	Asn	Phe	Ala 100	Val	Gly	Ala	Ala	Pro 105	His	Pro	Phe	Leu	His 110	Arg	Tyr
Tyr	Gln	Arg 115	Gln	Leu	Ser	Ser	Thr 120	Tyr	Arg	Asp	Leu	Arg 125	Lys	Gly	Val
Tyr	Val 130	Pro	Tyr	Thr	Gln	Gly 135	Lys	Trp	Glu	Gly	Glu 140	Leu	Gly	Thr	Asp
Leu 145	Val	Ser	Ile	Pro	His 150	Gly	Pro	Asn	Val	Thr 155	Val	Arg	Ala	Asn	Ile 160
Ala	Ala	Ile	Thr	Glu 165	Ser	Asp	Lys	Phe	Phe 170	Ile	Asn	Gly	Ser	Asn 175	Trp
Glu	Gly	Ile	Leu 180	Gly	Leu	Ala	Tyr	Ala 185	Glu	Ile	Ala	Arg	Leu 190	Cys	Gly
Ala	Gly	Phe 195	Pro	Leu	Asn	Gln	Ser 200	Glu	Val	Leu	Ala	Ser 205	Val	Gly	Gly
Ser	Met 210	Ile	Ile	Gly	Gly	Ile 215	Asp	His	Ser	Leu	Tyr 220	Thr	Gly	Ser	Leu
Trp 225	Tyr	Thr	Pro	Ile	Arg 230	Arg	Glu	Trp	Tyr	Tyr 235	Glu	Val	Ile	Ile	Val 240
Arg	Val	Glu	Ile	Asn 245	Gly	Gln	Asp	Leu	Lys 250	Met	Asp	Cys	Lys	Glu 255	Tyr
Asn	Tyr	Asp	Lys 260	Ser	Ile	Val	Asp	Ser 265	Gly	Thr	Thr	Asn	Leu 270	Arg	Leu
Pro	Lys	Lys 275	Val	Phe	Glu	Ala	Ala 280	Val	Lys	Ser	Ile	Lys 285	Ala	Ala	Ser
Ser	Thr 290	Glu	Lys	Phe	Pro	Asp 295	Gly	Phe	Trp	Leu	Gly 300	Glu	Gln	Leu	Val
Cys 305	Trp	Gln	Ala	Gly	Thr 310	Thr	Pro	Trp	Asn	Ile 315	Phe	Pro	Val	Ile	Ser 320
Leu	Tyr	Leu	Met	Gly 325	Glu	Val	Thr	Asn	Gln 330	Ser	Phe	Arg	Ile	Thr 335	Ile
Leu	Pro	Gln	Gln 340	Tyr	Leu	Arg	Pro	Val 345	Glu	Asp	Val	Ala	Thr 350	Ser	Gln
Asp	Asp	Cys 355	Tyr	Lys	Phe	Ala	Ile 360	Ser	Gln	Ser	Ser	Thr 365	Gly	Thr	Val

- 8 -

```
Met Gly Ala Val Ile Met Glu Gly Phe Tyr Val Val Phe Asp Arg Ala
Arg Lys Arg Ile Gly Phe Ala Val Ser Ala Cys His Val His Asp Glu
                                        395
Phe Arg Thr Ala Ala Val Glu Gly Pro Phe Val Thr Leu Asp Met Glu
                                    410
Asp Cys Gly Tyr Asn Ile Pro Gln Thr Asp Glu Ser Thr Leu Met Thr
            420
                                425
Ile Ala Tyr Val Met Ala Ala Ile Cys Ala Leu Phe Met Leu Pro Leu
                            440
Cys Leu Met Val Cys Gln Trp Arg Cys Leu Arg Cys Leu Arg Gln Gln
                        455
His Asp Asp Phe Ala Asp Asp Ile Ser Leu Leu Lys
                    470
<210> 7
<211> 2043
<212> DNA
<213> Mus musculus
<400> 7
atggcccag cgctgcactg gctcctgcta tgggtgggct cgggaatgct gcctgcccag 60
qqaacccatc teggcateeg getgeeeett egeageggee tggeagggee acccetggge 120
ctqaqqctqc cccqqqaqac tqacqaqqaa tcqqagqagc ctggccggag aggcagcttt 180
gtggagatgg tggacaacct gaggggaaag tccggccagg gctactatgt ggagatgacc 240
gtaggcagcc cccacagac gctcaacatc ctggtggaca cgggcagtag taactttgca 300
gtgggggctg ccccacaccc tttcctgcat cgctactacc agaggcagct gtccagcaca 360
tategagaee teegaaaggg tgtgtatgtg cectacaeee agggeaagtg ggagggggaa 420
ctqqqcaccq acctqqtqaq catccctcat ggccccaacg tcactqtgcg tgccaacatt 480
gctgccatca ctgaatcgga caagttcttc atcaatggtt ccaactggga gggcatccta 540
gggctggcct atgctgagat tgccaggccc gacgactett tggagccctt etttgactcc 600
ctqqtqaaqc aqaccacat teccaacate ttttecetge agetetgtgg egetggette 660
cccctcaacc aqaccgaggc actggcctcg gtgggaggga gcatgatcat tggtggtatc 720
gaccactege tatacaeggg cagtetetgg tacacaecea teeggeggga gtggtattat 780
gaagtgatca ttgtacgtgt ggaaatcaat ggtcaagatc tcaagatgga ctgcaaggag 840
tacaactacg acaagagcat tgtggacagt gggaccacca accttegett geccaagaaa 900
gtatttgaag ctgccgtcaa gtccatcaag gcagcctcct cgacggagaa gttcccggat 960
ggettttgge taggggagea getggtgtge tggeaageag geaegaeeee ttggaacatt 1020
ttcccagtca tttcacttta cctcatgggt gaagtcacca atcagtcctt ccgcatcacc 1080
atcetteete ageaataeet aeggeeggtg gaggaegtgg ceaegteeea agacgaetgt 1140
tacaaqttcq ctqtctcaca qtcatccacq qqcactqtta tggqaqccqt catcatqqaa 1200
ggtttctatg tcgtcttcga tcgagcccga aagcgaattg gctttgctgt cagcgcttgc 1260
catgtgcacg atgagttcag gacggcggca gtggaaggtc cgtttgttac ggcagacatg 1320
gaagactgtg gctacaacat tccccagaca gatgagtcaa cacttatgac catagcctat 1380
gtcatggcgg ccatctgcgc cctcttcatg ttgccactct gcctcatggt atgtcagtgg 1440
egetgeetge gttgeetgeg ceaecageae gatgaetttg etgatgaeat etecetgete 1500
aagtaaggag getegtggge agatgatgga gaegeeeetg gaecacatet gggtggttee 1560
ctttggtcac atgagttgga gctatggatg gtacctgtgg ccagagcacc tcaggaccct 1620
caccaacctg ccaatgcttc tggcgtgaca gaacagagaa atcaggcaag ctggattaca 1680
gggcttgcac ctgtaggaca caggagaggg aaggaagcag cgttctggtg gcaggaatat 1740
ccttaggcac cacaaacttg agttggaaat tttgctgctt gaagcttcag ccctgaccct 1800
ctgcccaqca tcctttaqaq tctccaacct aaaqtattct ttatgtcctt ccagaagtac 1860
tggcgtcata ctcaggctac ccggcatgtg tccctgtggt accctggcag agaaagggcc 1920
```

aatctcattc cetgetggcc aaagtcagca gaagaaggtg aagtttgcca gttgctttag 1980 tgatagggac tgcagactca agcctacact ggtacaaaga ctgcgtcttg agataaacaa 2040

gaa

2043

<210> 8

<211> 501

<212> PRT

<213> Mus musculus

<400> 8

Met Ala Pro Ala Leu His Trp Leu Leu Leu Trp Val Gly Ser Gly Met 1 5 10 15

Leu Pro Ala Gln Gly Thr His Leu Gly Ile Arg Leu Pro Leu Arg Ser 20 25 30

Gly Leu Ala Gly Pro Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp 35 40 45

Glu Glu Ser Glu Glu Pro Gly Arg Gly Ser Phe Val Glu Met Val 50 55 60

Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr 65 70 75 80

Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser 85 90 95

Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr $100 \hspace{1.5cm} 105 \hspace{1.5cm} 110 \hspace{1.5cm}$

Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val 115 120 125

Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp 130 135 140

Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val Arg Ala Asn Ile 145 150 155 160

Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser Asn Trp
165 170 175

Glu Gly Ile Leu Gly Leu Ala Tyr Ala Glu Ile Ala Arg Pro Asp Asp 180 185 190

Ser Leu Glu Pro Phe Phe Asp Ser Leu Val Lys Gln Thr His Ile Pro 195 200 205

Asn Ile Phe Ser Leu Gln Leu Cys Gly Ala Gly Phe Pro Leu Asr. Gln 210 215 220

Thr Glu Ala Leu Ala Ser Val Gly Gly Ser Met Ile Ile Gly Gly Ile 225 230 235 240

Asp His Ser Leu Tyr Thr Gly Ser Leu Trp Tyr Thr Pro Ile Arg Arg 245 250 255

Glu Trp Tyr Tyr Glu Val Ile Ile Val Arg Val Glu Ile Asn Gly Gln 260 265 270

Asp Leu Lys Met Asp Cys Lys Glu Tyr Asn Tyr Asp Lys Ser Ile Val 275 280 285

Asp Ser Gly Thr Thr Asn Leu Arg Leu Pro Lys Lys Val Phe Glu Ala 290 295 300

- 10 -

Ala Val Lys Ser Ile Lys Ala Ala Ser Ser Thr Glu Lys Phe Pro Asp 315 Gly Phe Trp Leu Gly Glu Gln Leu Val Cys Trp Gln Ala Gly Thr Thr Pro Trp Asn Ile Phe Pro Val Ile Ser Leu Tyr Leu Met Gly Glu Val Thr Asn Gln Ser Phe Arq Ile Thr Ile Leu Pro Gln Gln Tyr Leu Arg 355 360 Pro Val Glu Asp Val Ala Thr Ser Gln Asp Asp Cys Tyr Lys Phe Ala Val Ser Gln Ser Ser Thr Gly Thr Val Met Gly Ala Val Ile Met Glu 390 Gly Phe Tyr Val Val Phe Asp Arg Ala Arg Lys Arg Ile Gly Phe Ala 405 410 Val Ser Ala Cys His Val His Asp Glu Phe Arg Thr Ala Ala Val Glu Gly Pro Phe Val Thr Ala Asp Met Glu Asp Cys Gly Tyr Asn Ile Pro Gln Thr Asp Glu Ser Thr Leu Met Thr Ile Ala Tyr Val Met Ala Ala 455 Ile Cys Ala Leu Phe Met Leu Pro Leu Cys Leu Met Val Cys Gln Trp Arg Cys Leu Arg Cys Leu Arg His Gln His Asp Asp Phe Ala Asp Asp 490 Ile Ser Leu Leu Lys 500 <210> 9 <211> 2088 <212> DNA <213> Homo sapiens atgctgcccg gtttggcact gctcctgctg gccgcctgga cggctcgggc gctggaggta 60 cccactgatg gtaatgctgg cctgctggct gaaccccaga ttgccatgtt ctgtggcaga 120 ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggaccaaa 180 acctgcattg ataccaagga aggcatcctg cagtattgcc aagaagtcta ccctgaactg 240 cagatcacca atgtqqtaqa agccaaccaa ccagtgacca tccagaactg gtgcaagcgg 300 ggccgcaagc agtgcaagac ccatccccac tttgtgattc cctaccgctg cttagttggt 360 gagtttgtaa gtgatgccct tctcgttcct gacaagtgca aattcttaca ccaggagagg 420 atggatgttt gcgaaactca tetteactgg cacaccgtcg ccaaagagac atgcagtgag 480 aagagtacca acttgcatga ctacggcatg ttgctgccct gcggaattga caagttccga 540 ggggtagagt ttgtgttgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600 geggaggagg atgaetegga tgtetggtgg ggeggageag acaeagaeta tgeagatggg 660 agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720 gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780 ccctacqaaq aaqccacaqa qaqaaccacc aqcattqcca ccaccaccac caccaccaca 840 gagtetgtgg aagaggtggt tegagtteet acaacagcag ecagtacece tgatgeegtt 900 gacaagtatc tcgagacacc tggggatgag aatgaacatg cccatttcca gaaagccaaa 960 gagaggettg aggecaagea eegagagaga atgteecagg teatgagaga atgggaagag 1020

```
qcaqaacgtc aagcaaagaa cttgcctaaa gctgataaga aggcagttat ccagcatttc 1080
caggagaaag tggaatcttt ggaacaggaa gcagccaacg agagacagca gctggtggag 1140
acacacatgg ccagagtgga agccatgctc aatgaccgcc gccgcctggc cctggagaac 1200
tacatcaccg ctctgcaggc tgttcctcct cggcctcgtc acgtgttcaa tatgctaaag 1260
aaqtatqtcc qcqcaqaaca gaaggacaga cagcacaccc taaagcattt cgagcatgtg 1320
cqcatqqtqq atcccaaqaa agccgctcag atccggtccc aggttatgac acacctccgt 1380
gtgatttatg agcgcatgaa tcagtctctc tccctgctct acaacgtgcc tgcagtggcc 1440
gaggagattc aggatgaagt tgatgagctg cttcagaaag agcaaaacta ttcagatgac 1500
gtcttggcca acatgattag tgaaccaagg atcagttacg gaaacgatgc tctcatgcca 1560
tetttgaccg aaacgaaaac caccgtggag etcetteceg tgaatggaga gtteageetg 1620
gacgatetee ageegtggea ttettttggg getgaetetg tgccagecaa cacagaaaac 1680
gaagttgage etgttgatge eegeeetget geegaeegag gaetgaeeae tegaeeaggt 1740
tctgggttga caaatatcaa gacggaggag atctctgaag tgaagatgga tgcagaattc 1800
cqacatqact caggatatga agttcatcat caaaaattgg tgttctttgc agaagatgtg 1860
qqttcaaaca aaqqtqcaat cattggactc atggtgggcg gtgttgtcat agcgacagtg 1920
atcgtcatca ccttggtgat gctgaagaag aaacagtaca catccattca tcatggtgtg 1980
qtqqaqqttq acgccgctgt caccccagag gagcgccacc tgtccaagat gcagcagaac 2040
ggctacgaaa atccaaccta caagttcttt gagcagatgc agaactag
<210> 10
<211> 695
<212> PRT
<213> Homo sapiens
<400> 10
Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
             20
Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
                            120
Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys
Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu
145
Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
                                    170
                165
Asp Lys Phe Arq Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
                                185
```

- 12 -

A	7 ~~	77.07	7 ~~	Cox	7.7.	7 00	7.7 ~	C111	α_{11}	-

Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val 195 200 205

Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys 210 215 220

Val Val Glu Val Ala Glu Glu Glu Glu Val Ala Glu Val Glu Glu Glu 225 230 235 240

Glu Ala Asp Asp Asp Glu Asp Glu Asp Glu Asp Glu Val Glu Glu 245 250 255

Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile
260 265 270

Ala Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg 275 280 285

Val Pro Thr Thr Ala Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu 290 295 300

Glu Thr Pro Gly Asp Glu Asn Glu His Ala His Phe Gln Lys Ala Lys 305 310 315 320

Glu Arg Leu Glu Ala Lys His Arg Glu Arg Met Ser Gln Val Met Arg 325 330 335

Glu Trp Glu Glu Ala Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp 340 345 350

Lys Lys Ala Val Ile Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu 355 360 365

Gln Glu Ala Ala Asn Glu Arg Gln Gln Leu Val Glu Thr His Met Ala 370 380

Arg Val Glu Ala Met Leu Asn Asp Arg Arg Leu Ala Leu Glu Asn 385 390 395 400

Tyr Ile Thr Ala Leu Gln Ala Val Pro Pro Arg Pro Arg His Val Phe 405 410 415

Asn Met Leu Lys Lys Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His 420 425 430

Thr Leu Lys His Phe Glu His Val Arg Met Val Asp Pro Lys Lys Ala 435 440 445

Ala Gln Ile Arg Ser Gln Val Met Thr His Leu Arg Val Ile Tyr Glu 450 460

Arg Met Asn Gln Ser Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala 465 470 475 480

Glu Glu Ile Gln Asp Glu Val Asp Glu Leu Leu Gln Lys Glu Gln As
n 485 490 495

Tyr Ser Asp Asp Val Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser 500 505 510

- 13 -

Tyr Gly Asn Asp Ala Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr 520 515 Val Glu Leu Leu Pro Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln 535 Pro Trp His Ser Phe Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn Glu Val Glu Pro Val Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser 580 585 Glu Val Lys Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys 615 Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val 630 635 Ile Val Ile Thr Leu Val Met Leu Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arq His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys 680 Phe Phe Glu Gln Met Gln Asn <210> 11 <211> 2088 <212> DNA <213> Homo sapiens <400> 11 atgotgoccg gtttggcact gctcctgctg gccgcctgga cggctcgggc gctggaggta 60 cccactgatg gtaatqctgg cctgctggct gaaccccaga ttgccatgtt ctgtggcaga 120 ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggaccaaa 180 acctgcattg ataccaagga aggcatcctg cagtattgcc aagaagtcta ccctgaactg 240 cagatcacca atgtggtaga agccaaccaa ccagtgacca tccagaactg gtgcaagcgg 300 ggccgcaagc agtgcaagac ccatccccac tttgtgattc cctaccgctg cttagttggt 360 gagtttqtaa qtqatqccct tctcqttcct qacaaqtqca aattcttaca ccaqqaqaqq 420 atggatgttt gcgaaactca tcttcactgg cacaccgtcg ccaaagagac atgcagtgag 480 aagagtacca acttgcatga ctacggcatg ttgctgccct gcggaattga caagttccga 540 ggggtagagt ttgtgtgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600 gcggaggagg atgactcgga tgtctggtgg ggcggagcag acacagacta tgcagatggg 660 agtgaagaca aaqtaqtaqa aqtaqcaqaq qaqqaaqaaq tqqctqaqqt qqaaqaaqaa 720 gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780 ccctacgaag aagccacaga gagaaccacc agcattgcca ccaccaccac caccaccaca 840 gagtetgtgg aagaggtggt tegagtteet acaacagcag ceagtacece tgatgeegtt 900 gacaagtato togagacaco tggggatgag aatgaacatg cocatttoca gaaagccaaa 960 gagaggcttg aggccaagca ccgagagaga atgtcccagg tcatgagaga atgggaagag 1020 gcagaacgtc aagcaaaqaa cttgcctaaa gctgataaga aggcagttat ccagcatttc 1080 caggagaaag tggaatcttt ggaacaggaa gcagccaacg agagacagca gctggtggag 1140

acacacatgg ccagagtgga agccatgctc aatgaccgcc gccgcctggc cctggagaac 1200 tacatcaccg ctctgcaggc tgttcctcct cggcctcgtc acgtgttcaa tatgctaaag 1260 aaqtatqtcc qcqcaqaaca qaaqqacaqa caqcacaccc taaaqcattt cqaqcatqtq 1320 cgcatggtgg atcccaagaa agccgctcag atccggtccc aggttatgac acacctccgt 1380 qtqatttatg agegeatgaa teagtetete teeetgetet acaaegtgee tgeaqtggee 1440 gaggagattc aggatgaagt tgatgagctg cttcagaaag agcaaaacta ttcagatgac 1500 gtcttggcca acatgattag tgaaccaagg atcagttacg gaaacgatgc tctcatgcca 1560 tetttgaceg aaacgaaaac cacegtggag etcetteeeg tgaatggaga gtteageetg 1620 gacgatetee ageegtggea ttettttggg getgaetetg tgecageeaa cacagaaaac 1680 gaagttgage etgttgatge eegeeetget geegaeegag gaetgaeeae tegaeeaggt 1740 tctgggttga caaatatcaa gacggaggag atctctgaag tgaatctgga tgcagaattc 1800 cgacatgact caggatatga agttcatcat caaaaattgg tgttctttgc agaagatgtg 1860 ggttcaaaca aaggtgcaat cattggactc atggtgggcg gtgttgtcat agcgacagtg 1920 ategteatea cettggtgat getgaagaag aaacagtaca catecattea teatggtgtg 1980 gtggaggttg acgccgctgt caccccagag gagcgccacc tgtccaagat gcagcagaac 2040 ggctacgaaa atccaaccta caagttcttt gagcagatgc agaactag <210> 12 <211> 695 <212> PRT <213> Homo sapiens <400> 12 Met Leu Pro Gly Leu Ala Leu Leu Leu Ala Ala Trp Thr Ala Arg Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu 120 Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys 135 Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu 145 Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile 165 170 Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val 200

- 15 -Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys 215 Val Val Glu Val Ala Glu Glu Glu Val Ala Glu Val Glu Glu Glu Glu Ala Asp Asp Glu Asp Glu Asp Gly Asp Glu Val Glu Glu Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile Ala Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arq 280 Val Pro Thr Thr Ala Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu 295 Glu Thr Pro Gly Asp Glu Asn Glu His Ala His Phe Gln Lys Ala Lys 315 Glu Arg Leu Glu Ala Lys His Arg Glu Arg Met Ser Gln Val Met Arg Glu Trp Glu Glu Ala Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp 345 Lys Lys Ala Val Ile Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu Gln Glu Ala Ala Asn Glu Arg Gln Gln Leu Val Glu Thr His Met Ala Arg Val Glu Ala Met Leu Asn Asp Arg Arg Leu Ala Leu Glu Asn Tyr Ile Thr Ala Leu Gln Ala Val Pro Pro Arg Pro Arg His Val Phe Asn Met Leu Lys Lys Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His Thr Leu Lys His Phe Glu His Val Arg Met Val Asp Pro Lys Lys Ala 440 Ala Gln Ile Arq Ser Gln Val Met Thr His Leu Arq Val Ile Tyr Glu Arg Met Asn Gln Ser Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala Glu Glu Ile Gln Asp Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn 490 485 Tyr Ser Asp Asp Val Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser 500 505 Tyr Gly Asn Asp Ala Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr 520 Val Glu Leu Leu Pro Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln 535

- 16 -

Pro Trp His Ser Phe Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn 550 555 Glu Val Glu Pro Val Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser 585 Glu Val Asn Leu Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val 625 630 Ile Val Ile Thr Leu Val Met Leu Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys 680 Phe Phe Glu Gln Met Gln Asn 695 <210> 13 <211> 2088 <212> DNA <213> Homo sapiens <400> 13 atgetgeeeg gtttggeaet geteetgetg geegeetgga eggeteggge getggaggta 60 cccactgatg gtaatgctgg cctgctggct gaaccccaga ttgccatgtt ctgtggcaga 120 ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggaccaaa 180 acctgcattg ataccaagga aggcatcctg cagtattgcc aagaagtcta ccctgaactg 240 cagatcacca atgtggtaga agccaaccaa ccagtgacca tccagaactg gtgcaagcgg 300 ggccgcaagc agtgcaagac ccatccccac tttgtgattc cctaccgctg cttagttggt 360 gagtitgtaa gtgatgccct tctcgttcct gacaagtgca aattcttaca ccaggagagg 420 atggatgttt gegaaactea tetteaetgg cacacegteg ceaaagagae atgeagtgag 480 aaqaqtacca acttqcatqa ctacqqcatq ttqctqccct qcqqaattqa caaqttccqa 540 ggggtagagt ttgtgttgt cccactggct gaagaaagtg acaatgtgga ttctgctgat 600 gcggaggagg atgactcgga tgtctggtgg ggcggagcag acacagacta tgcagatggg 660 agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720 gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780 ccctacgaag aagccacaga gagaaccacc agcattgcca ccaccaccac caccaccaca 840 gaqtctqtqq aaqaqqtqqt tcqaqttcct acaacaqcag ccagtacccc tgatgccqtt 900 gacaagtatc tegagacacc tggggatgag aatgaacatg cccattteca gaaagccaaa 960 gagaggettg aggecaagea eegagagaga atgteeeagg teatgagaga atgggaagag 1020 gcagaacgtc aagcaaagaa cttgcctaaa gctgataaga aggcagttat ccagcatttc 1080 caggagaaag tggaatcttt ggaacaggaa gcagccaacg agagacagca gctggtggag 1140 acacacatgg ccaqaqtqqa aqccatgctc aatgaccgcc gccgcctggc cctggagaac 1200 tacatcaccg ctctgcaggc tgttcctcct cggcctcgtc acgtgttcaa tatgctaaag 1260 aagtatgtcc gcgcagaaca gaaggacaga cagcacaccc taaagcattt cgagcatgtg 1320 cgcatggtgg atcccaagaa agccgctcag atccggtccc aggttatgac acacctccgt 1380 gtgatttatg agcgcatgaa tcagtctctc tccctgctct acaacgtgcc tgcagtggcc 1440 gaggagattc aggatgaagt tgatgagctg cttcagaaag agcaaaacta ttcagatgac 1500 gtcttggcca acatqattag tgaaccaagg atcagttacg gaaacgatgc tctcatgcca 1560

tetttgaceg aaacgaaaac cacegtggag etectteeeg tgaatggaga gtteageetg 1620 gacgatetee ageegtggea ttettttggg getgactetg tgecageeaa cacagaaaac 1680 gaagttgage etgttgatge eegeeetget geegacegag gaetgaceae tegaceaggt 1740 tetgggttga caaatateaa gaeggaggag atetetgaag tgaagatgga tgecageagte 1740 egacatgact eaggatatga agtteateat caaaaaattgg tgttetttge agaagatgtg 1860 ggtteaaaca aaggtgeaat eattggacte ateggegeg gtgttgteat agegaagatgg getgaagaag aaacagtaca eateggtggeg gtgttgteat eateeatea eettggtgat getgaagaag aaacagtaca eateeatea eaggtggaggttg aegeegetgt eaceecagag gagegeeaee tgteeaagat geageagatge 2040 ggetacgaaa ateeaaceta caagttettt gageagatge agaactag 2088
<213> Homo sapiens
<pre><400> 14 Met Leu Pro Gly Leu Ala Leu Leu Leu Ala Ala Trp Thr Ala Arg 1 5 10 15</pre>
Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro 20 25 30
Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln 35 40 45
Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp 50 55 60
Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu 65 70 75 80
Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn 85 90 95
Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu 115 120 125
Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys 130 135 140
Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu 145 150 155 160
Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile 165 170 175
Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu 180 185 190
Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val 195 200 205
Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys 210 220
Val Val Glu Val Ala Glu Glu Glu Glu Val Ala Glu Val Glu Glu 225 230 235 240

Glu	Ala	Asp	Asp	Asp 245	Glu	Asp	Asp	Glu	Asp 250	Gly	Asp	Glu	Val	Glu 255	Glu
Glu	Ala	Glu	Glu 260	Pro	Tyr	Glu	Glu	Ala 265	Thr	Glu	Arg	Thr	Thr 270	Ser	Ile
Ala	Thr	Thr 275	Thr	Thr	Thr	Thr	Thr 280	Glu	Ser	Val	Glu	Glu 285	Val	Val	Arg
Val	Pro 290	Thr	Thr	Ala	Ala	Ser 295	Thr	Pro	qaA	Ala	Val 300	Asp	Lys	Tyr	Leu
Glu 305	Thr	Pro	Gly	Asp	Glu 310	Asn	Glu	His	Ala	His 315	Phe	Gln	Lys	Ala	Lys 320
Glu	Arg	Leu	Glu	Ala 325	Lys	His	Arg	Glu	Arg 330	Met	Ser	Gln	Val	Met 335	Arg
Glu	Trp	Glu	Glu 340	Ala	Glu	Arg	Gln	Ala 345	Lys	Asn	Leu	Pro	Lys 350	Ala	Asp
Lys	Lys	Ala 355	Val	Ile	Gln	His	Phe 360	Gln	Glu	Lys	Val	Glu 365	Ser	Leu	Glu
Gln	Glu 370	Ala	Ala	Asn	Glu	Arg 375	Gln	Gln	Leu	Val	Glu 380	Thr	His	Met	Ala
Arg 385	Val	Glu	Ala	Met	Leu 390	Asn	Asp	Arg	Arg	Arg 395	Leu	Ala	Leu	Glu	Asn 400
Tyr	Ile	Thr	Ala	Leu 405	Gln	Ala	Val	Pro	Pro 410	Arg	Pro	Arg	His	Val 415	Phe
Asn	Met	Leu	Lys 420	Lys	Tyr	Val	Arg	Ala 425	Glu	Gln	Lys	Asp	Arg 430	Gln	His
m1			42.0					123					130		
Tnr	Leu	Lys 435		Phe	Glu	His	Val 440		Met	Val	Asp	Pro 445		Lys	Ala
		435	His	Phe Ser			440	Arg				445	Lys		
Ala	Gln 450	435 Ile	His Arg		Gln	Val 455	440 Met	Arg Thr	His	Leu	Arg 460	445 Val	Lys Ile	Tyr	Glu
Ala Arg 465	Gln 450 Met	435 Ile Asn	His Arg Gln	Ser	Gln Leu 470	Val 455 Ser	440 Met Leu	Arg Thr Leu	His Tyr	Leu Asn 475	Arg 460 Val	445 Val Pro	Lys Ile Ala	Tyr Val	Glu Ala 480
Ala Arg 465 Glu	Gln 450 Met Glu	435 Ile Asn Ile	His Arg Gln	Ser Ser Asp	Gln Leu 470 Glu	Val 455 Ser Val	440 Met Leu Asp	Arg Thr Leu Glu	His Tyr Leu 490	Leu Asn 475 Leu	Arg 460 Val Gln	445 Val Pro Lys	Lys Ile Ala Glu	Tyr Val Gln 495	Glu Ala 480 Asn
Ala Arg 465 Glu Tyr	Gln 450 Met Glu Ser	435 Ile Asn Ile Asp	His Arg Gln Gln Asp	Ser Ser Asp 485	Gln Leu 470 Glu Leu	Val 455 Ser Val	440 Met Leu Asp	Arg Thr Leu Glu Met 505	His Tyr Leu 490	Leu Asn 475 Leu Ser	Arg 460 Val Gln Glu	445 Val Pro Lys Pro	Lys Ile Ala Glu Arg 510	Tyr Val Gln 495 Ile	Glu Ala 480 Asn Ser
Ala Arg 465 Glu Tyr	Gln 450 Met Glu Ser	Asn Ile Asp Asn 515	His Arg Gln Gln Asp 500 Asp	Ser Ser Asp 485 Val	Gln Leu 470 Glu Leu Leu	Val 455 Ser Val Ala	440 Met Leu Asp Asn	Arg Thr Leu Glu Met 505 Ser	His Tyr Leu 490 Ile	Leu Asn 475 Leu Ser	Arg 460 Val Gln Glu	445 Val Pro Lys Pro Thr 525	Lys Ile Ala Glu Arg 510	Tyr Val Gln 495 Ile	Glu Ala 480 Asn Ser

- 19 -

```
Glu Val Glu Pro Val Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr
                                     570
Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser
Glu Val Lys Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val
His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
                         615
                                              620
Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val
Ile Phe Ile Thr Leu Val Met Leu Lys Lys Gln Tyr Thr Ser Ile
His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg
                                 665
His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys
        675
Phe Phe Glu Gln Met Gln Asn
<210> 15
<211> 2094
<212> DNA
<213> Homo sapiens
<400> 15
atgctgcccg gtttggcact gctcctgctg gccgcctgga cggctcgggc gctggaggta 60
cccactgatg gtaatgctgg cctgctggct gaaccccaga ttgccatgtt ctgtggcaga 120
ctqaacatqc acatqaatgt ccagaatggg aagtgggatt cagatccatc agggaccaaa 180
acctqcattq ataccaaqqa aggcatcctg cagtattgcc aagaagtcta ccctgaactg 240
cagatcacca atgtggtaga agccaaccaa ccagtgacca tccagaactg gtgcaagcgg 300
ggccgcaagc agtgcaagac ccatccccac tttgtgattc cctaccgctg cttagttggt 360
qaqtttqtaa qtqatqccct tctcgttcct gacaagtgca aattcttaca ccaggagagg 420
atggatgttt gcgaaactca tcttcactgg cacaccgtcg ccaaagagac atgcagtgag 480
aagagtacca acttgcatga ctacggcatg ttgctgccct gcggaattga caagttccga 540
ggggtagagt ttgtgtgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600
gcggaggagg atgactcgga tgtctggtgg ggcggagcag acacagacta tgcagatggg 660 agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720
qaaqccqatq atqacqagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780
ccctacgaag aagccacaga gagaaccacc agcattgcca ccaccaccac caccaccaca 840
gagtctgtgg aagaggtggt tcgagttcct acaacagcag ccagtacccc tgatgccgtt 900
gacaagtatc tcgagacacc tggggatgag aatgaacatg cccatttcca gaaagccaaa 960
qaqaqqcttq aqqccaaqca ccqaqagaga atgtcccagg tcatgagaga atgggaagag 1020
gcagaacgtc aagcaaagaa cttgcctaaa gctgataaga aggcagttat ccagcatttc 1080
caggagaaag tggaatcttt ggaacaggaa gcagccaacg agagacagca gctggtggag 1140
acacacatgg ccagagtgga agccatgctc aatgaccgcc gccgcctggc cctggagaac 1200
tacatcaccg etetgeagge tgtteeteet eggeetegte aegtgtteaa tatgetaaag 1260
aagtatqtcc qcqcaqaaca gaaggacaga cagcacaccc taaagcattt cgagcatgtg 1320
equatqqtqq atcccaaqaa aqccqctcaq atccqqtccc aggttatgac acacctccgt 1380
gigatitatg agegeatgaa teagtetete teeetgetet acaaegtgee tgeagtggee 1440
gaggagattc aggatgaagt tgatgagctg cttcagaaag agcaaaacta ttcagatgac 1500
qtcttqqcca acatqattag tgaaccaagg atcagttacg gaaacgatgc tctcatgcca 1560
tetttgaceg aaacgaaaac caccgtggag etcetteeeg tgaatggaga gttcageetg 1620
gacqatetee agecqtqqca ttettttggg getgaetetg tgecagecaa cacagaaaac 1680
```

qaaqttqaqc ctgttgatgc ccgccctgct gccgaccgag gactgaccac tcgaccaggt 1740 totgggttga caaatatcaa gacggaggag atototgaag tgaagatgga tgcagaatto 1800 cgacatgact caggatatga agttcatcat caaaaattgg tgttctttgc agaagatgtg 1860 ggttcaaaca aaggtgcaat cattggactc atggtgggcg gtgttgtcat agcgacagtg 1920 atogtoatca cottggtgat gotgaagaag aaacagtaca catccattca toatggtgtg 1980 gtggaggttg acgccgctgt caccccagag gagcgccacc tgtccaagat gcagcagaac 2040 ggctacgaaa atccaaccta caagttettt gagcagatge agaacaagaa gtag 2094 <210> 16 <211> 697 <212> PRT <213> Homo sapiens <400> 16 Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg Ala Leu Glu Val Pro Thr Asp Cly Asn Ala Gly Leu Leu Ala Glu Pro Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys 135 Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu 180 Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val 200 Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys Val Val Glu Val Ala Glu Glu Glu Val Ala Glu Val Glu Glu Glu 225 Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu 250

Glu	Ala	Glu	Glu 260	Pro	Tyr	Glu	Glu	Ala 265	Thr	Glu	Arg	Thr	Thr 270	Ser	Ile
Ala	Thr	Thr 275	Thr	Thr	Thr	Thr	Thr 280	Glu	Ser	Val	Glu	Glu 285	Val	Val	Arg
Val	Pro 290	Thr	Thr	Ala	Ala	Ser 295	Thr	Pro	Asp	Ala	Val 300	Asp	Lys	Tyr	Leu
Glu 305	Thr	Pro	Gly	Asp	Glu 310	Asn	Glu	His	Ala	His 315	Phe	Gln	Lys	Ala	Lys 320
Glu	Arg	Leu	Glu	Ala 325	Lys	His	Arg	Glu	Arg 330	Met	Ser	Gln	Val	Met 335	Arg
Glu	Trp	Glu	Glu 340	Ala	Glu	Arg	Gln	Ala 345	Lys	Asn	Leu	Pro	Lys 350	Ala	Asp
Lys	Lys	Ala 355	Val	Ile	Gln	His	Phe 360	Gln	Glu	Lys	Val	Glu 365	Ser	Leu	Glu
Gln	Glu 370	Ala	Ala	Asn	Glu	Arg 375	Gln	Gln	Leu	Val	Glu 380	Thr	His	Met	Ala
Arg 385	Val	Glu	Ala	Met	Leu 390	Asn	Asp	Arg	Arg	Arg 395	Leu	Ala	Leu	Glu	Asr 400
Tyr	Ile	Thr	Ala	Leu 405	Gln	Ala	Val	Pro	Prc 410	Arg	Pro	Arg	His	Val 415	Phe
Asn	Met	Leu	Lys 420	Lys	Tyr	Val	Arg	Ala 425	Glu	Gln	Lys	Asp	Arg 430	Gln	His
Thr	Leu	Lys 435		Phe	Glu	His	Val 440	Arg	Met	Val	Asp	Pro 445	Lys	Lys	Ala
Ala	Gln 450		Arg	Ser	Gln	Val 455	Met	Thr	His	Leu	Arg 460	Val	Ile	Tyr	Glı
Arg 465		Asn	Gln	Ser	Leu 470	Ser	Leu	Leu	Tyr	Asn 475	Val	Pro	Ala	Val	Ala 480
Glu	Glu	Ile	: Gln	Asp 485		Val	Asp	Glu	Leu 490		Gln	Lys	Glu	Gln 495	Ası
Tyr	Ser	Asp	500		Leu	Ala	Asn	Met 505		Ser	Glu	Pro	Arg 510	Ile	Sei
Tyr	Gly	Asn 515		Ala	Leu	Met	Pro 520		Leu	Thr	Glu	Thr 525		Thr	Thi
Val	. Glu 530		ı Leu	Pro	Val	Asn 535	Gly	Glu	Phe	Ser	Leu 540	Asp	Asp	Leu	Glı
Pro 545		His	s Ser	Phe	: Gly 550		Asp	Ser	Val	Pro 555		Asn	Thr	Glu	Ası 560
Glu	ı Val	Glu	ı Pro	Val		Ala	. Arg	Pro	Ala		Asp	Arg	Gly	Leu 575	Th

- 22 -Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser 580 585 Glu Val Lys Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val 595 600 His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys 615 Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr Leu Val Met Leu Lys Lys Cln Tyr Thr Ser Ile His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arq His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys 680 Phe Phe Glu Gln Met Gln Asn Lys Lys 690 695 <210> 17 <211> 2094 <212> DNA <213> Homo sapiens <400> 17

atgetgeeeg gtttggeact geteetgetg geegeetgga eggeteggge getggaggta 60 cccactgatg gtaatgctgg cctgctggct gaaccccaga ttgccatgtt ctgtggcaga 120 ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggaccaea 180 acctgcattg ataccaagga aggcatcctg cagtattgcc aagaagtcta ccctgaactg 240 cagatcacca atgtggtaga agccaaccaa ccagtgacca tccagaactg gtgcaagcgg 300 ggccgcaagc agtgcaagac ccatccccac tttgtgattc cctaccgctg cttagttggt 360 gagtttgtaa gtgatgccct tctcgttcct gacaagtgca aattcttaca ccaggagagg 420 atggatgttt gcgaaactca tcttcactgg cacaccgtcg ccaaagagac atgcagtgag 480 aagagtacca acttgcatga ctacggcatg ttgctgccct geggaattga caagttccga 540 ggggtagagt ttgtgtgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600 gcggaggagg atgactcgga tgtctggtgg ggcggagcag acacagacta tgcagatggg 660 agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720 gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780 ccctacgaag aagccacaga gagaaccacc agcattgcca ccaccaccac caccaccaca 840 gagtetgtgg aagaggtggt tegagtteet acaacagcag ecagtacece tgatgeegtt 900 gacaagtatc tcgagacacc tggggatgag aatgaacatg cccatttcca gaaagccaaa 960 gagaggettg aggecaagea eegagagaga atgteecagg teatgagaga atgggaagag 1020 gcagaacqtc aaqcaaaqaa cttqcctaaa qctqataaqa aqqcaqttat ccaqcatttc 1080 caggagaaag tggaatcttt ggaacaggaa gcagccaacg agagacagca gctggtggag 1140 acacacatgg ccagagtgga agccatgctc aatgaccgcc gccgcctggc cctggagaac 1200 tacatcaccg ctctgcaggc tgttcctcct cggcctcgtc acgtgttcaa tatgctaaag 1260 aagtatgtcc gcgcagaaca gaaggacaga cagcacaccc taaagcattt cgagcatgtg 1320 cgcatggtgg atcccaaqaa agccgctcaq atccggtccc aggttatgac acacctccgt 1380 gtgatttatg agcgcatgaa tcagtctctc tccctgctct acaacgtgcc tgcagtggcc 1440 gaggagattc aggatgaagt tgatgagctg cttcagaaag agcaaaacta ttcagatgac 1500 gtettggcca acatgattag tgaaccaagg atcagttacg gaaacgatge tetcatgcca 1560 tetttgaceg aaacqaaaac caccqtqqaq etcetteeeg tgaatqqaqa qttcaqeetq 1620 gacgatetee ageogtggea ttettttggg getgaetetg tgccagecaa cacagaaaac 1680 gaagttgage ctgttgatge cegecetget geegacegag gaetgaceae tegaceaggt 1740 tetgggttga caaatateaa qacqqaqqaq atetetgaag tgaatetqqa tgeaqaatte 1800

- 23 -

cgacatgact caggatatga agttcatcat caaaaattgg tgttctttgc agaagatgtg 1860 ggttcaaaca aaggtgcaat cattggacte atggtgggcg gtgttgtcat agcgacagtg 1920 atcgtcatca ccttggtgat gctgaagaag aaacagtaca catccattca tcatggtgtg 1980 gtggaggttg acgccgctgt cacccagag gagcgccacc tgtccaagat gcagcagaca 2040 ggctacgaaa atccaaccta caagttctt gagcagatgc agaacaagaa gtag 2094

<210> 18

<211> 697

<212> PRT

<213> Homo sapiens

<400> 18

Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg 1 5 10 15

Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
20 25 30

Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln 35 40 45

Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp 50 55

Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu 65 70 75 80

Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn 85 90 95

Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val

Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu 115 120 125

Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys 130 140

Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu 145 150 155 160

Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile
165 170 175

Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu
180 185 190

Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val 195 200 205

Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys 210 215 220

Val Val Glu Val Ala Glu Glu Glu Glu Val Ala Glu Val Glu Glu Glu 225 230 235 240

Glu Ala Asp Asp Glu Asp Glu Asp Glu Asp Glu Val Glu Glu 245 250 255

Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile

- 24 -

Ala Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg 280 Val Pro Thr Thr Ala Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu 295 Glu Thr Pro Gly Asp Glu Asn Glu His Ala His Phe Gln Lys Ala Lys 310 315 Glu Arg Leu Glu Ala Lys His Arg Glu Arg Met Ser Gln Val Met Arg Glu Trp Glu Glu Ala Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp Lys Lys Ala Val Ile Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu 360 Gln Glu Ala Ala Asn Glu Arq Gln Gln Leu Val Glu Thr His Met Ala 375 Arg Val Glu Ala Met Leu Asn Asp Arg Arg Arg Leu Ala Leu Glu Asn 395 Tyr Ile Thr Ala Leu Gln Ala Val Pro Pro Arg Pro Arg His Val Phe 405 410 Asn Met Leu Lys Lys Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His 425 Thr Leu Lys His Phe Glu His Val Arg Met Val Asp Pro Lys Lys Ala Ala Gln Ile Arg Ser Gln Val Met Thr His Leu Arg Val Ile Tyr Glu 455 Arg Met Asn Gln Ser Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala Glu Glu Ile Gln Asp Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn Tyr Ser Asp Asp Val Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser 505 Tyr Gly Asn Asp Ala Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr 520 Val Glu Leu Leu Pro Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln 530 Pro Trp His Ser Phe Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn 555 Glu Val Glu Pro Val Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser

585

PCT/IB01/00797

- 25 -

WO 01/49097

```
Glu Val Asn Leu Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val
                            €00
His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
                        615
Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val
Ile Val Ile Thr Leu Val Met Leu Lys Lys Gln Tyr Thr Ser Ile
                                    650
                645
His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg
                                665
His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys
Phe Phe Glu Gln Met Gln Asn Lys Lys
                        695
<210> 19
<211> 2094
<212> DNA
<213> Homo sapiens
<400> 19
atgctgeecg gtttggeact gctcctgctg gccgcctgga cggctcgggc gctggaggta 60
cccactgatg gtaatgctgg cctgctggct gaaccccaga ttgccatgtt ctgtgqcaga 120
ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggaccaaa 180
acctgcattq ataccaaqqa aggcatcctg cagtattgcc aagaagtcta ccctgaactg 240
cagateacea atqtqqtaqa aqccaaccaa ccagtgacca tecagaactg gtgcaagegg 300
ggecgeaage agtgeaagae ceateceeae tttgtgatte cetacegetg ettagttggt 360
gagtttgtaa gtgatgccct tctcgttcct gacaagtgca aattcttaca ccaggagagg 420
atggatgttt gcgaaactca tcttcactgg cacaccgtcg ccaaagagac atgcagtgag 480
aagaqtacca acttqcatqa ctacqqcatq ttqctqccct gcggaattga caagttccga 540
ggggtagagt ttgtgtgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600
gcggaggagg atgactcgga tgtctggtgg ggcggagcag acacagacta tgcagatggg 660
agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720
gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780
cectacqaaq aaqceacaqa qaqaaccacc agcattgcca ccaccaccac caccaccaca 840
qaqtctqtqq aaqaqqtgqt tcgagttcct acaacagcag ccagtacccc tgatgccgtt 900
gacaagtate tegagacace tggggatgag aatgaacatg cecattteca gaaagecaaa 960
gagaggettg aggecaagca eegagagaga atgteecagg teatgagaga atgggaagag 1020
gcagaacgtc aagcaaagaa cttgcctaaa gctgataaga aggcagttat ccagcatttc 1080
caggagaaag tggaatettt ggaacaggaa gcagccaacg agagacagca gctggtggag 1140
acacacatgg ccagagtgga agccatgctc aatgaccgcc gccgcctggc cctggagaac 1200
tacatcaccg ctctgcaggc tgttcctcct cggcctcgtc acgtgttcaa tatqctaaag 1260
aaqtatqtcc qcqcaqaaca gaaggacaga cagcacaccc taaagcattt cgagcatgtg 1320
cqcatqqtqq atcccaaqaa aqccgctcag atccggtccc aggttatgac acacctccgt 1380
gtgatttatg agcgcatgaa tcagtctctc tccctgctct acaacgtgcc tgcagtggcc 1440
gaggagattc aggatgaagt tgatgagctg cttcagaaag agcaaaacta ttcagatgac 1500
gtettggeca acatgattag tgaaccaagg atcagttacg gaaacgatge tetcatgeca 1560
tetttgaceg aaacgaaaac cacegtggag eteetteeeg tgaatggaga gtteageetg 1620
gacgatetec agecgtggea ttettttggg getgaetetg tgccagecaa cacagaaaac 1680
```

gaagttgage etgttgatge eegecetget geegaeegag gaetgaeeae tegaeeaggt 1740 tctgggttga caaatatcaa gacggaggag atctctgaag tgaagatgga tgcagaattc 1800 cgacatgact caggatatga agttcatcat caaaaaattgg tgttctttgc agaagatgtg 1860 ggttcaaaca aaggtgcaat cattggactc atggtgggcg gtgttgtcat agcgacagtg 1920 atottoatca cottggtgat gotgaagaag aaacagtaca catccattca toatggtgtg 1980 gtggaggttg acgccgctgt caccccagag gagcgccacc tgtccaagat gcagcagaac 2040

ggctacgaaa atccaaccta caagttettt gagcagatge agaacaagaa gtag

<210> 20

<211> 697

<212> PRT

<213> Homo sapiens

<400> 20

Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro 20 25 30

Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln \$35\$

Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp 50 55 60

Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu 65 70 75 80

Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn 85 90 95

Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val $100\,$

Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu 115 120 125

Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys 130 140

Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu 145 150 155

Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile 165 170 175

Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Aia Glu Glu
180 185 190

Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val

Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys 210 220

Val Val Glu Val Ala Glu Glu Glu Glu Val Ala Glu Val Glu Glu Glu 225 235 240

Glu Ala Asp Asp Asp Glu Asp Glu Asp Glu Asp Glu Val Glu Glu 245 250 255

Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile 260 265 270

Ala Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg 275 280 280

- 27 -

Val	Pro 290	Thr	Thr	Ala	Ala	Ser 295	Thr	Pro	Asp	Ala	Val 300	Asp	Lys	Tyr	Leu
Glu 305	Thr	Pro	Gly	Asp	Glu 310	Asn	Glu	His	Ala	His 315	Phe	Gln	Lys	Ala	Lys 320
Glu	Arg	Leu	Glu	Ala 325	Lys	His	Arg	Glu	Arg 330	Met	Ser	Gln	Val	Met 335	Arg
Glu	Trp	Glu	Glu 340	Ala	Glu	Arg	Gln	Ala 345	Lys	Asn	Leu	Pro	Lys 350	Ala	Asp
Lys	Lys	Ala 355	Val	Ile	Gln	His	Phe 360	Gln	Glu	Lys	Val	Glu 365	Ser	Leu	Glu
Gln	Glu 370	Ala	Ala	Asn	Glu	Arg 375	Gln	Gln	Leu	Val	Glu 380	Thr	His	Met	Ala
Arg 385	Val	Glu	Ala	Met	Leu 390	Asn	Asp	Arg	Arg	Arg 395	Leu	Ala	Leu	Glu	Asn 400
Tyr	Ile	Thr	Ala	Leu 405	Gln	Ala	Val	Pro	Pro 410	Arg	Pro	Arg	His	Val 415	Phe
Asn	Met		Lys 420	Lys	Tyr	Val	Arg	Ala 425	Glu	Gln	Lys	Asp	Arg 430	Gln	His
Thr	Leu	Lys 435	His	Phe	Glu	His	Val 440	Arg	Met	Val	Asp	Pro 445	Lys	Lys	Ala
Ala	Gln 450	Ile	Arg	Ser	Gln	Val 455	Met	Thr	His	Leu	Arg 460	Val	Ile	Tyr	Glu
Arg 465	Met	Asn	Gln	Ser	Leu 470	Ser	Leu	Leu	Tyr	Asn 475	Val	Pro	Ala	Val	Ala 480
Glu	Glu	Ile	Gln	Asp 485	Glu	Val	Asp	Glu	Leu 490	Leu	Gln	Lys	Glu	Gln 495	Asn
Tyr	Ser	Asp	Asp 500	Val	Leu	Ala	Asn	Met 505	Ile	Ser	Glu	Pro	Arg 510	Ile	Ser
Tyr	Gly	Asn 515	Asp	Ala	Leu	Met	Pro 520	Ser	Leu	Thr	Glu	Thr 525	Lys	Thr	Thr
Val	Glu 530	Leu	Leu	Pro	Val	Asn 535	Gly	Glu	Phe	Ser	Leu 540	Asp	Asp	Leu	Gln
Pro 545	Trp	His	Ser	Phe	Gly 550	Ala	Asp	Ser	Val	Pro 555	Ala	Asn	Thr	Glu	Asn 560
Glu	Val	Glu	Pro	Val 565	Asp	Ala	Arg	Pro	Ala 570	Ala	Asp	Arg	Gly	Leu 575	Thr
Thr	Arg	Pro	Gly 580	Ser	Gly	Leu	Thr	Asn 585	Ile	Lys	Thr	Glu	Glu 590	Ile	Ser
Glu	Val	Lys 595		Asp	Ala	Glu	Phe 600	Arg	His	Asp	Ser	Gly 605	Tyr	Glu	Val
His	His 610		Lys	Leu	Val	Phe 615	Phe	Ala	Glu	Asp	Val 620	Gly	Ser	Asn	Lys

- 28 -

```
Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val
Ile Phe Ile Thr Leu Val Met Leu Lys Lys Gln Tyr Thr Ser Ile
His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg
                                665
His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys
Phe Phe Glu Gln Met Gln Asn Lys Lys
<210> 21
<211> 1341
<212> DNA
<213> Homo sapiens
<400> 21
atggctagca tgactggtgg acagcaaatg ggtcgcggat ccacccagca cggcatccgg 60
etgeeeetge geagegeet ggggggegee eecetgggge tgeggetgee eegggagaee 120
qacqaaqaqc ccqaqqaqcc cqqccqqagg ggcagctttg tggagatggt ggacaacctg 180
aggggcaagt cggggcaggg ctactacgtg gagatgaccg tgggcagccc cccgcagacg 240
ctcaacatcc tggtggatac aggcagcagt aactttgcag tgggtgctgc cccccacccc 300
ttectgeate getactacea gaggeagetg tecageacat acegggaeet ceggaagggt 360
gtgtatgtgc cctacaccca gggcaagtgg gaaggggagc tgggcaccga cctggtaagc 420
atoccccatq qccccaacqt cactgtgcgt gccaacattg ctgccatcac tgaatcagac 480
aagttettea teaaeggete caaetgggaa ggeateetgg ggetggeeta tgetgagatt 540
gccaggcctg acgactccct ggagcctttc tttgactctc tggtaaagca gacccacgtt 600
cccaacctct tctccctgca cctttgtggt gctggcttcc ccctcaacca gtctgaagtg 660
ctggcctctg tcggagggag catgatcatt ggaggtatcg accactcgct gtacacaggc 720
agtototggt atacacccat coggogggag tggtattatg aggtoatcat tgtgcgggtg 780
gagatcaatq qacaqqatct gaaaatggac tgcaaggagt acaactatga caagagcatt 840
gtggacagtg gcaccaccaa cettegtttg cecaagaaag tgtttgaage tgeagtcaaa 900
tocatcaagg cagoctocto cacggagaag ttocotgatg gtttotggot aggagagcag 960
ctggtgtgct ggcaagcagg caccaccct tggaacattt tcccagtcat ctcactctac 1020
ctaatgggtg aggttaccaa ccagtccttc cgcatcacca tccttccgca gcaatacctg 1080
cggccagtgg aagatgtggc cacgtcccaa gacgactgtt acaagtttgc catctcacag 1140
teatecaegg geaetgttat gggagetgtt ateatggagg gettetaegt tgtetttgat 1200
cgggcccgaa aacgaattgg ctttgctgtc agcgcttgcc atgtgcacga tgagttcagg 1260
acggcagcgg tggaaggccc ttttgtcacc ttggacatgg aagactgtgg ctacaacatt 1320
ccacagacag atgagtcatg a
<210> 22
<211> 446
<212> PRT
<213> Homo sapiens
<400> 22
Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Gly Ser Thr Gln
His Gly Ile Arg Leu Pro Leu Arg Ser Gly Leu Gly Gly Ala Pro Leu
Gly Leu Arg Leu Pro Arg Glu Thr Asp Glu Glu Pro Glu Glu Pro Gly
                             40
```

Arg	Arg 50	Gly	Ser	Phe	Val	Glu 55	Met	Val	Asp	Asn	Leu 60	Arg	Gly	Lys	Ser
Gly 65	Gln	Gly	Tyr	Tyr	Val 70	Glu	Met	Thr	Val	Gly 75	Ser	Pro	Pro	Gln	Thr 80
Leu	Asn	Ile	Leu	Val 85	Asp	Thr	Gly	Ser	Ser 90	Asn	Phe	Ala	Val	Gly 95	Ala
Ala	Pro	His	Pro 100	Phe	Leu	His	Arg	Tyr 105	Tyr	Gln	Arg	Gln	Leu 110	Ser	Ser
Thr	Tyr	Arg 115	Asp	Leu	Arg	Lys	Gly 120	Val	Tyr	Val	Pro	Туг 125	Thr	Gln	Gly
Lys	Trp 130	Glu	Gly	Glu	Leu	Gly 135	Thr	Asp	Leu	Val	Ser 140	Ile	Pro	His	Gly
Pro 145	Asn	Val	Thr	Val	Arg 150	Ala	Asn	Ile	Ala	Ala 155	Ile	Thr	Glu	Ser	Asp 160
Lys	Phe	Phe	Ile	Asn 165	Gly	Ser	Asn	Trp	Glu 170	Gly	Ile	Leu	Gly	Leu 175	Ala
Tyr	Ala	Glu	Ile 180	Ala	Arg	Pro	Asp	Asp 185	Ser	Leu	Glu	Pro	Phe 190	Phe	Asp
Ser	Leu	Val 195	Ľys	Gln	Thr	His	Val 200	Pro	Asn	Leu	Phe	Ser 205	Leu	His	Leu
Cys	Gly 210	Ala	Gly	Phe	Pro	Leu 215	Asn	Gln	Ser	Glu	Val 220	Leu	Ala	Ser	Val
Gly 225	Gly	Ser	Met	Ile	Ile 230	Gly	Gly	Ile	Asp	His 235	Ser	Leu	Tyr	Thr	Gly 240
Ser	Leu	Trp	Tyr	Thr 245	Pro	Ile	Arg	Arg	Glu 250	Trp	Tyr	Tyr	Glu	Val 255	Ile
Ile	Val	Arg	Val 260	Glu	Ile	Asn	Gly	Gln 265	Asp	Leu	Lys	Met	Asp 270	Cys	Lys
Glu	Tyr	Asn 275	Tyr	Asp	Lys	Ser	Ile 280	Val	Asp	Ser	Gly	Thr 285	Thr	Asn	Leu
Arg	Leu 290	Pro	Lys	Lys	Val	Phe 295	Glu	Ala	Ala	Val	Lys 300	Ser	Ile	Lys	Ala
Ala 305		Ser	Thr	Glu	Lys 310	Phe	Pro	Asp	Gly	Phe 315	Trp	Leu	Gly	Glu	Glr 320
Leu	Val	Cys	Trp	Gln 325	Ala	Gly	Thr	Thr	Pro 330	Trp	Asn	Ile	Phe	Pro 335	Val
Ile	Ser	Leu	Tyr 340	Leu	Met	Gly	Glu	Val 345	Thr	Asn	Gln	Ser	Phe 350	Arg	Ile
Thr	Ile	Leu 355	Pro	Gln	Gln	Tyr	Leu 360	Arg	Pro	Val	Glu	Asp 365	Val	Ala	Thr
Ser	Gln 370		Asp	Cys	Tyr	Lys 375	Phe	Ala	Ile	Ser	Gln 380	Ser	Ser	Thr	Gly

- 30 -

Thr Val Met Gly Ala Val Ile Met Glu Gly Phe Tyr Val Val Phe Asp Arg Ala Arg Lys Arg Ile Gly Phe Ala Val Ser Ala Cys His Val His 410 Asp Glu Phe Arg Thr Ala Ala Val Glu Gly Pro Phe Val Thr Leu Asp 425 420 Met Glu Asp Cys Gly Tyr Asn Ile Pro Gln Thr Asp Glu Ser 440 <210> 23 <211> 1380 <212> DNA <213> Homo sapiens <400> 23 atggctagca tgactggtgg acagcaaatg ggtcgcggat cgatgactat ctctgactct 60 ccgcgtgaac aggacggatc cacccagcac ggcatccggc tgcccctgcg cagcggcctg 120 gggggggcc ccctggggct gcggctgcc cgggagaccg acgaagagcc cgaggagccc 180 ggccggaggg gcagctttgt ggagatggtg gacaacctga ggggcaagtc ggggcagggc 240 tactacqtqq aqatqacqt qqqcaqccc ccqcaqacqc tcaacatcct qqtqqataca 300 ggcagcagta actttgcagt gggtgctgcc ccccacccct tcctgcatcg ctactaccag 360 aggeagetgt ceageacata cegggaeete eggaagggtg tgtatgtgee etacacecag 420 ggcaagtggg aaggggaget gggcaccgac etggtaagca teecceatgg ecceaacgte 480 actytycyty ccaacattyc tyccatcact gaatcagaca agttetteat caacygetec 540 aactqqqaaq qcatcctqqq qctqqcctat gctqagattg ccaggcctga cgactccctg 600 gageetttet tigaetetet ggtaaageag acceaegtte ceaacetett etecetgeae 660 ctttqtqqtq ctqqcttccc cctcaaccag tctgaagtgc tggcctctgt cggagggagc 720 atgatcattg gaggtatcga ccactcgctg tacacaggca gtctctggta tacacccatc 780 eggegggagt ggtattatga ggtcatcatt gtgegggtgg agatcaatgg acaggatetg 840 aaaatqqact qcaaqqaqta caactatgac aagagcattg tggacagtgg caccaccaac 900 cttegtttgc ccaagaaagt gtttgaagct gcagtcaaat ccatcaaggc agcctcctcc 960 acggagaagt teectgatgg tttetggeta ggagageage tggtgtgetg geaageagge 1020 accacccctt ggaacatttt cccagtcatc tcactctacc taatgggtga ggttaccaac 1080 cagteettee geateaceat cetteegeag caatacetge ggccagtgga agatgtggec 1140 acqtcccaaq acqactqtta caagtttgcc atctcacagt catccacggg cactgttatg 1200 ggagetgtta teatggaggg ettetaegtt gtetttgate gggeecgaaa acgaattgge 1260 tttgctgtca gcgcttgcca tgtgcacgat gagttcagga cggcagcggt ggaaggccct 1320 tttgtcacct tggacatgga agactgtggc tacaacattc cacagacaga tgagtcatga 1380 <210> 24 <211> 459 <212> PRT <213> Homo sapiens <400> 24 Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Gly Ser Met Thr 5 Ile Ser Asp Ser Pro Arg Glu Gln Asp Gly Ser Thr Gln His Gly Ile 20 Arg Leu Pro Leu Arg Ser Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly 55

Ser 65	Phe	Val	Glu	Met	Val 70	Asp	Asn	Leu	Arg	Gly 75	Lys	Ser	Gly	Gln	Gly 80
Tyr	Tyr	Val	Glu	Met 85	Thr	Val	Gly	Ser	Pro 90	Pro	Gln	Thr	Leu	Asn 95	Ile
Leu	Val	Asp	Thr 100	Gly	Ser	Ser	Asn	Phe 105	Ala	Val	Gly	Ala	Ala 110	Pro	His
Pro	Phe	Leu 115	His	Arg	Tyr	Tyr	Gln 120	Arg	Gln	Leu	Ser	Ser 125	Thr	Tyr	Arg
Asp	Leu 130	Arg	Lys	Gly	Val	Tyr 135	Val	Pro	Tyr	Thr	Gln 140	Gly	ГÀа	Trp	Glu
Gly 145	Glu	Leu	Gly	Thr	Asp 150	Leu	Val	Ser	Ile	Pro 155	His	Gly	Pro	Asn	Val 160
Thr	Val	Arg	Ala	Asn 165	Ile	Ala	Ala	Ile	Thr 170	Glu	Ser	Asp	Lys	Phe 175	Phe
Ile	Asn	Gly	Ser 180	Asn	Trp	Glu	Gly	Ile 185	Leu	Gly	Leu	Ala	Tyr 190	Ala	Glu
Ile	Ala	Arg 195	Pro	Asp	Asp	Ser	Leu 200	Glu	Pro	Phe	Phe	Asp 205	Ser	Leu	Val
Lys	Gln 210	Thr	His	Val	Pro	Asn 215	Leu	Phe	Ser	Leu	His 220	Leu	Cys	Gly	Ala
Gly 225	Phe	Pro	Leu	Asn	Gln 230	Ser	Glu	Val	Leu	Ala 235	Ser	Val	Gly	Gly	Ser 240
Met	Ile	Ile	Gly	Gly 245	Ile	Asp	His	Ser	Leu 250	Tyr	Thr	Gly	Ser	Leu 255	Trp
Tyr	Thr	Pro	Ile 260	Arg	Arg	Glu	Trp	Tyr 265	Tyr	Glu	Val	Ile	Ile 270	Val	Arg
Val	Glu	Ile 275	Asn	Gly	Gln	Asp	Leu 280	Lys	Met	Asp	Cys	Lys 285	Glu	Tyr	Asn
Tyr	Asp 290	Lys	Ser	Ile	Val	Asp 295		Gly	Thr	Thr	Asn 300	Leu	Arg	Leu	Pro
Lys 305		Val	Phe	Glu	Ala 310	Ala	Val	Lys	Ser	Ile 315	Lys	Ala	Ala	Ser	Ser 320
Thr	Glu	Lys	Phe	Pro 325		Gly	Phe	Trp	Leu 330	Gly	Glu	Gln	Leu	Val 335	Cys
Trp	Gln	Ala	Gly 340		Thr	Pro	Trp	Asn 345		Phe	Pro	Val	Ile 350	Ser	Leu
Tyr	Leu	. Met 355	Gly	Glu	Val	Thr	Asn 360		Ser	Phe	Arg	Ile 365	Thr	Ile	Lev
Pro	Gln 370		Tyr	Leu	Arg	Pro 375		Glu	Asp	Val	Ala 380	Thr	Ser	Gln	Asp
Asp		Tyr	Lys	Phe	Ala 390		e Ser	Gln	Ser	Ser 395		Gly	Thr	Val	Met 400

- 32 -

```
Gly Ala Val Ile Met Glu Gly Phe Tyr Val Val Phe Asp Arg Ala Arg
Lys Arq Ile Gly Phe Ala Val Ser Ala Cys His Val His Asp Glu Phe
                                425
Arg Thr Ala Ala Val Glu Gly Pro Phe Val Thr Leu Asp Met Glu Asp
Cys Gly Tyr Asn Ile Pro Gln Thr Asp Glu Ser
                        455
<210> 25
<211> 1302
<212> DNA
<213> Homo sapiens
<400> 25
atgactcage atggtatteg tetgecactg egtageggte tgggtggtge tecactgggt 60
gtggagatgg tggacaacet gaggggcaag teggggcagg getactaegt ggagatgaee 180
gtgggcagcc ccccgcagac gctcaacatc ctggtggata caggcagcag taactttgca 240
gtgggtgctg cccccaccc cttcctgcat cgctactacc agaggcaget gtccagcaca 300
taccgggacc tccggaaggg tgtgtatgtg ccctacaccc agggcaagtg ggaaggggag 360
ctgggcaccg acctggtaag catcccccat ggccccaacg tcactgtgcg tgccaacatt 420
getgecatea etgaateaga caagttette ateaaegget eeaaetggga aggeateetg 480
gggetggeet atgetgagat tgeeaggeet gaegaeteee tggageettt etttgaetet 540
ctggtaaagc agacccacgt teecaaccte ttetecetge acetttgtgg tgetggette 600
conctoaacc agtotgaagt gotggootet gtoggaggga goatgatoat tggaggtato 660
gaccastege tgtacacagg cagtetetgg tatacaceca teeggeggga gtggtattat 720
gaggtcatca ttgtgcgggt ggagatcaat ggacaggatc tgaaaatgga ctgcaaggag 780 tacaactatg acaagagcat tgtggacagt ggcaccacca accttcgttt gcccaagaaa 840
gtgtttgaag ctgcagtcaa atccatcaag gcagceteet ccaeggagaa gtteeetgat 900
ggtttctggc taggagagca gctggtgtgc tggcaagcag gcaccacccc ttggaacatt 960
ttcccagtca tctcactcta cctaatgggt gaggttacca accagtcctt ccgcatcacc 1020
atcetteege ageaatacet geggeeagtg gaagatgtgg ceaegteeca agaegaetgt 1080
tacaagtttg ccatctcaca gtcatccacg ggcactgtta tgggagctgt tatcatggag 1140
ggcttctacg ttgtctttga tcgggcccga aaacgaattg gctttgctgt cagcgcttgc 1200
catgtgcacg atgagttcag gacggcagcg gtggaaggcc cttttgtcac cttggacatg 1260
gaagactgtg gctacaacat tccacagaca gatgagtcat ga
<210> 26
<211> 433
<212> PRT
<213> Homo sapiens
<400> 26
Met Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser Gly Leu Gly Gly
Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp Glu Glu Pro Glu
Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val Asp Asn Leu Arg
Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr Val Gly Ser Pro
Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser Ser Asn Phe Ala
                     70
```

- 33 -

Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr Tyr Gln Arg Gln 85 90 95

Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val Tyr Val Pro Tyr $100 \,$ $\,$ $105 \,$ $\,$ $110 \,$

Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp Leu Val Ser Ile 115 120 125

Pro His Gly Pro Asn Val Thr Val Arg Ala Asn Ile Ala Ala Ile Thr 130 135 140

Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser Asn Trp Glu Gly Ile Leu 145 $$ 150 $$ 155 $$ 160

Gly Leu Ala Tyr Ala Glu Ile Ala Arg Fro Asp Asp Ser Leu Glu Pro 165 170 175

Phe Phe Asp Ser Leu Val Lys Gln Thr His Val Pro Asn Leu Phe Ser 180 185 190

Leu His Leu Cys Gly Ala Gly Phe Pro Leu Asn Gln Ser Glu Val Leu
195 200 205

Ala Ser Val Gly Gly Ser Met Ile Ile Gly Gly Ile Asp His Ser Leu 210 215 220

Tyr Thr Gly Ser Leu Trp Tyr Thr Pro Ile Arg Arg Glu Trp Tyr Tyr 225 230 235 249

Glu Val Ile 1le Val Arg Val Glu Ile Asn Gly Gln Asp Leu Lys Met 245 250 255

Asp Cys Lys Glu Tyr Asn Tyr Asp Lys Ser Ile Val Asp Ser Gly Thr 260 265 270

Thr Asn Leu Arg Leu Pro Lys Lys Val Phe Glu Ala Ala Val Lys Ser 275 280 285

Ile Lys Ala Ala Ser Ser Thr Glu Lys Phe Pro Asp Gly Phe Trp Leu 290 295 300

Gly Glu Gln Leu Val Cys Trp Gln Ala Gly Thr Thr Pro Trp Asn Ile 305 310 315 320

Phe Pro Val Ile Ser Leu Tyr Leu Met Gly Glu Val Thr Asn Gln Ser 325 330 335

Phe Arg Ile Thr Ile Leu Pro Gln Gln Tyr Leu Arg Pro Val Glu Asp 340 345

Val Ala Thr Ser Gln Asp Asp Cys Tyr Lys Phe Ala Ile Ser Gln Ser 355 360 365

Ser Thr Gly Thr Val Met Gly Ala Val Ile Met Glu Gly Phe Tyr Val 370 375 380

Val Phe Asp Arg Ala Arg Lys Arg Ile Gly Phe Ala Val Ser Ala Cys 385 390 395 400

His Val His Asp Glu Phe Arg Thr Ala Ala Val Glu Gly Pro Phe Val 405 410 415

- 34 -

```
Thr Leu Asp Met Glu Asp Cys Gly Tyr Asn Ile Pro Gln Thr Asp Glu
                                425
Ser
<210> 27
<211> 1278
<212> DNA
<213> Homo sapiens
<400> 27
atggctagea tgactggtgg acagcaaatg ggtcgcggat cgatgactat ctctgactct 60
ccgctggact ctggtatcga aaccgacgga tcctttgtgg agatggtgga caacctgagg 120
ggcaagtegg ggcagggeta ctaegtggag atgaeegtgg geageeeece geagaegete 180
aacatcctqq tqqatacaqq cagcaqtaac tttgcaqtgg gtgctgcccc ccaccccttc 240
ctgcatcgct actaccagag gcagctgtcc agcacatacc gggacctccg gaagggtgtg 300
tatgtgccct acacccaggg caagtgggaa ggggagctgg gcaccgacct ggtaagcatc 360
ccccatggcc ccaacgtcac tgtgcgtgcc aacattgctg ccatcactga atcagacaag 420
ttetteatea aeggeteeaa etgggaagge ateetgggge tggeetatge tgagattgee 480
aggeotgaeg actocotgga gootttottt gactototgg taaagcagac coacgttoco 540
aacctcttct ccctgcacct ttgtggtgct ggcttccccc tcaaccagtc tgaagtgctg 600
geetetgteg gagggageat gateattgga ggtategaee aetegetgta cacaggeagt 660
ctctggtata cacccatccg gcgggagtgg tattatgagg tcatcattgt gcgggtggag 720
atcaatggac aggatctgaa aatggactgc aaggagtaca actatgacaa gagcattgtg 780
gacagtggca ccaccaacct tegtttgccc aagaaagtgt ttgaagctgc agtcaaatcc 840
atcaaggcag cotcotccac ggagaagtto cotgatggtt totggotagg agagcagotg 900
gtgtgctggc aagcaggcac caccccttgg aacattttcc cagtcatctc actctaccta 960
atgggtgagg ttaccaacca gtccttccgc atcaccatcc ttccgcagca atacctgcgg 1020
ccagtggaag atgtggccac gtcccaagac gactgttaca agtttgccat ctcacagtca 1080
tccacgggca ctgttatggg agctgttatc atggagggct tctacgttgt ctttgatcgg 1140
gcccgaaaac gaattggctt tgctgtcagc gcttgccatg tgcacgatga gttcaggacg 1200
qeaqeqqtqq aaqqeeettt tqteacettg gacatggaag actgtggeta caacatteca 1260
cagacagatg agtcatga
<210> 28
<211> 425
<212> PRT
<213> Homo sapiens
Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Gly Ser Met Thr
Ile Ser Asp Ser Pro Leu Asp Ser Gly Ile Glu Thr Asp Gly Ser Phe
Val Glu Met Val Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr
Val Glu Met Thr Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val
Asp Thr Gly Ser Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe
Leu His Arg Tyr Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu
Arg Lys Gly Val Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu
Leu Gly Thr Asp Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val
        115
                            120
```

- 35 -

Arg Ala Asn Ile Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn 130 135 140

Arg Pro Asp Asp Ser Leu Glu Pro Phe Phe Asp Ser Leu Val Lys Gln
165 170 175

Thr His Val Pro Asn Leu Phe Ser Leu His Leu Cys Gly Ala Gly Phe 180 185 190

Pro Leu Asn Gln Ser Glu Val Leu Ala Ser Val Giy Gly Ser Met Ile 195 200 205

Ile Gly Gly Ile Asp His Ser Leu Tyr Thr Gly Ser Leu Trp Tyr Thr 210 220

Pro Ile Arg Arg Glu Trp Tyr Tyr Glu Val Ile Ile Val Arg Val Glu 225 230 235 240

Ile Asn Gly Gln Asp Leu Lys Met Asp Cys Lys Glu Tyr Asn Tyr Asp 245 250 255

Lys Ser Ile Val Asp Ser Gly Thr Thr Asn Leu Arg Leu Pro Lys Lys 260 265 270

Val Phe Glu Ala Ala Val Lys Ser Ile Lys Ala Ala Ser Ser Thr Glu 275 280 285

Lys Phe Pro Asp Gly Phe Trp Leu Gly Glu Gln Leu Val Cys Trp Gln 290 295 300

Ala Gly Thr Thr Pro Trp Asn Ile Phe Pro Val Ile Ser Leu Tyr Leu 305 310 315 320

Met Gly Glu Val Thr Asn Gln Ser Phe Arg Ile Thr Ile Leu Pro Gln 325 330 335

Gln Tyr Leu Arg Pro Val Glu Asp Val Ala Thr Ser Gln Asp Asp Cys 340 350

Tyr Lys Phe Ala Ile Ser Gln Ser Ser Thr Gly Thr Val Met Gly Ala 355 360 365

Val Ile Met Glu Gly Phe Tyr Val Val Phe Asp Arg Ala Arg Lys Arg 370 375 380

Ile Gly Phe Ala Val Ser Ala Cys His Val His Asp Glu Phe Arg Thr 385 390 395 400

Ala Ala Val Glu Gly Pro Phe Val Thr Leu Asp Met Glu Asp Cys Gly 405 410415

Tyr Asn Ile Pro Gln Thr Asp Glu Ser 420 425

<210> 29

<211> 1362

<212> DNA

<213> Homo sapiens

<400> 29 atggcccaag ccctgccctg gctcctgctg tggatggcg cgggagtgct gcctgcccac 60 ggeacceage aeggeateeg getgeceetg egeageggee tggggggege eeceettgggg 120 gtggagatgg tggacaacct gaggggcaag tcggggcagg gctactacgt ggagatgacc 240 gtgggcagcc ccccgcagac gctcaacatc ctggtggata caggcagcag taacttt.gca 300 gtgggtgctg cccccaccc cttcctgcat cgctactacc agaggcagct gtccagcaca 360 taccgggacc tccggaaggg tgtgtatgtg ccctacaccc agggcaagtg ggaaggggag 420 ctgggcaccg acctggtaag catcocccat ggccccaacg tcactgtgcg tgccaacatt 480 getgecatea etgaateaga caagttette ateaaegget ceaaetggga aggeateetg 540 gggctggcct atgctgagat tgccaggcct gacgactccc tggagccttt ctttgactct 600 ctggtaaagc agacccacgt teccaacete ttetecetge acetttgtgg tgetggette 660 cccctcaacc agtctgaagt gctggcctct gtcggaggga gcatgatcat tggaggtatc 720 gaccactege tgtacacagg cagtetetgg tatacaceca teeggeggga gtggtattat 780 gaggtcatca ttgtgcgggt ggagatcaat ggacaggatc tgaaaatgga ctgcaaggag 840 tacaactatg acaagagcat tgtggacagt ggcaccacca accttcgttt gcccaagaaa 900 qtqtttqaaq ctqcaqtcaa atccatcaaq gcaqcctcct ccacggagaa gttccctgat 960 ggtttetgge taggagagea getggtgtge tggeaageag geaceacece ttggaacatt 1020 tteccagtea teteacteta ectaatggt gaggttacca accagteett cegcateace 1080 atcetteege ageaatacet geggeeagtg gaagatgtgg ceaegteeea agaegaetgt 1140 tacaagtttg ccatctcaca gtcatccacg ggcactgtta tgggagctgt tatcatggag 1200 ggettetacg ttgtetttga tegggeeega aaacgaattg getttgetgt cagegettge 1260 catqtgcacg atgagttcag gacggcagcg gtggaaggcc cttttgtcac cttggacatg 1320 qaaqactqtq qctacaacat tccacagaca gatgagtcat ga <210> 30 <211> 453 <212> PRT <213> Homo sapiens <400> 30 Met Ala Gln Ala Leu Pro Trp Leu Leu Trp Met Gly Ala Gly Van 1.0 Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr 105 Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp 135 Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val Arg Ala Asn Ile 145 150 155

- 37 -

Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser Asn Trp 170 Glu Gly Ile Leu Gly Leu Ala Tyr Ala Glu Ile Ala Arg Pro Asp Asp Ser Leu Glu Pro Phe Phe Asp Ser Leu Val Lys Gln Thr His Val Pro 200 Asn Leu Phe Ser Leu Gln Leu Cys Gly Ala Gly Phe Pro Leu Asn Gln 215 Ser Glu Val Leu Ala Ser Val Gly Gly Ser Met Ile Ile Gly Gly Ile Asp His Ser Leu Tyr Thr Gly Ser Leu Trp Tyr Thr Pro Ile Arg Arg 250 Glu Trp Tyr Tyr Glu Val Ile Ile Val Arg Val Glu Ile Asn Gly Gln Asp Leu Lys Met Asp Cys Lys Glu Tyr Asn Tyr Asp Lys Ser Ile Val Asp Ser Gly Thr Thr Asn Leu Arg Leu Pro Lys Lys Val Pne Glu Ala 295 Ala Val Lys Ser Ile Lys Ala Ala Ser Ser Thr Glu Lys Phe Pro Asp Gly Phe Trp Leu Gly Glu Gln Leu Val Cys Trp Gln Ala Gly Thr Thr Pro Trp Asn Ile Phe Pro Val Ile Ser Leu Tyr Leu Met Gly Glu Val 345 Thr Asn Gln Ser Phe Arg Ile Thr Ile Leu Pro Gln Gln Tyr Leu Arg 360 Pro Val Glu Asp Val Ala Thr Ser Gln Asp Asp Cys Tyr Lys Phe Ala Ile Ser Gln Ser Ser Thr Gly Thr Val Met Gly Ala Val Ile Met Glu 390 395 Gly Phe Tyr Val Val Phe Asp Arg Ala Arg Lys Arg Ile Gly Phe Ala Val Ser Ala Cys His Val His Asp Glu Phe Arg Thr Ala Ala Val Glu 420 Gly Pro Phe Val Thr Leu Asp Met Glu Asp Cys Gly Tyr Asn Ile Pro 435 440

Gln Thr Asp Glu Ser 450

<210> 31 <211> 1380 <212> DNA - 38 -

<213> Homo sapiens

<400> 31 atggcccaag ccctgccctg gctcctgctg tggatgggcg cgggagtgct gcctgcccac 60 ggcacccage acggcatccg getgeceetg egeageggee tggggggege eeceetgggg 120 ctgcggctgc cccgggagac cgacgaagag cccgaggage ccggccggag gggcagcttt 180 gtggagatgg tggacaacct gaggggcaag tcggggcagg gctactacgt ggagatgacc 240 gtgggcagcc ccccgcagac gctcaacatc ctggtggata caggcagcag taactttgca 300 gtgggtgetg ecceecacee ettectgeat egetactace agaggeaget gtecageaca 360 taccgggacc tccggaaggg tgtgtatgtg ccctacaccc agggcaagtg ggaaggggag 420 ctgggcaccg acctggtaag catcccccat ggccccaacg tcactgtgcg tgccaacatt 480 getgecatea etgaateaga caagttette ateaaegget ceaaetggga aggeateetg 540 gggctggcct atgctgagat tgccaggcct gacgactece tggagccttt ctttgactet 600 etggtaaage agacceacgt teccaacete ttetecetge acetttgtgg tgetggette 660 ccctcaacc aqtctgaagt gctggcctct gtcggaggga gcatgatcat tggaggtate 720 gaccactege tgtacacagg cagtetetgg tatacaceca teeggeggga gtggtattat 780 gaggtcatca ttgtgcgggt ggagatcaat ggacaggatc tgaaaatgga ctgcaaggag 840 tacaactatg acaagagcat tgtggacagt ggcaccacca accttcgttt gcccaagaaa 900 gtgtttgaag ctgcagtcaa atccatcaag gcagcctcct ccacggagaa gttccctgat 960 ggtttctggc taggagagca gctggtgtgc tggcaagcag gcaccacccc ttggaacatt 1020 ttcccagtca tctcactcta cctaatgggt gaggttacca accagtcctt ccgcatcacc 1080 atcetteege ageaatacet geggeeagtg gaagatgtgg ceaegteeca agacgaetgt 1140 tacaaqtttq ccatctcaca gtcatccacg ggcactgtta tgggagctgt tatcatggag 1200 ggettetacg ttgtetttga tegggeeega aaacgaattg getttgetgt eagegettge 1260 catgtgcacg atgagttcag gacggcagcg gtggaaggcc cttttgtcac cttggacatg 1320 gaagactgtg gctacaacat tccacagaca gatgagtcac agcagcagca gcagcagtga 1380 <210> 32 <211> 459 <212> PRT <213> Homo sapiens <400> 32 Met Ala Gln Ala Leu Pro Trp Leu Leu Leu Trp Met Gly Ala Gly Val Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val 120 Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val Arg Ala Asn Ile

- Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser Asn Trp \$165\$ \$170\$ \$175\$
- Glu Gly Ile Leu Gly Leu Ala Tyr Ala Glu Ile Ala Arg Pro Asp Asp 180 185 190
- Ser Leu Glu Pro Phe Phe Asp Ser Leu Val Lys Gln Thr His Val Pro 195 200 205
- Asn Leu Phe Ser Leu Gln Leu Cys Gly Ala Gly Phe Pro Leu Asn Gln 210 215 220
- Ser Glu Val Leu Ala Ser Val Gly Gly Ser Met Ile Ile Gly Gly Ile 225 230 235 240
- Asp His Ser Leu Tyr Thr Gly Ser Leu Trp Tyr Thr Pro Ile Arg Arg 245 250 255
- Glu Trp Tyr Tyr Glu Val Ile Ile Val Arg Val Glu Ile Asn Gly Gln
 260 265 270
- Asp Leu Lys Met Asp Cys Lys Glu Tyr Asn Tyr Asp Lys Ser Ile Val 275 280 285
- Asp Ser Gly Thr Thr Asn Leu Arg Leu Pro Lys Lys Val Phe Glu Ala 290 295 300
- Ala Val Lys Ser Ile Lys Ala Ala Ser Ser Thr Glu Lys Phe Pro Asp 305 310 315
- Gly Phe Trp Leu Gly Glu Gln Leu Val Cys Trp Gln Ala Gly Thr Thr 325 330 335
- Pro Trp Asn Ile Phe Pro Val Ile Ser Leu Tyr Leu Met Gly Glu Val 340 345 350
- Thr Asn Gln Ser Phe Arg Ile Thr Ile Leu Pro Gln Gln Tyr Leu Arg 355 360 365
- Pro Val Glu Asp Val Ala Thr Ser Gln Asp Asp Cys Tyr Lys Phe Ala 370 375 380
- Ile Ser Gln Ser Ser Thr Gly Thr Val Met Gly Ala Val Ile Met Glu 385 395 400
- Gly Phe Tyr Val Val Phe Asp Arg Ala Arg Lys Arg Ile Gly Phe Ala 405 410 415
- Val Ser Ala Cys His Val His Asp Glu Phe Arg Thr Ala Ala Val Glu 420 425 430
- Gly Pro Phe Val Thr Leu Asp Met Glu Asp Cys Gly Tyr Asn Ile Pro 435 440
- Gln Thr Asp Glu Ser His His His His His His 450 455

<210> 33

<211> 25

WO 01/49097

- 40 -

PCT/IB01/00797

```
<212> PRT
<213> Homo sapiens
Ser Glu Gln Gln Arg Arg Pro Arg Asp Pro Glu Val Val Asn Asp Glu
Ser Ser Leu Val Arg His Arg Trp Lys
             20
<210> 34
<211> 19
<212> PRT
<213> Homo sapiens
Ser Glu Gln Leu Arg Gln Gln His Asp Asp Phe Ala Asp Asp Ile Ser
Leu Leu Lys
<210> 35
<211> 29
<212> DNA
<213> Homo sapiens
<400> 35
gtggatccac ccagcacggc atccggctg
                                                                   29
<210> 36
<211> 36
<212> DNA
<213> Homo sapiens
<400> 36
gaaagctttc atgactcatc tgtctgtgga atgttg
                                                                   36
<210> 37
<211> 39
<212> DNA
<213> Homo sapiens
                                                                   39
gatcgatgac tatctctgac tctccgcgtg aacaggacg
<210> 38
<211> 39
<212> DNA
<213> Homo sapiens
<400> 38
gatccgtcct gttcacgcgg agagtcagag atagtcatc
                                                                   39
<210> 39
<211> 77
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Hu-Asp2
```

- 41 -

```
<400> 39
cggcatccgg ctgcccctgc gtagcggtct gggtggtgct ccactgggtc tgcgtctgcc 60
ccgggagacc gacgaag
<210> 40
<211> 77
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: Hu-Asp2
<400> 40
cttcgtcggt ctcccggggc agacgcagac ccagtggagc accacccaga ccgctacgca 60
ggggcagccg gatgccg
<210> 41
<211> 51
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Caspase 8
      Cleavage Site
<400> 41
                                                            51
gatogatgac tatototgac totocgotgg actotggtat cgaaaccgac g
<210> 42
<211> 51
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Caspase 8
      Cleavage Site
                                                                   51
gatecgtegg tttegatace agagteeage ggagagteag agatagteat e
<210> 43
<211> 32
<212> DNA
<213> Homo sapiens
                                                                   32
aaggateett tgtggagatg gtggacaace tg
<210> 44
<211> 36
<212> DNA
<213> Homo sapiens
<400> 44
                                                                   36
gaaagettte atgacteate tgtetgtgga atgttg
<210> 45
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: 6-His tag
```

```
47
                                                        22
iccac tegaceaggt te
48
51
DNA
Artificial Sequence
Description of Artificial Sequence: primer
taaat tocagcacac tggctactto ttgttctgca totcaaagaa c
                                                        51
49
26
Artificial Sequence
Description of Artificial Sequence: primer
                                                        26
taaat teeageacae tggeta
50
1287
DNA
Artificial Sequence
Description of Artificial Sequence: Hu-Asp2(b)
delta TM
50
ccaag ccctgccctg gctcctgctg tggatgggcg cgggagtgct gcctgcccac 60
ccage acggeatecg getgeccetg egeageggee tgggggggege ecceetgggg 120
gatgg tggacaacct gaggggcaag tcggggcagg gctactacgt ggagatgacc 240
cagoo cocogoagao gotoaacato otggtggata caggoagcag taactttgca 300
tgctg cccccaccc cttcctgcat cgctactacc agaggcagct gtccagcaca 360
```

PCT/IB01/00797 1/49097 - 42 -45 24 atca tcaccatcac catg 46 24 Artificial Sequence Description of Artificial Sequence: 6-His tag 46 24 ıtggt gatggtgatg atgc 47 22 DNA Artificial Sequence Description of Artificial Sequence: primer

taccqqqacc tccqqaaggg tgtgtatgtg ccctacaccc agggcaagtg ggaaggggag 420 ctgggcaccg acctggtaag catececcat ggccccaacg tcactgtgcg tgccaacatt 480 getgecatea etgaateaga caagttette ateaaegget ceaaetggga aggeateetg 540 gggetggeet atgetgagat tgeeaggett tgtggtgetg getteeeeet caaccagtet 600 gaagtgctgg cctctgtcgg agggagcatg atcattggag gtatcgacca ctcgctgtac 660 acaggcagte tetggtatae acceateegg egggagtggt attatgaggt cateattgtg 720 cqqqtqgaga tcaatggaca ggatctgaaa atggactgca aggagtacaa ctatgacaag 780 agcattgtgg acagtggcac caccaacctt cgtttgccca agaaagtgtt tgaagctgca 840 gtcaaatcca tcaaggcagc ctcctccacg gagaagttcc ctgatggttt ctggctagga 900 gaqcagctgg tgtgctggca agcaggcacc accccttgga acattttccc agtcatctca 960 ctctacctaa tgggtgaggt taccaaccag tccttccgca tcaccatcct tccgcagcaa 1020 tacctgcggc cagtggaaga tgtggccacg tcccaagacg actgttacaa gtttgccatc 1080 tcacagtcat ccacgggcac tgttatggga gctgttatca tggagggctt ctacgttgtc 1140 tttgatcggg cccgaaaacg aattggcttt gctgtcagcg cttgccatgt gcacgatgag 1200 ttcaggacgg cagcggtgga aggccctttt gtcaccttgg acatggaaga ctgtggctac 1260 aacattccac agacagatga gtcatga <210> 51 <211> 428 <212> PRT <213> Artificial Sequence <223> Description of Artificial Sequence: Hu-Asp2(b) delta TM Met Ala Gln Ala Leu Pro Trp Leu Leu Trp Met Gly Ala Gly Val Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp 135 Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val Arg Ala Asn Ile Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser Asn Trp Glu Gly Ile Leu Gly Leu Ala Tyr Ala Glu Ile Ala Arg Leu Cys Gly 185

- 44 -

Ala Gly Phe Pro Leu Asn Gln Ser Glu Val Leu Ala Ser Val Gly Gly 200 Ser Met Ile Ile Gly Gly Ile Asp His Ser Leu Tyr Thr Gly Ser Leu Trp Tyr Thr Pro Ile Arg Arg Glu Trp Tyr Tyr Glu Val Ile Ile Val Arg Val Glu Ile Asn Gly Gln Asp Leu Lys Met Asp Cys Lys Glu Tyr 250 Asn Tyr Asp Lys Ser Ile Val Asp Ser Gly Thr Thr Asn Leu Arg Leu Pro Lys Lys Val Phe Glu Ala Ala Val Lys Ser Ile Lys Ala Ala Ser Ser Thr Glu Lys Phe Pro Asp Gly Phe Trp Leu Gly Glu Gln Leu Val 295 Cys Trp Gln Ala Gly Thr Thr Pro Trp Asn Ile Phe Pro Val Ile Ser Leu Tyr Leu Met Gly Glu Val Thr Asn Gln Ser Phe Arg Ile Thr Ile Leu Pro Gln Gln Tyr Leu Arg Pro Val Glu Asp Val Ala Thr Ser Gln 345 Asp Asp Cys Tyr Lys Phe Ala Ile Ser Cln Ser Ser Thr Cly Thr Val Met Gly Ala Val Ile Met Glu Gly Phe Tyr Val Val Phe Asp Arg Ala 375 Arg Lys Arg Ile Gly Phe Ala Val Ser Ala Cys His Val His Asp Glu 390 395 Phe Arg Thr Ala Ala Val Glu Gly Pro Phe Val Thr Leu Asp Met Glu Asp Cys Gly Tyr Asn Ile Pro Gln Thr Asp Glu Ser <21.0> 52 <211> 1305 <212> DNA <213> Artificial Sequence <223> Description of Artificial Sequence: Hu-Asp2(b) delta TM <400> 52 atggcccaag ccctgccctg gctcctgctg tggatgggcg cgggagtgct gcctgcccac 60 ggcacccagc acggcatccg gctgcccctg cgcagcggcc tgggggggcgc ccccctgggg 120 gtggagatgg tggacaacct gaggggcaag tcggggcagg gctactacgt ggagatgacc 240 gtgggcagcc ccccgcagac gctcaacatc ctggtggata caggcagcag taactttgca 300 gtgggtgetg cececeaece etteetgeat egetaetaee agaggeaget gteeageaea 360 taccgggacc tccggaaggg tgtgtatgtg ccctacaccc agggcaagtg ggaaggggag 420

```
ctgggcaccg acctggtaag catcccccat ggccccaacg tcactgtgcg tgccaacatt 480
qctqccatca ctgaatcaga caagttcttc atcaacggct ccaactggga aggcatcctg 540
gggctggcct atgctgagat tgccaggctt tgtggtgctg gcttccccct caaccagtct 600
gaagtgctgg cctctgtcgg agggagcatg atcattggag gtatcgacca ctcgctgtac 660
acaggcagtc tetggtatac acceateegg egggagtggt attatgaggt cateattgtg 720
cgggtggaga tcaatggaca ggatctgaaa atggactgca aggagtacaa ctatgacaag 780
agcattgtgg acagtggcac caccaacctt cgtttgccca agaaagtgtt tgaagctgca 840
gtcaaatcca tcaaggcage etectecaeg gagaagttee etgatggttt etggetagga 900
gagcagctgg tgtgctggca agcaggcacc accccttgga acattttccc agtcatctca 960
ctctacctaa tgggtgaggt taccaaccag tectteegea teaccateet teegeageaa 1020
tacctgegge cagtggaaga tgtggeeaeg teccaagaeg actgttacaa gtttgeeate 1080
tcacagtcat ccacgggcac tgttatggga gctgttatca tggagggctt ctacgttgtc 1140
tttgatcggg cccgaaaacg aattggcttt gctgtcagcg cttgccatgt gcacgatgag 1200
ttcaggacgg cagcggtgga aggccctttt gtcaccttgg acatggaaga ctgtggctac 1260
aacattccac agacagatga gtcacagcag cagcagcagc agtga
<210> 53
<211> 434
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Hu-Asp2(b)
      delta TM
<400> 53
Met Ala Gln Ala Leu Pro Trp Leu Leu Leu Trp Met Gly Ala Gly Val
Leu Pro Ala His Gly Thr Gln His Gly Ile Arg Leu Pro Leu Arg Ser
Gly Leu Gly Gly Ala Pro Leu Gly Leu Arg Leu Pro Arg Glu Thr Asp
Glu Glu Pro Glu Glu Pro Gly Arg Arg Gly Ser Phe Val Glu Met Val
Asp Asn Leu Arg Gly Lys Ser Gly Gln Gly Tyr Tyr Val Glu Met Thr
Val Gly Ser Pro Pro Gln Thr Leu Asn Ile Leu Val Asp Thr Gly Ser
Ser Asn Phe Ala Val Gly Ala Ala Pro His Pro Phe Leu His Arg Tyr
Tyr Gln Arg Gln Leu Ser Ser Thr Tyr Arg Asp Leu Arg Lys Gly Val
                                                125
                            120
Tyr Val Pro Tyr Thr Gln Gly Lys Trp Glu Gly Glu Leu Gly Thr Asp
Leu Val Ser Ile Pro His Gly Pro Asn Val Thr Val Arg Ala Asn Ile
                                        155
                    150
Ala Ala Ile Thr Glu Ser Asp Lys Phe Phe Ile Asn Gly Ser Asn Trp
Glu Gly Ile Leu Gly Leu Ala Tyr Ala Glu Ile Ala Arg Leu Cys Gly
                                185
```

- 46 -

Ala Gly Phe Pro Leu Asn Gln Ser Glu Val Leu Ala Ser Val Gly Gly 200 Ser Met Ile Ile Gly Gly Ile Asp His Ser Leu Tyr Thr Gly Ser Leu 215 Trp Tyr Thr Pro Ile Arg Arg Glu Trp Tyr Tyr Glu Val Ile Ile Val Arg Val Glu Ile Asn Gly Gln Asp Leu Lys Met Asp Cys Lys Glu Tyr Asn Tyr Asp Lys Ser Ile Val Asp Ser Gly Thr Thr Asn Leu Arg Leu Pro Lys Lys Val Phe Glu Ala Ala Val Lys Ser Ile Lys Ala Ala Ser Ser Thr Glu Lys Phe Pro Asp Gly Phe Trp Leu Gly Glu Gln Leu Val Cys Trp Gln Ala Gly Thr Thr Pro Trp Asn Ile Phe Pro Val Ile Ser 315 Leu Tyr Leu Met Gly Glu Val Thr Asn Gln Ser Phe Arg Ile Thr Ile 330 325 Leu Pro Gln Gln Tyr Leu Arg Pro Val Glu Asp Val Ala Thr Ser Gln Asp Asp Cys Tyr Lys Phe Ala Ile Ser Gin Ser Ser Thr Gly Thr Val Met Gly Ala Val Ile Met Glu Gly Phe Tyr Val Val Phe Asp Arg Ala 375 370 Arg Lys Arg Ile Gly Phe Ala Val Ser Ala Cys His Val His Asp Glu Phe Arg Thr Ala Ala Val Glu Gly Pro Phe Val Thr Leu Asp Met Glu 410 Asp Cys Gly Tyr Asn Ile Pro Gln Thr Asp Glu Ser His His His His 425 His His

<210> 54 <211> 2310 <212> DNA <213> Homo sapiens

<400> 54
atgctgcccg gtttggcact gctcctgctg gccgcctgga cggctcgggc gctggaggta 60
cccactgatg gtaatgctgg cctgctggct gaaccccaga ttgccatgtt ctgtggcaga 120
ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggaccaaa 180
acctgcattg ataccaagga aggcatcctg cagtattgcc aagaagtcta ccctgaactg 240
cagatcacca atgtggtaga agccaaccaa ccagtgacca tccagaactg gtgcaagcgg 300
ggccgcaagc agtgcaagac ccatccccac tttgtgattc cctaccgctg cttagttggt 360

- 47 -

```
gaqtttgtaa gtgatgccct tctcgttcct gacaagtgca aattcttaca ccaggagagg 420
atggatgttt gcgaaactca tetteaetgg cacacegteg ccaaagagae atgeagtgaq 480
aaqaqtacca acttqcatqa ctacqqcatq ttgctgccct gcggaattga caagttccga 540
qqqqtaqaqt ttgtgtgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600
qcqqaqqaqq atqactcgqa tgtctggtgg ggcggagcag acacagacta tgcagatggg 660
agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720
gaageegatg atgacgagga egatgaggat ggtgatgagg tagaggaaga ggetgaggaa 780
coctacgaag aagccacaga gagaaccacc agcattgcca ccaccaccac caccaccaca 840
gagtetgtgg aagaggtggt tegagaggtg tgetetgaac aageegagae ggggeegtge 900
cgagcaatga tetecegetg gtactttgat gtgactgaag ggaagtgtge eccattett 960
tacqqqqat qtqqcqqcaa ccqqaacaac tttqacacag aagagtactg catggccgtg 1020
tgtggcagcg ccatgtccca aagtttactc aagactaccc aggaacctct tggccgagat 1080
cetqttaaac ttcctacaac aqcaqccaqt acccetqatg cegttgacaa gtatetegag 1140
acacctgggg atgagaatga acatgcccat ttccagaaag ccaaagagag gcttgaggcc 1200
aagcaccgag agagaatgtc ccaggtcatg agagaatggg aagaggcaga acgtcaagca 1260
aagaacttgc ctaaagctga taagaaggca gttatccagc atttccagga gaaagtggaa 1320
tetttggaac aggaagcage caacgagaga cagcagetgg tggagacaca catggecaga 1380
qtqqaaqcca tgctcaatga ccgccgccgc ctggccctgg agaactacat caccgctctg 1440
caqqctqttc ctcctcggcc tcgtcacgtg ttcaatatgc taaagaagta tgtccgcgca 1500
gaacagaagg acagacagca caccctaaag catttcgagc atgtgcgcat ggtggatccc 1560
aaqaaaqccq ctcaqatccq qtcccaqqtt atqacacacc tccqtgtgat ttatgagcgc 1620
atquateaqt eteteteet getetaeaac gtgeetgeag tggeegagga gatteaggat 1680
gaagttgatg agctgcttca gaaagagcaa aactattcag atgacgtctt ggccaacatg 1740
attagtgaac caaggatcag ttacggaaac gatgetetea tgccatettt gaccgaaacg 1800
aaaaccaccg tggagctcct tcccgtgaat ggagagttca gcctggacga tctccagccg 1860
tggcattett ttggggetga etetgtgeea gecaacacag aaaacgaagt tgageetgtt 1920
gatgecegee etgetgeega eegaggaetg accaetegae eaggttetgg gttgacaaat 1980
atcaagacgg aggagatete tgaagtgaag atggatgeag aatteegaea tgaeteagga 2040
tatgaagttc atcatcaaaa attggtgttc tttgcagaag atgtgggttc aaacaaaggt 2100
gcaatcattg gactcatggt gggcggtgtt gtcatagcga cagtgatcgt catcaccttg 2160
qtqatqctqa aqaaqaaaca qtacacatcc attcatcatq qtqtqqtqqa qqttqacqcc 2220
qctqtcaccc caqaqqaqcg ccacctgtcc aagatgcagc agaacggcta cgaaaatcca 2280
acctacaagt tctttgagca gatgcagaac
<210> 55
<211> 770
<212> PRT
<213> Homo sapiens
<400> 55
Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu
Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn
                 85
Trp Cys Lys Arg Gly Arg Lys Cln Cys Lys Thr His Pro His Phe Val
Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu
```

120

125

Val	Pro 130	Asp	Lys	Cys	Lys	Phe 135	Leu	His	Gln	Glu	Arg 140	Met	Asp	Val	Cys
Glu 145	Thr	His	Leu	His	Trp 150	His	Thr	Val	Ala	Lys 155	Glu	Thr	Cys	Ser	Glu 160
Lys	Ser	Thr	Asn	Leu 165	His	Asp	Tyr	Gly	Met 170	Leu	L€u	Pro	Cys	Gly 175	Ile
Asp	Lys	Phe	Arg 180	Gly	Val	Glu	Phe	Val 185	Cys	Cys	Pro	Leu	Ala 190	Glu	Glu
Ser	Asp	Asn 195	Val	Asp	Ser	Ala	Asp 200	Ala	Glu	Glu	Asp	Asp 205	Ser	Asp	Val
Trp	Trp 210	Gly	Gly	Ala	Asp	Thr 215	Asp	Tyr	Ala	Asp	Gly 220	Ser	Glu	Asp	Lys
Val 225	Val	Glu	Val	Ala	Glu 230	Glu	Glu	Glu	Val	Ala 235	Glu	Val	Glu	Glu	Glu 240
Glu	Ala	Asp	Asp	Asp 245	Glu	Asp	Asp	Glu	Asp 250	Gly	Asp	Glu	Val	Glu 255	Glu
Glu	Ala	Glu	Glu 260	Pro	Tyr	Glu	Glu	Ala 265	Thr	Glu	Arg	Thr	Thr 270	Ser	Ile
Ala	Thr	Thr 275	Thr	Thr	Thr	Thr	Thr 280	Glu	Ser	Val	Glu	Glu 285	Val	Val	Arg
Glu	Val .290	Cys	Ser	Glu	Gln	Ala 295	Glu	Thr	Gly	Pro	300	Arg	Ala	Met	Ile
Ser 305	Arg	Trp	Tyr	Phe	Asp 310	Val	Thr	Glu	Gly	Lys 315	Cys	Ala	Pro	Phe	Phe 320
Tyr	Gly	Gly	Cys	Gly 325	Gly	Asn	Arg	Asn	Asn 330	Phe	Asp	Thr	Glu	Glu 335	Tyr
Cys	Met	Ala	Val 340	Cys	Gly	Ser	Ala	Met 345	Ser	Gln	Ser	Leu	Leu 350	Lys	Thr
Thr	Gln	Glu 355	Pro	Leu	Ala	Arg	Asp 360	Pro	Val	Lys	Leu	Pro 365	Thr	Thr	Ala
Ala	Ser 370	Thr	Pro	Asp	Ala	Val 375	Asp	Lys	Tyr	Leu	Glu 380	Thr	Pro	Gly	Asp
Glu 385		Glu	His	Ala	His 390	Phe	Gln	Lys	Ala	Lys 395	Glu	Arg	Leu	Glu	Ala 400
Lys	His	Arg	Glu	Arg 405	Met	Ser	Gln	Val	Met 410	Arg	Glu	Trp	Glu	Glu 415	Ala
Glu	Arg	Gln	Ala 420	Lys	Asn	Leu	Pro	Lys 425	Ala	Asp	Lys	Lys	Ala 430	Val	Ile
Gln	His	Phe 435		Glu	Lys	Val	Glu 440	Ser	Leu	Glu	Gln	Glu 445	Ala	Ala	Asn
Glu	Arg		Gln	Leu	Val	Glu 455	Thr	His	Met	Ala	Arg	Val	Glu	Ala	Met

Leu Asn Asp Arg Arg Leu Ala Leu Glu Asn Tyr Ile Thr Ala Leu 470 Gln Ala Val Pro Pro Arg Pro Arg His Val Phe Asn Met Leu Lys Lys Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His Thr Leu Lys His Phe Glu His Val Arg Met Val Asp Pro Lys Lys Ala Ala Gln Ile Arg Ser 520 Gln Val Met Thr His Leu Arg Val Ile Tyr Glu Arg Met Asn Gln Ser Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala Glu Glu Ile Gln Asp 550 Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn Tyr Ser Asp Asp Val Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser Tyr Gly Asn Asp Ala Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr Val Glu Leu Leu Pro 600 Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln Pro Trp His Ser Phe Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn Glu Val Glu Pro Val 635 630 Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser 650 Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys Met Asp 665 Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly 695 700 Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr Leu Val Met Leu Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln Met 760

Gln Asn 770 - 50 -

```
<210> 56
<211> 2253
<212> DNA
<213> Homo sapiens
<400> 56
atgetgeeeg gtttggeact geteetgetg geogeetgga eggeteggge getggaggta 60
cccactgatg gtaatgctgg cctgctggct gaaccccaga ttgccatgtt ctgtggcaga 120
ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggaccaaa 180
acctgcattg ataccaagga aggcateetg cagtattgee aagaagteta ceetgaactg 240
caqatcacca atqtqqtaqa aqccaaccaa ccaqtgacca tccagaactg gtgcaagcgg 300
ggccgcaage agtgcaagac ccatccccac tttgtgattc cctaccgctg cttagttggt 360
qaqtitqtaa qiqatqccch tctcqttcct gacaagtgca aəttcttaca ccaggagagg 420
atggatgttt gcgaaactca tottcactgg cacaccgtcg ccaaagagac atgcagtgag 480
aagagtacca acttgcatga ctacggcatg ttgctgccct gcggaattga caagttccga 540
qqqqtaqaqt ttgtgtgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600
geggaggagg atgaetegga tgtetggtgg ggeggageag acaeagaeta tgeagatggg 660
agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720
gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780
coctacgaag aagccacaga gagaaccacc agcattgcca ccaccaccac caccaccaca 840
gagtetgtgg aagaggtggt tegagaggtg tgetetgaac aageegagae ggggeegtge 900
eqaqeaatqa tetecegetq qtaetttqat gtgactgaag ggaagtgtge cecattettt 960
tacggeggat gtggeggeaa ceggaacaac tttgacacag aagagtactg catggeegtg 1020
tgtggcageg ccattectac aacagcagec agtacecetg atgeegttga caagtatete 1080
gagacaccig gggatgagaa tgaacatgcc catttccaga aagccaaaga gaggcttgag 1140
gccaagcacc gagagagaat gtcccaggtc atgagagaat gggaagaggc agaacgtcaa 1200
qcaaaqaact tqcctaaaqc tqataaqaaq qcaqttatcc agcatttcca ggagaaagtg 1260
gaatetttgg aacaggaage agecaacgag agacagcage tggtggagae acacatggee 1320
agagtggaag ccatgctcaa tgaccgccgc cgcctggccc tggagaacta catcaccgct 1380
ctgcaggctg ttcctcctcg gcctcgtcac gtgttcaata tgctaaagaa gtatgtccgc 1440
qcaqaacaqa aqqacaqaca qcacacccta aagcatttcg agcatgtgcg catggtggat 1500
cccaaqaaaq ccqctcaqat ccqqtcccaq qttatgacac acctccgtgt gatttatgag 1560
cgcatgaatc agtctctctc cctgctctac aacgtgcctg cagtggccga ggagattcag 1620
gatgaagttg atgagctgct tcagaaagag caaaactatt cagatgacgt cttggccaac 1680
atgattagtg aaccaaggat cagttacgga aacgatgctc tcatgccatc tttgaccgaa 1740
acqaaaacca ccqtqqaqct ccttcccqtq aatggagagt tcagcctgga cgatctccag 1800
cogtggcatt cttttggggc tgactctgtg ccagccaaca cagaaaacga agttgagcct 1860
qttqatqccc qccctqctqc cqaccqaqqa ctqaccactc gaccaggttc tgggttgaca 1920
aatatcaaga cggaggagat ctctgaagtg aagatggatg cagaattccg acatgactca 1980
ggatatgaag ticatcatca aaaattggtg ttctttgcag aagatgtggg ttcaaacaaa 2040
qqtqcaatca ttqqactcat qqtqqqcqqt qttqtcatag cgacagtgat cgtcatcacc 2100
ttggtgatgc tgaagaagaa acagtacaca tccattcatc atggtgtggt ggaggttgac 2160
geogetytea eeccagagga gegeeacety tecaagatye ageagaacyg etacgaaaat 2220
ccaacctaca agttctttga gcagatgcag aac
<210> 57
<211> 751
<212> PRT
<213> Homo sapiens
<400> 57
Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
                                 25
Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
```

Thr 65	Lys	Glu	Gly	Ile	Leu 70	Gln	Tyr	Cys	Gln	Glu 75	Val	Tyr	Pro	Glu	Leu 80
Gln	Ile	Thr	Asn	Val 85	Val	Glu	Ala	Asn	Gln 90	Pro	Vāl	Thr	Ile	Gln 95	Asn
Trp	Cys	Lys	Arg 100	Gly	Arg	Lys	Gln	Cys 105	Lys	Thr	His	Pro	His 110	Phe	Val
Ile	Pro	Tyr 115	Arg	Cys	Leu	Val	Gly 120	Glu	Phe	Val	Ser	Asp 125	Ala	Leu	Leu
Val	Pro 130	Asp	Lys	Cys	Lys	Phe 135	Leu	Hıs	Gln	Glu	Arg 140	Met	Asp	Val	Cys
Glu, 145		His	Leu	His	Trp 150	His	Thr	Val	Ala	Lys 155	Glu	Thr	Cys	Ser	Glu 160
Lys	Ser	Thr	Asn	Leu 165	His	Asp	Tyr	Gly	Met 170	Leu	Leu	Pro	Cys	Gly 1 7 5	Ile
Asp	Lys	Phe	Arg 180	Gly	Val	Glu	Phe	Val 185	Cys	Cys	Pro	Leu	Ala 190	Glu	Glu
Ser	Asp	Asn 195	Val	Asp	Ser	Ala	Asp 200	Ala	Glu	Glu	Asp	Asp 205	Ser	Asp	Val
_	Trp 210	Gly	Gly	Ala	Asp	Thr 215	Asp	Tyr	Ala	Asp	Gly 220	Ser	Glu	Asp	Lys
Val 225	Val	Glu	Val	Ala	Glu 230	Glu	Glu	Glu	Val	Ala 235	Glu	Val	Glu	Glu	Glu 240
Glu	Ala	Asp	Asp	Asp 245	Glu	Asp	Asp	Glu	Asp 250	Cly	Asp	Glu	Val	Glu 255	Glu
Glu	Ala	Glu	Glu 260	Pro	Tyr	Glu	Glu	Ala 265	Thr	Glu	Arg	Thr	Thr 270	Ser	Ile
Ala	Thr	Thr 275		Thr	Thr	Thr	Thr 280	Glu	Ser	Val	Glu	Glu 285	Val	Val	Arg
Glu	Val 290				Gln			Thr	Gly	Pro	Cys 300	Arg	Ala	Met	Ile
Ser 305	_	Trp	Tyr	Phe	Asp 310	Val	Thr	Glu	Gly	Lys 315	Cys	Ala	Pro	Phe	Phe 320
Tyr	Gly	Gly	Cys	Gly 325		Asn	Arg	Asn	Asn 330	Phe	Asp	Thr	Glu	Glu 335	Tyr
Cys	Met	Ala	. Val 340		Gly	Ser	Ala	Ile 345		Thr	Thr	Ala	Ala 350	Ser	Thr
Pro	Asp	Ala 355		Asp	Lys	Tyr	Leu 360		Thr	Pro	Gly	Asp 365	Glu	Asn	Glu
His	Ala 370		Phe	Gln	Lys	Ala 375		Glu	Arg	Leu	Glu 380	Ala	Lys	His	Arg
Glu 385		Met	Ser	Gln	Val		Arg	Glu	Trp	Glu 395		Ala	Glu	Arg	Glr. 400

Ala	Lys	Asn	Leu	Pro 405	Lys	Ala	Asp	Lys	Lys 410	Ala	Val	Ile	Gln	His 415	Phe
Gln	Glu	Lys	Val 420	Glu	Ser	Leu	Glu	Gln 425	Glu	Ala	Ala	Asn	Glu 430	Arg	Gln
Gln	Leu	Val 435	Glu	Thr	His	Met	Ala 440	Arg	Val	Glu	Ala	Met 445	Leu	Asn	Asp
Arg	Arg 450	Arg	Leu	Ala	Leu	Glu 455	Asn	Tyr	Ile	Thr	Ala 460	Leu	Gln	Ala	Val
Pro 465	Pro	Arg	Pro	Arg	His 470	Val	Phe	Asn	Met	Leu 475	Lys	Lys	Tyr	Val	Arg 480
Ala	Glu	Gln	Lys	Asp 485	Arg	Gln	His	Thr	Leu 490	Lys	His	Phe	Glu	His 495	Val
Arg	Met	Val	Asp 500	Pro	Lys	Lys	Ala	Ala 505	Gln	Ile	Arg	Ser	Gln 510	Val	Met
Thr	His	Leu 515	Arg	Val	Ile	Tyr	Glu 520	Arg	Met	Asn	Gln	Ser 525	Leu	Ser	Leu
Leu	Tyr 530	Asn	Val	Pro	Ala	Val 535	Ala	Glu	Glu	Ile	Gln 540	Asp	Glu	Val	Asp
Glu 545	Leu	Leu	Gln	Lys	Glu 550	Gln	Asn	Tyr	Ser	Asp 555	Asp	Val	Leu	Ala	Asrı 560
Met	Ile	Ser	Glu	Pro 565	Arg	Ile	Ser	Tyr	Gly 570	Asn	Asp	Ala	Leu	Met 575	Pro
Ser	Leu	Thr	Glu 580	Thr	Lys	Thr	Thr	Val 585	Glu	Leu	Leu	Pro	Val 590	Asn	Gly
Glu	Phe	Ser 595	Leu	Asp	Asp	Leu	Gln 600	Pro	Trp	His	Ser	Phe 605	Gly	Ala	Asp
Ser	Val 610	Pro	Ala	Asn	Thr	Glu 615	Asn	Glu	Val	Glu	Pro 620	Val	Asp	Ala	Arg
Pro 625	Ala	Ala	Asp	Arg	Gly 630	Leu	Thr	Thr	Arg	Pro 635	Gly	Ser	Gly	Leu	Thr 640
Asn	Ile	Lys	Thr	Glu 645	Glu	Ile	Ser	Glu	Val 650	Lys	Met	Asp	Ala	Glu 655	Phe
Arg	His	Asp	Ser 660	Gly	Tyr	Glu	Val	His 665	His	Gln	Lys	Leu	Val 670	Phe	Phe
Ala	Glu	Asp 675	Val	Gly	Ser	Asn	Lys 680	Gly	Ala	Ile	Ile	Gly 685	Leu	Met	Val
Gly	Gly 690	Val	Val	Ile	Ala	Thr 695	Val	Ile	Val	Ile	Thr 700	Leu	Val	Met	Leu
Lys 705	Lys	Lys	Gln	Tyr	Thr 710	ser	Ile	His	His	Gly 715	Val	Val	Glu	Val	Asp 720
Ala	Ala	Val	Thr	Pro	Glu	Glu	Arg	His	Leu 730	Ser	Lys	Met	Gln	Gln 735	Asn

- 53 -

```
Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln Met Gln Asn
<210> 58
<211> 2316
<212> DNA
<213> Homo sapiens
<400> 58
atgctgccg gtttggcact gctcctgctg gccgcctgga cggctcgggc gctggaggta 60
cccactgatg gtaatgctgg cctgctggct gaaccccaga ttgccatgtt ctgtggcaga 120
ctqaacatqc acatqaatqt ccaqaatggg aagtgggatt cagatccatc agggaccaaa 180
accigcatty araccaagga aggeateety cagtattyce aagaagteta ecctyaacty 240
cagateacea atgtggtaga agecaaeeaa eeagtgaeea teeagaaetg gtgeaagegg 300
ggccgcaagc agtgcaagac ccatccccac tttgtgattc cctaccgctg cttagttggt 360
qaqtttqtaa qtqatqccct tctcqttcct gacaagtgca aattcttaca ccaggagagg 420
atggatgttt gegaaactea tetteaetgg cacacegteg ceaaagagae atgcagtgag 480
aagagtacca acttgcatga ctacggcatg ttgctgccct gcggaattga caagttccga 540
ggggtagagt ttgtgtgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600
qcqqaqqaqq atqactcqqa tqtctqqtgg ggcggagcag acacagacta tgcagatggg 660
agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720
gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780
ccctacgaag aagccacaga gagaaccacc agcattgcca ccaccaccac caccaccaca 840
gagtetgtgg aagaggtggt tegagaggtg tgetetgaac aageegagae ggggeegtge 900
cgagcaatga tetecegetg gtactttgat gtgactgaag ggaagtgtge cccattettt 960
tacggeggat gtggcggcaa ccggaacaac tttgacacag aagagtactg catggccgtg 1020
tgtggeageg ceatgteeca aagtttacte aagactacee aggaacetet tggeegagat 1080
cctqttaaac ttcctacaac agcagccagt acccctgatg ccgttgacaa gtatctcgag 1140
acacetqqqq atqaqaatqa acatgeecat ttecagaaag ccaaagagag gettgaggee 1200
aagcaccgag agagaatgtc ccaggtcatg agagaatggg aagaggcaga acgtcaagca 1260
aagaacttgc ctaaagctga taagaaggca gttatccagc atttccagga gaaagtggaa 1320
tetttggaac aggaagcage caacgagaga cagcagetgg tggagacaca catggecaga 1380
gtggaageca tgctcaatga cegeegeege etggeeetgg agaactacat caeegetetg 1440
caggetgtte etectogged tegteacgtg ttcastatge tasagaagta tgtcegegea 1500
qaacaqaaqq acaqacaqca caccctaaag catttcgagc atgtgcgcat ggtggatccc 1560
aagaaageeg eteagateeg gteecaggtt atgacacace teegtgtgat ttatgagege 1620
atgaatcagt ctctctccct gctctacaac gtgcctgcag tggccgagga gattcaggat 1680
gaagttgatg agctgcttca gaaagagcaa aactattcag atgacgtctt ggccaacatg 1740
attaqtqaac caaqqatcaq ttacqqaaac qatgctctca tgccatcttt gaccgaaacg 1800
aaaaccaccg tggagctcct tcccgtgaat ggagagttca gcctggacga tctccagccg 1860
tggcattett ttggggetga etetgtgeca gecaacacag aaaacgaagt tgageetgtt 1920
gatgcccgcc ctgctgccga ccgaggactg accactcgac caggttctgg gttgacaaat 1980
atcaagacgg aggagatete tgaagtgaag atggatgeag aatteegaea tgaeteagga 2040
tatgaagttc atcatcaaaa attggtgttc tttgcagaag atgtgggttc aaacaaaggt 2100
geaatcattg gacteatggt gggeggtgtt gteatagega eagtgategt cateacettg 2160
gtgatgctga agaagaaaca gtacacatcc attcatcatg gtgtggtgga ggttgacgcc 2220
getgteacce cagaggageg ceacetgtee aagatgeage agaaeggeta egaaaateea 2280
acctacaaqt tctttqaqca qatqcagaac aagaag
                                                                  2316
<210> 59
<211> 772
<212> PRT
<213> Homo sapiens
<400> 59
Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
```

Gln	Ile	Ala 35	Met	Phe	Cys	Gly	Arg 40	Leu	Asn	Met	His	Met 45	Asn	Val	Gln
Asn	Gly 50	Lys	Trp	Asp	Ser	Asp 55	Pro	Ser	Gly	Thr	Lys 60	Thr	Cys	Ile	Asp
Thr 65	Lys	Glu	Gly	Ile	Leu 70	Gln	Tyr	Cys	Gln	Glu 75	Val	Tyr	Pro	Glu	Leu 80
Gln	Ile	Thr	Asn	Val 85	Val	Glu	Ala	Asn	Gln 90	Pro	Val	Thr	Ile	Gln 95	Asn
Trp	Суѕ	Lys	Arg 100	Gly	Arg	Lys	Gln	Cys 105	Lys	Thr	His	Pro	His 110	Phe	Val
Ile	Pro	Tyr 115	Arg	Cys	Leu	Val	Gly 120	Glu	Phe	Val	Ser	Asp 125	Ala	Leu	Leu
Val	Pro 130	Asp	Lys	Cys	Lys	Phe 135	Leu	His	Gln	Glu	Arg 140	Met	Asp	Val	Cys
Glu 145	Thr	His	Leu	His	Trp 150	His	Thr	Val	Ala	Lys 155	Glu	Thr	Cys	Ser	Glu 160
Lys	Ser	Thr	Asn	Leu 165	His	Asp	Tyr	Gly	Met 170	Leu	Leu	Pro	Cys	Gly 175	Ile
Asp	Lys	Phe	Arg 180	Gly	Val	Glu	Phe	Val 185	Cys	Cys	Pro	Leu	Ala 190	Glu	Glu
Ser	Asp	Asn 195	Val	Asp	Ser	Ala	Asp 200	Ala	Glu	Glu	Asp	Asp 205	Ser	Asp	Val
Trp	Trp 210	Gly	Gly	Ala	Asp	Thr 215	Asp	Tyr	Ala	Asp	Gly 220	Ser	Gl.u	Asp	Lys
Val 225	Val	Glu	Val	Ala	Glu 230	Glu	Glu	Glu	Val	Ala 235	Glu	Val	G] u	Glu	Glu 240
Glu	Ala	Asp	Asp	Asp 245	Glu	Asp	Asp	Glu	Asp 250	Gly	Asp	Glu	Val	Glu 255	Glu
Glu	Ala	Glu	Glu 260	Pro	Tyr	Glu	Glu	Ala 265	Thr	Glu	Arg	Thr	Thr 270	Ser	Ile
Ala	Thr	Thr 275	Thr	Thr	Thr	Thr	Thr 280	Glu	Ser	Val	Glu	Glu 285	Val	Val	Arg
Glu	Val 290	Cys	Ser	Glu	Gln	Ala 295	Glu	Thr	Gly	Pro	Cys 300	Arg	Ala	Met	Ile
Ser 305	Arg	Trp	Tyr	Phe	Asp 310	Val	Thr	Glu	Gly	Lys 315	Cys	Ala	Pro	Phe	Ph∈ 320
Tyr	Gly	Gly	Cys	Gly 325	Gly	Asn	Arg	Asn	Asn 330	Phe	Asp	Thr	Glu	Glu 335	Tyr
Cys	Met	Ala	Val 340	Cys	Gly	Ser	Ala	Met 345	Ser	Gln	Ser	Leu	Leu 350	Lys	Thr
Thr	Gln	Glu 355	Pro	Leu	Ala	Arg	Asp 360	Pro	Val	Lys	Leu	Pro 365	Thr	Thr	Ala

Ala	Ser 370	Thr	Pro	Asp	Ala	Val 375	Asp	Lys	Tyr	Leu	Glu 380	Thr	Pro	Gly	Asp
Glu 385	Asn	Glu	His	Ala	His 390	Phe	Gln	Lys	Ala	Lys 395	Glu	Arg	Leu	Glu	Ala 400
Lys	His	Arg	Glu	Arg 405	Met	Ser	Gln	Val	Met 410	Arg	Glu	Trp	Glu	Glu 415	Ala
Glu	Arg	Gln	Ala 420	Lys	Asn	Leu	Pro	Lys 425	Ala	Asp	Lys	Lys	Ala 430	Val	Ile
Gln	His	Phe 435	Gln	Glu	Lys	Val	Glu 440	Ser	Leu	Glu	Gln	Glu 445	Ala	Ala	Asn
Glu	Arg 450	Gln	Gln	Leu	Val	Glu 455	Thr	His	Met	Ala	Arg 460	Val	Glu	Ala	Met
Leu 465	Asn	Asp	Arg	Arg	Arg 470	Leu	Ala	Leu	Glu	Asn 475	Tyr	Ile	Thr	Ala	Leu 480
Gln	Ala	Val	Pro	Pro 485	Arg	Pro	Arg	His	Val 490	Phe	Asn	Met	Leu	Lys 495	Lys
Tyr	Val	Arg	Ala 500	Glu	Gln	Lys	Asp	Arg 505	Gln	His	Thr	Leu	Lys 510	His	Phe
Glu	His	Val 515	Arg	Met	Val	Asp	Pro 520	Lys	Lys	Ala	Ala	Gln 525	Ile	Arg	Ser
Gln	Val 530	Met	Thr	His	Leu	Arg 535	Val	Ile	Tyr	Glu	Arg 540	Met	Asn	Gln	Ser
Leu 545	Ser	Leu	Leu	Tyr	Asn 550	Val	Pro	Ala	Val	Ala 555	Glu	Glu	Ile	Gln	Asp 560
Glu	Val	Asp	Glu	Leu 565	Leu	Gln	Lys	Glu	Gln 570	Asn	Tyr	Ser	Asp	Asp 575	Val
Leu	Ala	Asn	Met 580	Ile	Ser	Glu	Pro	Arg 585	Ile	Ser	Tyr	Gly	Asn 590	Asp	Ala
Leu	Met	Pro 595	Ser	Leu	Thr	Glu	Thr 600	Lys	Thr	Thr	Val	Glu 605	Leu	Leu	Pro
Val	Asn 610	Gly	Glu	Phe	Ser	Leu 615	Asp	Asp	Leu	Gln	Pro 620	Trp	His	Ser	Phe
Gly 625	Ala	Asp	Ser	Val	Pro 630	Ala	Asn	Thr	Glu	Asn 635	Glu	Val	Glu	Pro	Val 640
Asp	Ala	Arg	Pro	Ala 645	Ala	Asp	Arg	Gly	Leu 650	Thr	Thr	Arg	Pro	Gly 655	Ser
Gly	Leu	Thr	Asn 660	Ile	Lys	Thr	Glu	Glu 665	Ile	Ser	Glu	Val	Lys 670	Met	Asp
Ala	Glu	Phe 675	Arg	His	Asp	Ser	Gly 680	Tyr	Glu	Val	His	His 685	Gln	Lys	Leu
Val	Phe 690		Ala	Glu	Asp	Val 695	Gly	Ser	Asn	Lys	Gly 700	Ala	Ile	Ile	Gly

- 56 -

```
Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr Leu
                                        715
Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val
Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys Met
                                745
                                                    750
            740
Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln Met
                            760
Gln Asn Lys Lys
    770
<210> 60
<211> 2259
<212> DNA
<213> Homo sapiens
<400> 60
atgctgcccg gtttggcact gctcctgctg gccgcctgga cggctcgggc gctggaggta 60
cceactqatq qtaatqctqq cctqctqqct gaaccccaga ttgccatgtt ctgtggcaga 120
ctgaacatgc acatgaatgt ccaqaatggg aagtgggatt cagatccatc agggaccaaa 180
acctgcattg ataccaagga aggcatcctg cagtattgcc aagaagtcta ccctgaactg 240
cagatcacca atgtggtaga agccaaccaa ccagtgacca tccagaactg gtgcaaqcqq 300
qqccqcaaqc aqtqcaaqac ccatccccac tttqtgattc cctaccgctg cttagttggt 360
qaqtttqtaa qtqatqcct tctcqttcct qacaaqtqca aattcttaca ccaqqaqagg 420
atggatgttt gcgaaactca tottcactgg cacaccgtcg ccaaagagac atgcagtgag 480
aagagtacca acttgcatga ctacggcatg ttgctgccct gcggaattga caagttccga 540
ggggtagagt ttgtgtgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600
gcggaggagg atgactcgga tgtctggtgg ggcggagcag acacagacta tgcagatggg 660
aqtqaaqaca aaqtaqtaqa aqtaqcaqaq qaqqaaqaaq tqqctqaggt ggaagaaqaa 720
gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780
ccctacqaaq aaqccacaqa qaqaaccacc agcattgcca ccaccaccac caccaccaca 840
gagtetgtgg aagaggtggt tegagaggtg tgetetgaae aageegagae ggggeegtge 900
cgagcaatga tctcccgctg gtactttgat gtgactgaag ggaagtgtgc cccattcttt 960
tacggcggat gtggcggcaa ccggaacaac tttgacacag aagagtactg catggccgtg 1020
tgtggcageg ccattectac aacageagec agtaceeetg atgeegttga caagtatete 1080
gagacacctg gggatgagaa tgaacatgcc catttccaga aagccaaaga gaggcttgag 1140
gccaagcacc gagagagaat gtcccaggtc atgagagaat gggaagaggc agaacgtcaa 1200
gcaaagaact rgcctaaagc tgataagaag gcagttatcc agcatttcca ggagaaagtg 1260
gaatetttgg aacaggaage agecaacgag agacagcage tggtggagae acacatggee 1320
agagtggaag ccatgctcaa tgaccgccgc cgcctggccc tggagaacta catcaccgct 1380
ctgcaggctg ttcctcctcg gcctcgtcac gtgttcaata tgctaaagaa gtatgtccgc 1440
qcaqaacaqa aqqacaqaca qcacacccta aaqcatttcg aqcatgtgcg catggtggat 1500
cccaagaaag ccgctcagat ccggtcccag gttatgacac acctccgtgt gatttatgag 1560
cgcatgaatc agtetetete cetgetetac aacgtgeetg cagtggeega ggagatteag 1620
gatgaagttg atgagetget teagaaagag caaaactatt cagatgaegt ettggeeaac 1680
atgattagtg aaccaaggat cagttacgga aacgatgctc tcatgccatc tttgaccgaa 1740
acgaaaacca ccgtggagct ccttcccgtg aatggagagt tcagcctgga cgatctccag 1800
ccgtggcatt cttttggggc tgactctgtg ccagccaaca cagaaaacga agttgagcct 1860
gttgatgeec geeetgetge egacegagga etgaceaete gaceaggtte tgggttgaca 1920
aatatcaaga eggaggagat etetgaagtg aagatggatg cagaatteeg acatgactea 1980
ggatatgaag ttcatcatca aaaattggtg ttctttgcag aagatgtggg ttcaaacaaa 2040
ggtgcaatca ttggactcat ggtgggcggt gttgtcatag cgacagtgat cgtcatcacc 2100
ttggtgatgc tgaaqaaqaa acagtacaca tccattcatc atggtgtggt ggaggttgac 2160
gccgctgtca ccccagagga gcgccacctg tccaagatgc agcagaacgg ctacgaaaat 2220
ccaacctaca agttetttga gcagatgcag aacaagaag
```

- <210> 61
- <211> 753
- <212> PRT
- <213> Homo sapiens
- <400> 61
- Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
 1 5 10 15
- Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro 20 25 30
- Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln
 35 40 45
- Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp
- Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu 65 70 75 80
- Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn 85 90 95
- Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val
- Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu 115 120 125
- Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys 130 135 140
- Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu 145 150 155 160
- Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys Gly Ile 165 170 175
- Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro Leu Ala Glu Glu 180 185 190
- Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val 195 200 205
- Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys 210 215 220
- Val Val Glu Val Ala Glu Glu Glu Glu Val Ala Glu Val Glu Glu 225 230 235 240
- Glu Ala Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu 245 250 255
- Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile 260 265 270
- Ala Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg 275 280 285
- Glu Val Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala Met Ile 290 295 300

Ser 305	Arg	Trp	Tyr	Phe	Asp 310	Val	Thr	Glu	Gly	Lys 315	Cys	Ala	Pro	Phe	Ph∈ 320
Tyr	Gly	Gly	Cys	Gly 325	Gly	Asn	Arg	Asn	Asn 330	Phe	Asp	Thr	Glu	Glu 335	Туг
Cys	Met	Ala	Val 340	Cys	Gly	Ser	Ala	Ile 345	Pro	Thr	Thr	Ala	Ala 350	Ser	Thr
Pro	Asp	Ala 355	Val	Asp	Lys	Tyr	Leu 360	Glu	Thr	Pro	Gly	Asp 365	Glu	Asn	Glu
His	Ala 370	His	P'ne	Gln	Lys	Ala 375	Lys	Glu	Arg	Leu	Glu 380	Ala	Lys	His	Arg
Glu 385	Arg	Met	Ser	Gln	Val 390	Met	Arg	Glu	Trp	Glu 395	Glu	Ala	Glu	Arg	Gln 400
Ala	Lys	Asn	Leu	Pro 405	Lys	Ala	Asp	Lys	Lys 410	Ala	Val	Ile	Gln	His 415	Phe
Gln	Glu	Lys	Val 420	Glu	Ser	Leu	Glu	Gln 425	Glu	Ala	Ala	Asn	Glu 430	Arg	Glr
Gln	Leu	Val 435	Glu	Thr	His	Met	Ala 440	Arg	Val	Glu	Ala	Met 445	Leu	Asn	Asp
Arg	Arg 450	Arg	Leu	Ala	Leu	Glu 455	Asn	Tyr	Ile	Thr	Ala 460	Leu	Gln	Ala	Val
Pro 465	Pro	Arg	Pro	Arg	His 470	Val	Fhe	Asn	Met	Leu 475	Lys	Lys	Tyr	Val	Arg 480
Ala	Glu	Gln	Lys	Asp 485	Arg	Gln	His	Thr	Leu 490	Lys	His	Phe	Glu	H15 495	Val
Arg	Met	Val	Asp 500	Pro	Lys	Lys	Ala	Ala 505	Gln	Ile	Arg	Ser	Gln 510	Val	Met
Thr	His	Leu 515	Arg	Val	Ile	Tyr	Glu 520	Arg	Met	Asn	Gln	Ser 525	Leu	Ser	Leu
Leu	Tyr 530	Asn	Val	Pro	Ala	Val 535	Ala	Glu	Glu	Ile	Gln 540	Asp	Glu	Val	Asp
Glu 5 4 5	Leu	Leu	Gln	Lys	Glu 550	Gln	Asn	Tyr	Ser	Asp 555	Asp	Val	Leu	Ala	Asn 560
Met	Ile	Ser	Glu	Pro 565	Arg	Ile	Ser	Tyr	Gly 570	Asn	Asp	Ala	Leu	Met 575	Pro
Ser	Leu	Thr	Glu 580	Thr	Lys	Thr	Thr	Val 585	Glu	Leu	Leu	Pro	Val 590	Asn	Gly
Glu	Phe	Ser 595	Leu	Asp	Asp	Leu	Gln 600	Pro	Trp	His	Ser	Phe 605	Gly	Ala	Asp
Ser	Val 610	Pro	Ala	Asn	Thr	Glu 615	Asn	Glu	Val	Glu	Pro 620	Val	Asp	Ala	Arg
Pro 625	Ala	Ala	Asp	Arg	Gly 630	Leu	Thr	Thr	Arg	Pro 635	Gly	Ser	Gly	Leu	Thr 640

- 59 -

Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys Met Asp Ala Glu Phe 650 645 Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr Leu Val Met Leu 695 690 Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln Met Gln Asn Lys 745 Lys <210> 62 <211> 8 <212> PRT <213> Artificial Sequence <223> Description of Artificial Sequence: synthetic <400> 62 Leu Glu Val Leu Phe Gln Gly Pro <210> 63 <211> 10 <212> PRT <213> Artificial Sequence <223> Description of Artificial Sequence: synthetic <400> 63 Ser Glu Val Asn Leu Asp Ala Glu Phe Arg <210> 64 <211> 10 <212> PRT <213> Artificial Sequence <223> Description of Artificial Sequence synthetic Ser Glu Val Lys Met Asp Ala Glu Phe Arg

PCT/IB01/00797 WO 01/49097

- 60 -

```
<21.0> 65
<211> 15
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: synthetic
Arg Arg Gly Gly Val Val Ile Ala Thr Val Ile Val Gly Glu Arg
                                     10
<210> 66
<211> 4
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Peptide
<400> 66
Asn Leu Asp Ala
<210> 67
<211> 8
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Peptide
<400> 67
Glu Val Lys Met Asp Ala Glu Phe
<210> 68
<211> 5
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Peptide
 <400> 68
 Gly Arg Arg Gly Ser
 <210> 69
 <211> 6
 <212> PRT
 <213> Artificial Sequence
 <223> Description of Artificial Sequence: Peptide
 <400> 69
```

- 61 -

```
Thr Gln His Gly Ile Arg
<210> 70
<211> 6
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Peptide
<400> 70
Glu Thr Asp Glu Glu Pro
<210> 71
<211> 15
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Peptide
Met Cys Ala Glu Val Lys Met Asp Ala Glu Phe Lys Asp Asn Pro
<210> 72
<211> 5
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: synthetic
<400> 72
Asp Ala Glu Phe Arg
<210> 73
<211> 5
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: synthetic
<400> 73
Ser Glu Val Asn Leu
```